<journal><article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="3.0" role="ECC" store="2" contenteditable="false"><front store="3" contenteditable="false"><jou role="ECC" store="4" contenteditable="false"><name1 role="ECC" store="5" contenteditable="false">Endocrine Connections</name1></jou><!--<journal-meta><journal-id journal-id-type="CATS">IJCL</journal-id><journal-id journal-id-type="publisher-code">JCL</journal-id><journal-title-group><journal-title>Journal of Cosmetic and Laser Therapy</journal-title><abbrev-journal-title abbrev-type="pubmed">J Cosmet Laser Ther</abbrev-journal-title></journal-title-group><issn pub-type="ppub">1476-4172</issn><issn pub-type="epub">1476-4180</issn><publisher><publisher-name>Informa Healthcare</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>--><article-meta store="6" contenteditable="false"><!--<article-id pub-id-type="doi">10.3109/14764172.2015.2222222</article-id>--><!--<article-id pub-id-type="publisher-id">2222222</article-id>--><!--punc--><oa store="7" contenteditable="true">CC BY</oa><!--punc--><article-categories store="8" contenteditable="true"><subj-group subj-group-type="heading" store="9" contenteditable="true"><subject store="10" contenteditable="true">Research</subject></subj-group></article-categories><title-group store="11" contenteditable="true"><article-title store="12" contenteditable="true">Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction<query title="Please check and approve the title." data-time="1584108450" data-username="Editor" id="1" contenteditable="false" changetime="13/03/2020 19:37:29" store="13"><i class="fa fa-question-circle fa-1x fa-1x" style="color:red;" onclick="addQueryText(1);" contenteditable="true" store="14"></i></query></article-title><alt-title alt-title-type="rrh" store="15" contenteditable="true">Checkpoint inhibitor induced thyroid dysfunction</alt-title><alt-title alt-title-type="lrh" store="16" contenteditable="true">A Olsson-Brown <i store="17" contenteditable="true">et al.</i></alt-title></title-group><contrib-group store="18" contenteditable="true"><contrib contrib-type="author" corresp="no" store="19" contenteditable="true"><name store="20" contenteditable="true"><surname store="21" contenteditable="true">Anna</surname> <given-names store="22" contenteditable="true">Olsson-Brown</given-names></name><xref ref-type="aff" rid="AF0001" store="23" contenteditable="true"><sup store="24" contenteditable="true">1</sup></xref></contrib><!--punc-->, <!--punc--><contrib contrib-type="author" corresp="no" store="25" contenteditable="true"><name store="26" contenteditable="true"><surname store="27" contenteditable="true">Rosemary</surname> <given-names store="28" contenteditable="true">Lord</given-names></name><xref ref-type="aff" rid="AF0002" store="29" contenteditable="true"><sup store="30" contenteditable="true">2</sup></xref></contrib><!--punc-->, <!--punc--><contrib contrib-type="author" corresp="no" store="31" contenteditable="true"><name store="32" contenteditable="true"><surname store="33" contenteditable="true">Joseph</surname> <given-names store="34" contenteditable="true">Sacco</given-names></name><xref ref-type="aff" rid="AF0002" store="35" contenteditable="true"><sup store="36" contenteditable="true">2</sup></xref><!--punc--><sup store="37" contenteditable="true">,</sup><!--punc--><xref ref-type="aff" rid="AF0003" store="38" contenteditable="true"><sup store="39" contenteditable="true">3</sup></xref></contrib><!--punc-->, <!--punc--><contrib contrib-type="author" corresp="no" store="40" contenteditable="true"><name store="41" contenteditable="true"><surname store="42" contenteditable="true">Jonathan<query title="Please check and approve the author list." data-time="1584108451" data-username="Editor" id="2" contenteditable="false" changetime="13/03/2020 19:37:29" store="43"><i class="fa fa-question-circle fa-1x fa-1x" style="color:red;" onclick="addQueryText(2);" contenteditable="true" store="44"></i></query></surname> <given-names store="45" contenteditable="true">Wagg</given-names></name><xref ref-type="aff" rid="AF0004" store="46" contenteditable="true"><sup store="47" contenteditable="true">4</sup></xref></contrib><!--punc-->, <!--punc--><contrib contrib-type="author" corresp="no" store="48" contenteditable="true"><name store="49" contenteditable="true"><surname store="50" contenteditable="true">Mark</surname> <given-names store="51" contenteditable="true">Coles</given-names></name><xref ref-type="aff" rid="AF0005" store="52" contenteditable="true"><sup store="53" contenteditable="true">5</sup></xref></contrib><!--punc--> and <!--punc--><contrib contrib-type="author" corresp="no" store="54" contenteditable="true"><name store="55" contenteditable="true"><surname store="56" contenteditable="true">Munir</surname> <given-names store="57" contenteditable="true">Pirmohamed</given-names></name><xref ref-type="aff" rid="AF0001" store="58" contenteditable="true"><sup store="59" contenteditable="true">1</sup></xref></contrib><aff id="AF0001" store="60" contenteditable="true"><sup store="61" contenteditable="true">1</sup> Department of Molecular and Clinical Pharmacology, <institution store="62" contenteditable="true">University of Liverpool</institution>, Liverpool, <country store="63" contenteditable="true">UK</country></aff><aff id="AF0002" store="64" contenteditable="true"><sup store="65" contenteditable="true">2</sup> <institution store="66" contenteditable="true">The Clatterbridge Cancer Centre</institution>, Wirral, UK</aff><aff id="AF0003" store="67" contenteditable="true"><sup store="68" contenteditable="true">3</sup> Molecular and Clinical Cancer Medicine, <institution store="69" contenteditable="true">University of Liverpool<query title="Please check and approve the affiliation details." data-time="1584108452" data-username="Editor" id="3" contenteditable="false" changetime="13/03/2020 19:37:29" store="70"><i class="fa fa-question-circle fa-1x fa-1x" style="color:red;" onclick="addQueryText(3);" contenteditable="true" store="71"></i></query></institution>, Liverpool, UK</aff><aff id="AF0004" store="72" contenteditable="true"><sup store="73" contenteditable="true">4</sup> Roche Innovation Center, Basel, Switzerland</aff><aff id="AF0005" store="74" contenteditable="true"><sup store="75" contenteditable="true">5</sup> Kennedy Institute of Rheumatology, <institution store="76" contenteditable="true">University of Oxford</institution>, Oxford, UK</aff></contrib-group><author-notes store="77" contenteditable="true"><corresp id="c1" store="78" contenteditable="true">Correspondence should be addressed to A Olsson-Brown: acob@liv.ac.uk</corresp></author-notes><pub-date pub-type="ppub" store="79" contenteditable="true"><month store="80" contenteditable="true"></month><year store="81" contenteditable="true">2015</year></pub-date><pub-date pub-type="epub" store="82" contenteditable="true"><month store="83" contenteditable="true"></month><year store="84" contenteditable="true">2015</year></pub-date><volume1 store="85" contenteditable="true">9</volume1><issue store="86" contenteditable="true">4</issue><fpage store="87" contenteditable="true">1</fpage><lpage store="88" contenteditable="true"></lpage><permissions store="89" contenteditable="true"><copyright-statement store="90" contenteditable="true">© 2019 The authors, Published by Bioscientifica Ltd</copyright-statement><copyright-year store="91" contenteditable="true">https://doi.org/10.1530/EC-19-0473</copyright-year><vol store="92" contenteditable="true">Volume: 9</vol><iss store="93" contenteditable="true">Issue: 4</iss><copyright-holder store="94" contenteditable="true">Informa UK, Ltd.</copyright-holder></permissions><!--<self-uri content-type="pdf" xlinkhref="14764172.2015.2222222.pdf" store="95"></self>--><hr store="96" contenteditable="true"/><abstract1 store="97" contenteditable="true"><title1 store="98" contenteditable="true">Abstract</title1><pp1 store="99" contenteditable="true"><i store="100" contenteditable="true">Introduction:</i> Immune checkpoint inhibitors can lead to thyroid dysfunction. However<span class="ins cts-1" data-cid="3" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427122731" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:08pm">,</span> the understanding of the clinical phenotype of ICI-induced thyroid dysfunction in the real-world population is limited. The purpose of this study was to characterise the clinical patterns of dysfunction and evaluate the demographic, biochemical and immunological features associated with this patient cohort.</pp1><pp1 store="101" contenteditable="true"><i store="102" contenteditable="true">Materials and methods:</i> To characterise the longitudinal clinical course of thyroid dysfunction in patients from a single, UK regional cancer centre<span class="ins cts-1" data-cid="18" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427154690" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:09pm">,</span> a retrospective review of patients was conducted. Inclusion criteria included all patients treated with antiPD-1 checkpoint inhibitors (ICI), either as monotherapy (pembrolizumab/nivolumab) or in combination with a CTLA<query title="Please check that only approved gene and protein nomenclature is used in your paper (human genes in uppercase italics, human proteins in uppercase roman; mouse/rat genes with initial uppercase italics, mouse/rat proteins all uppercase roman). For more details, see https://ec.bioscientifica.com/page/author/author-guidelines#genes and correct if necessary." data-time="1584108453" data-username="Editor" id="4" contenteditable="false" changetime="13/03/2020 19:37:29" store="103"><i class="fa fa-question-circle fa-1x fa-1x" style="color:red;" onclick="addQueryText(4);" contenteditable="true" store="104"></i></query>-4 inhibitor (ipilimumab). Patterns of toxicity were evaluated together with assessment of antibody titres.</pp1><pp1 store="105" contenteditable="true"><i store="106" contenteditable="true">Results:</i> Over 16 months, thyroid dysfunction was seen in 13/90 and 3/13 patients treated with anti-PD1 monotherapy<span class="del cts-1" data-cid="19" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427181911" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:09pm" contenteditable="false" style="display: inline;">,</span> and in combination with ipilimumab, respectively. Patients either developed hyperthyroidism followed by hypothyroidism <span class="ins cts-1" data-cid="20" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427194325" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:09pm">(</span>12/16<span class="ins cts-1" data-cid="21" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427196208" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:09pm">)</span> or <i data-time="1584367646000" data-username="Annapoorni Swamynathan" contenteditable="true">de novo</i> hypothyroidism <span class="ins cts-1" data-cid="22" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427199344" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:09pm">(</span>4/16<span class="ins cts-1" data-cid="23" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427201014" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:10pm">)</span>. Most patients were female (<i data-time="1584367885000" data-username="Annapoorni Swamynathan" contenteditable="true">n</i> = 11). All patients required thyroid replacement therapy. There was no relationship between clinical pattern of dysfunction and the presence of thyroid autoantibodies.</pp1><pp1 store="107" contenteditable="true"><i store="108" contenteditable="true">Conclusions:</i> There are two distinct patterns of thyroid dysfunction in ICI-treated patients. Patients with thyroiditis develop subsequent hypothyroidism in the vast majority of cases. The potential benefit from steroids or other therapy to manage the hyperthyroid phase remains unclear. Early detection of these patients through appropriate monitoring will improve clinical management and early hormone replacement<span class="ins cts-1" data-cid="24" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427280126" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:11pm">,</span> reducing the symptomatic burden of hypothyroidism.</pp1></abstract1><kwd-group store="109" contenteditable="true"><title1 store="110" contenteditable="true">Key Words</title1><!--punc--> <!--punc--><kwd1 store="111" contenteditable="true">immune related adverse events</kwd1><!--punc-->, <!--punc--><kwd1 store="112" contenteditable="true">thyroid dysfunction</kwd1><!--punc-->, <!--punc--><kwd1 store="113" contenteditable="true">checkpoint inhibitors</kwd1><!--punc-->, <!--punc--><kwd1 store="114" contenteditable="true">tumour immunotherapy</kwd1></kwd-group></article-meta></front><hr store="115" contenteditable="true"/><body1 store="116" contenteditable="true"><sec sec-type="H1" store="117" contenteditable="true"><title1 title="H1" store="118" contenteditable="true">Introduction</title1><pp1 store="119" contenteditable="true">Oncological immune<query title="Please check and approve the identification of the section level headings." data-time="1584108454" data-username="Editor" id="5" contenteditable="false" changetime="13/03/2020 19:37:29" store="120"><i class="fa fa-question-circle fa-1x fa-1x" style="color:red;" onclick="addQueryText(5);" contenteditable="true" store="121"></i></query> checkpoint inhibitors (ICI) are transforming oncological practice (<xref ref-type="bibr" rid="CIT00001 CIT00002 CIT00003" store="122" contenteditable="true">1, 2, 3</xref>). The first ICI, <xref ref-type="scheme" language="US" store="123" contenteditable="true"><xref ref-type="scheme" language="UK" store="124" contenteditable="true">ipilimumab</xref></xref> (<xref ref-type="scheme" language="US" store="125" contenteditable="true"><xref ref-type="scheme" language="UK" store="126" contenteditable="true">Yervoy</xref></xref>®), a CTLA-4 inhibitor, was used exclusively in metastatic malignant melanoma post-licensing (<xref ref-type="bibr" rid="CIT00003 CIT00004" store="127" contenteditable="true">3, 4</xref>). Subsequently, the PD-1 ICIs, <xref ref-type="scheme" language="US" store="128" contenteditable="true"><xref ref-type="scheme" language="UK" store="129" contenteditable="true">nivolumab</xref></xref> (<xref ref-type="scheme" language="US" store="130" contenteditable="true"><xref ref-type="scheme" language="UK" store="131" contenteditable="true">Opidivo</xref></xref>®) and <xref ref-type="scheme" language="US" store="132" contenteditable="true"><xref ref-type="scheme" language="UK" store="133" contenteditable="true">pembrolizumab</xref></xref> (<xref ref-type="scheme" language="US" store="134" contenteditable="true"><xref ref-type="scheme" language="UK" store="135" contenteditable="true">Keytruda</xref></xref>®), have led to increased efficacy and, in general, a superior safety profile compared to CTLA-4 inhibitors (<xref ref-type="bibr" rid="CIT00005" title="5. WeberJSD’AngeloSPMinorDHodiFSGutzmerRNeynsBHoellerCKhushalaniNIMillerJrWHLaoCD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet: Oncology 2015 16 375–384. (https://doi.org/10.1016/S1470-2045(15)70076-8)" store="136" contenteditable="true">5</xref>). Efficacy can be further improved by combining <xref ref-type="scheme" language="US" store="137" contenteditable="true"><xref ref-type="scheme" language="UK" store="138" contenteditable="true">nivolumab</xref></xref> and <xref ref-type="scheme" language="US" store="139" contenteditable="true"><xref ref-type="scheme" language="UK" store="140" contenteditable="true">ipilimumab</xref></xref> (<xref ref-type="bibr" rid="CIT00001 CIT00002 CIT00006" store="141" contenteditable="true">1, 2, 6</xref>). ICIs are now used in the mainstream treatment of metastatic melanoma, non-small cell lung cancer renal cell carcinoma, <xref ref-type="scheme" language="US" store="142" contenteditable="true"><xref ref-type="scheme" language="UK" store="143" contenteditable="true">urothelial</xref></xref> and head and neck cancers (<xref ref-type="bibr" rid="CIT00007 CIT00008" store="144" contenteditable="true">7, 8</xref>). <xref ref-type="scheme" language="US" store="145" contenteditable="true"><xref ref-type="scheme" language="UK" store="146" contenteditable="true">Nivolumab</xref></xref> and <xref ref-type="scheme" language="US" store="147" contenteditable="true"><xref ref-type="scheme" language="UK" store="148" contenteditable="true">pembrolizumab</xref></xref> also hold global <xref ref-type="scheme" language="US" store="149" contenteditable="true">licences</xref> for additional indications including gastro-<xref ref-type="scheme" language="US" store="150" contenteditable="true">oesophageal</xref> adenocarcinoma, classical Hodgkin’s lymphoma and malignancies expressing microsatellite instability.</pp1><pp1 store="151" contenteditable="true">The use of ICIs has led to a range of novel adverse drug reactions (<xref ref-type="bibr" rid="CIT00001" title="1. LarkinJChiarion-SileniVGonzalezRGrobJJCoweyCLLaoCDSchadendorfDDummerRSmylieMRutkowskiP, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine 2015 373 23–34. (https://doi.org/10.1056/NEJMoa1504030)" store="152" contenteditable="true">1</xref>) (hereafter called immune related adverse events (<xref ref-type="scheme" language="US" store="153" contenteditable="true"><xref ref-type="scheme" language="UK" store="154" contenteditable="true">irAE</xref></xref>)) which resemble endogenous autoimmune disease (<xref ref-type="bibr" rid="CIT00009" title="9. RobertCRibasAWolchokJDHodiFSHamidOKeffordRWeberJSJoshuaAMHwuWJGangadharTC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014 384 1109–1117. (https://doi.org/10.1016/S0140-6736(14)60958-2)" store="155" contenteditable="true">9</xref>). Rash and colitis are the predominant <xref ref-type="scheme" language="US" store="156" contenteditable="true"><xref ref-type="scheme" language="UK" store="157" contenteditable="true">irAEs</xref></xref> caused by <xref ref-type="scheme" language="US" store="158" contenteditable="true"><xref ref-type="scheme" language="UK" store="159" contenteditable="true">ipilimumab</xref></xref>. The predominant endocrine <xref ref-type="scheme" language="US" store="160" contenteditable="true"><xref ref-type="scheme" language="UK" store="161" contenteditable="true">irAE</xref></xref> induced by <xref ref-type="scheme" language="US" store="162" contenteditable="true"><xref ref-type="scheme" language="UK" store="163" contenteditable="true">ipilimumab</xref></xref> is <xref ref-type="scheme" language="US" store="164" contenteditable="true"><xref ref-type="scheme" language="UK" store="165" contenteditable="true">hypophysitis</xref></xref>, occurring in 4<span class="del cts-1" data-cid="25" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427350492" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:12pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="26" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427350582" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:12pm">–</span>13% of patients (<xref ref-type="bibr" rid="CIT00001 CIT00002 CIT00004" store="166" contenteditable="true">1, 2, 4</xref>). Thyroid dysfunction is witnessed in 1<span class="del cts-1" data-cid="27" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427354790" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:12pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="28" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427354835" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:12pm">–</span>5% of patients (<xref ref-type="bibr" rid="CIT00001 CIT00002 CIT00004" store="167" contenteditable="true">1, 2, 4</xref>).</pp1><pp1 store="168" contenteditable="true">In the oncology setting, adverse events are graded using the Common Terminology Criteria for Adverse Events (CTCAE) criteria (<xref ref-type="bibr" rid="CIT00010" title="10. RibasAPuzanovIDummerRSchadendorfDHamidORobertCHodiFSSchachterJPavlickACLewisKD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet: Oncology 2015 16 908–918. (https://doi.org/10.1016/S1470-2045(15)00083-2)" store="169" contenteditable="true">10</xref>) from 1 to 5<span class="ins cts-1" data-cid="29" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427363904" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:12pm">,</span> with grade 1 representing mild toxicity and 5 representing death as a result of toxicity. As <xref ref-type="scheme" language="US" store="170" contenteditable="true"><xref ref-type="scheme" language="UK" store="171" contenteditable="true">monotherapy</xref></xref>, anti-PD-1 agents induce grade 3<span class="del cts-1" data-cid="37" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427430264" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:13pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="38" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427430301" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:13pm">/</span>4 (severe/life-threatening) <xref ref-type="scheme" language="US" store="172" contenteditable="true"><xref ref-type="scheme" language="UK" store="173" contenteditable="true">irAEs</xref></xref> in 15% of patients (<xref ref-type="bibr" rid="CIT00001 CIT00007" store="174" contenteditable="true">1, 7</xref>). The incidence of severe <xref ref-type="scheme" language="US" store="175" contenteditable="true"><xref ref-type="scheme" language="UK" store="176" contenteditable="true">irAEs</xref></xref> increases further with combination checkpoint blockade with grade 3<span class="del cts-1" data-cid="39" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427434842" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:13pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="40" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427434861" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:13pm">/</span>4 <xref ref-type="scheme" language="US" store="177" contenteditable="true"><xref ref-type="scheme" language="UK" store="178" contenteditable="true">irAEs</xref></xref> occurring in 58<span class="del cts-1" data-cid="41" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427437559" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:13pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="42" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427437608" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:13pm">–</span>68% of patients (<xref ref-type="bibr" rid="CIT00001 CIT00002" store="179" contenteditable="true">1, 2</xref>). The incidence of thyroid dysfunction is increased with PD-1 inhibitor therapy when compared with <xref ref-type="scheme" language="US" store="180" contenteditable="true"><xref ref-type="scheme" language="UK" store="181" contenteditable="true">ipilimumab</xref></xref> (<xref ref-type="bibr" rid="CIT00006 CIT00009 CIT00010" store="182" contenteditable="true">6, 9, 10</xref>). Whil<span class="del cts-1" data-cid="43" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427445878" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:14pm" contenteditable="false" style="display: inline;">st</span><span class="ins cts-1" data-cid="44" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427445913" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:14pm">e</span> the majority of <xref ref-type="scheme" language="US" store="183" contenteditable="true"><xref ref-type="scheme" language="UK" store="184" contenteditable="true">irAEs</xref></xref> are treatable and reversible with corticosteroid containing immunosuppression, the <xref ref-type="scheme" language="US" store="185" contenteditable="true"><xref ref-type="scheme" language="UK" store="186" contenteditable="true">endocrinopathies</xref></xref> appear to be irreversible<span class="del cts-1" data-cid="51" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427479753" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:14pm" contenteditable="false" style="display: inline;">,</span> and<span class="ins cts-1" data-cid="52" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427482724" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:14pm">,</span> in the majority of cases, require lifelong replacement therapy (<xref ref-type="bibr" rid="CIT00011" title="11. BertrandAKostineMBarnetcheTTruchetetMESchaeverbekeT. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine 2015 13 211. (https://doi.org/10.1186/s12916-015-0455-8)" store="187" contenteditable="true">11</xref>).</pp1><pp1 store="188" contenteditable="true">Thyroid dysfunction reported within metastatic malignant melanoma clinical trials included both hyperthyroidism and hypothyroidism (Supplementary Table 1, see section on <xref ref-type="supplementary-material" store="189" contenteditable="true">supplementary materials</xref> given at the end of this article) but the clinical and biochemical manifestations were not detailed. Radioisotope scanning of patients experiencing thyroid dysfunction has suggested a cytotoxic mechanism rather than autoantibody driven disease. Indeed, the association with autoantibodies remains unclear with variable results between studies (<xref ref-type="bibr" rid="CIT00012 CIT00013" store="190" contenteditable="true">12, 13</xref>). Active management of ICI-induced thyroiditis is required despite the fact that the acute toxicity is of lower grade than other <xref ref-type="scheme" language="US" store="191" contenteditable="true"><xref ref-type="scheme" language="UK" store="192" contenteditable="true">irAEs</xref></xref>. It is also generally permanent<span class="ins cts-1" data-cid="53" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427561923" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:16pm">,</span> with only limited reports of recovery (<xref ref-type="bibr" rid="CIT00014" title="14. SznolMPostowMADaviesMJPavlickACPlimackERShaheenMVeloskiCRobertC. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews 2017 58 70–76. (https://doi.org/10.1016/j.ctrv.2017.06.002)" store="193" contenteditable="true">14</xref>). No clinical predictors of thyroid toxicity following ICI therapy have been identified<span class="ins cts-1" data-cid="54" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427572068" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:16pm">,</span> and baseline TSH does not appear to predict the occurrence of thyroiditis (<xref ref-type="bibr" rid="CIT00012" title="12. MorgansteinDLLaiZSpainLDiemSLevineDMaceCGoreMLarkinJ. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clinical Endocrinology 2017 86 614–620. (https://doi.org/10.1111/cen.13297)" store="194" contenteditable="true">12</xref>). ICI treatment duration may be positively correlated with the occurrence of thyroiditis (<xref ref-type="bibr" rid="CIT00015" title="15. YamauchiISakaneYFukudaYFujiiTTauraDHirataMHirotaKUedaYKanaiYYamashitaY, et al. Clinical features of Nivolumab-induced thyroiditis: a case series study. Thyroid 2017 27 894–901. (https://doi.org/10.1089/thy.2016.0562)" store="195" contenteditable="true">15</xref>).</pp1><pp1 store="196" contenteditable="true">The aim of our paper was to <xref ref-type="scheme" language="US" store="197" contenteditable="true">characterise</xref> the longitudinal clinical course of thyroid dysfunction in patients from a single, UK regional cancer <xref ref-type="scheme" language="US" store="198" contenteditable="true">centre</xref> to determine if there is a characteristic pattern of biochemical abnormality, the proportion of patients experiencing clinically significant symptoms and the relationship of autoantibodies with biochemical change. Furthermore, we examined whether hypothyroidism was indeed the predominant manifestation of ICI-induced thyroid toxicity.</pp1></sec><sec sec-type="H1" store="199" contenteditable="true"><title1 title="H1" store="200" contenteditable="true">Materials and methods</title1><pp1 store="201" contenteditable="true">A retrospective review of case<span class="del cts-1" data-cid="69" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427682195" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:18pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="70" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427682220" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:18pm"> </span>notes of patients treated with anti-PD-1 ICIs for metastatic melanoma over a 16-month treatment period was undertaken at the <xref ref-type="scheme" language="US" store="202" contenteditable="true"><xref ref-type="scheme" language="UK" store="203" contenteditable="true">Clatterbridge</xref></xref> Cancer Centre, UK. The review included all patients treated with anti-PD1 ICI, either as <xref ref-type="scheme" language="US" store="204" contenteditable="true"><xref ref-type="scheme" language="UK" store="205" contenteditable="true">monotherapy</xref></xref> (<xref ref-type="scheme" language="US" store="206" contenteditable="true"><xref ref-type="scheme" language="UK" store="207" contenteditable="true">pembrolizumab</xref></xref>/<xref ref-type="scheme" language="US" store="208" contenteditable="true"><xref ref-type="scheme" language="UK" store="209" contenteditable="true">nivolumab</xref></xref>) or <xref ref-type="scheme" language="US" store="210" contenteditable="true"><xref ref-type="scheme" language="UK" store="211" contenteditable="true">nivolumab</xref></xref> in combination with <xref ref-type="scheme" language="US" store="212" contenteditable="true"><xref ref-type="scheme" language="UK" store="213" contenteditable="true">ipilimumab</xref></xref>, an anti-CTLA4 ICI. Patient electronic records were reviewed to identify patients with thyroid dysfunction defined as the presence of deranged thyroid function denoted by a T4 level outside the standard reference range. Patients were considered to have had thyroid dysfunction irrespective of their clinical symptoms (i.e. clinical and subclinical biochemical disturbance). The presentation, clinical course (biochemical and symptomatic) and emerging longitudinal biochemical patterns of toxicity were evaluated to determine the presence of specific clinical trajectories within the cohort. All patients found to have a single abnormal T4 level were evaluated to determine if the changes were transient or led to established thyroid dysfunction. Within this cohort<span class="ins cts-1" data-cid="71" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427775134" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:19pm">,</span> all patients found to have a single abnormal reading went on to develop either HH or DN. Thyroid autoantibody <xref ref-type="scheme" language="US" store="214" contenteditable="true">titres</xref> (thyroid receptor antibody (<xref ref-type="scheme" language="US" store="215" contenteditable="true"><xref ref-type="scheme" language="UK" store="216" contenteditable="true">TRAb</xref></xref>), Anti-thyroid peroxidase (TPO)) were also determined. Patients who had a diagnosis of pre-existing thyroid disorders (either hyper- or hypo<span class="del cts-1" data-cid="77" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427852858" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:20pm" contenteditable="false" style="display: inline;">- </span><xref ref-type="scheme" language="US" store="217" contenteditable="true"><xref ref-type="scheme" language="UK" store="218" contenteditable="true">thyroidism</xref></xref>) were excluded from the patient cohort. Aside from T4<span class="ins cts-1" data-cid="80" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427865408" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:21pm">,</span> if patients were found to have baseline biochemical parameters outside the normal ranges (<xref ref-type="scheme" language="US" store="219" contenteditable="true"><xref ref-type="scheme" language="UK" store="220" contenteditable="true">eg</xref></xref> TSH) but were subclinical and had no formal diagnosis of thyroid dysfunction, they were included in the cohort.</pp1><pp1 store="221" contenteditable="true">The local reference ranges for thyroid function tests were as follows: free T4 11.5<span class="del cts-1" data-cid="81" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427883379" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:21pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="82" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427883467" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:21pm">–</span>22.7 <xref ref-type="scheme" language="US" store="222" contenteditable="true"><xref ref-type="scheme" language="UK" store="223" contenteditable="true">pmol</xref></xref>/L; TSH 0.3<span class="del cts-1" data-cid="83" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427885651" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:21pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="84" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427885697" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:21pm">–</span>5.5 <xref ref-type="scheme" language="US" store="224" contenteditable="true"><xref ref-type="scheme" language="UK" store="225" contenteditable="true">mU</xref></xref>/L; Free T3 3.1–7 <xref ref-type="scheme" language="US" store="226" contenteditable="true"><xref ref-type="scheme" language="UK" store="227" contenteditable="true">pmol</xref></xref>/<span class="del cts-1" data-cid="14" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367938105" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:42pm" contenteditable="false" style="display: inline;">l</span><span class="ins cts-1" data-cid="15" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367938128" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:42pm" contenteditable="true">L</span>; <xref ref-type="scheme" language="US" store="228" contenteditable="true"><xref ref-type="scheme" language="UK" store="229" contenteditable="true">TRAb</xref></xref> 0.0<span class="del cts-1" data-cid="85" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427890254" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:21pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="86" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427890287" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:21pm">–</span>1.8 U/<span class="del cts-1" data-cid="16" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367940769" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:42pm" contenteditable="false" style="display: inline;">l</span><span class="ins cts-1" data-cid="17" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367940793" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:42pm" contenteditable="true">L</span><span class="del cts-1" data-cid="87" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427894175" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:21pm" contenteditable="false" style="display: inline;">;</span> and Anti-TPO 0.0<span class="del cts-1" data-cid="88" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427897029" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:21pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="89" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427897082" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:21pm">–</span>33.9 IU/<xref ref-type="scheme" language="US" store="230" contenteditable="true"><xref ref-type="scheme" language="UK" store="231" contenteditable="true">mL.</xref></xref></pp1><sec sec-type="H2" store="232" contenteditable="true"><title1 title="H2" store="233" contenteditable="true">Patient sampling and processing</title1><pp1 store="234" contenteditable="true">As part of the standard clinical management of ICI administration at the <xref ref-type="scheme" language="US" store="235" contenteditable="true"><xref ref-type="scheme" language="UK" store="236" contenteditable="true">Clatterbridge</xref></xref> Cancer Centre<span class="ins cts-1" data-cid="92" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427916940" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:21pm">,</span> all patients’ thyroid status (TSH, T4) is assessed at baseline. Recurrent testing of TSH (with T4 and T3 evaluated if TSH is found to be outside the reference range) is then performed on a 3-weekly basis<span class="ins cts-1" data-cid="100" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428056119" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:24pm">,</span> alongside a <xref ref-type="scheme" language="US" store="237" contenteditable="true">standardised</xref> biochemical panel including full blood count, urea and electrolytes, liver function tests, cortisol and random glucose levels. Patients experiencing thyroid dysfunction also undergo thyroid autoantibody assessment. Anti-thyroglobulin antibodies are not <xref ref-type="scheme" language="US" store="238" contenteditable="true">analysed</xref> in routine clinical practice, and therefore all living patients with thyroid dysfunction during ICI therapy were approached to donate a blood sample in line with the <xref ref-type="scheme" language="US" store="239" contenteditable="true"><xref ref-type="scheme" language="UK" store="240" contenteditable="true">Clatterbridge</xref></xref> <xref ref-type="scheme" language="US" store="241" contenteditable="true"><xref ref-type="scheme" language="UK" store="242" contenteditable="true">Biobank</xref></xref> ethical approval. Informed consent was obtained. The presence of anti-<xref ref-type="scheme" language="US" store="243" contenteditable="true"><xref ref-type="scheme" language="UK" store="244" contenteditable="true">Tg</xref></xref> antibodies was <xref ref-type="scheme" language="US" store="245" contenteditable="true">analysed</xref> by ELISA using a human anti-thyroglobulin ELISA kit (ab178631) on serum isolated from donated samples.</pp1></sec><sec sec-type="H2" store="246" contenteditable="true"><title1 title="H2" store="247" contenteditable="true">Data analysis</title1><pp1 store="248" contenteditable="true">Time to event is presented as median durations with associated interquartile ranges. Descriptive statistics are presented as means with 95% <span class="del cts-1" data-cid="101" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428098542" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:24pm" contenteditable="false" style="display: inline;">confidence interval</span><span class="ins cts-1" data-cid="102" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428098567" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:24pm">CI</span>s. Comparisons between groups have <xref ref-type="scheme" language="US" store="249" contenteditable="true">utilised</xref><span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367799000_dfound0_regex_style18" common_tag="1584367799000_ifound0_regex_style18" contenteditable="false" style="display: inline;"> Mann-Whitney </span><span store="1584367799000_i0" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367799000_ifound0_regex_style18" common_tag="1584367799000_ifound0_regex_style18" contenteditable="true"> Mann–Whitney </span>and <xref ref-type="scheme" language="US" store="250" contenteditable="true"><xref ref-type="scheme" language="UK" store="251" contenteditable="true">Kruskal</xref></xref><span class="del cts-1" data-cid="104" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428113071" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:25pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="105" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428113125" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:25pm">3-weekly basis</span>Wallis analyses, as appropriate. All statistical tests <xref ref-type="scheme" language="US" store="252" contenteditable="true">utilised</xref> a significance value of <span class="del cts-1" data-cid="4" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367907025" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="false" style="display: inline;">p</span><span class="ins cts-1" data-cid="5" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367907053" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="true"><i data-time="1584367908000" data-username="Annapoorni Swamynathan" contenteditable="true">P</i></span> &lt; 0.05.</pp1></sec></sec><sec sec-type="H1" store="253" contenteditable="true"><title1 title="H1" store="254" contenteditable="true">Results</title1><sec sec-type="H2" store="255" contenteditable="true"><title1 title="H2" store="256" contenteditable="true">Patient demographics</title1><pp1 store="257" contenteditable="true">Over the 16-month period, between February 2016 and May 2017, a total of 103 patients were treated with PD-1 ICIs for metastatic melanoma in the palliative setting. Ninety patients received <xref ref-type="scheme" language="US" store="258" contenteditable="true"><xref ref-type="scheme" language="UK" store="259" contenteditable="true">monotherapy<span class="ins cts-1" data-cid="106" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428129384" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:25pm">,</span></xref></xref> while 13 received combination treatment. Thyroid dysfunction was observed in 16/103 of patients; 13 out of the 90<span class="del cts-1" data-cid="107" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428161087" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:26pm" contenteditable="false" style="display: inline;"> were</span> receiv<span class="del cts-1" data-cid="108" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428167264" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:26pm" contenteditable="false" style="display: inline;">ing</span><span class="ins cts-1" data-cid="109" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428167299" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:26pm">ed</span> <xref ref-type="scheme" language="US" store="260" contenteditable="true"><xref ref-type="scheme" language="UK" store="261" contenteditable="true">monotherapy</xref></xref> and 3/13 received combination therapy. All patients within the cohort were Caucasian (<xref ref-type="table" rid="T1" store="262" contenteditable="true">Table 1</xref>). For all other patients, thyroid function remained within the normal range throughout therapy.<table-wrap id="T1" position="float" store="263" contenteditable="true"><label1 store="264" contenteditable="true"><b store="265" contenteditable="true">Table 1</b></label1><caption1 store="266" contenteditable="true"><p1 store="267" contenteditable="true"> Patient demographics by treatment group and pattern of thyroid dysfunction.</p1></caption1><table frame="box" store="268" id="table_1" contenteditable="false"><thead store="269" contenteditable="true"><tr store="270" contenteditable="true"><td store="271" contenteditable="true"><tp store="272" contenteditable="true">Parameter</tp></td><td store="273" contenteditable="true"><tp store="274" contenteditable="true">Monotherapy treatment group</tp></td><td store="275" contenteditable="true"><tp store="276" contenteditable="true">Combination therapy treatment group</tp></td><td store="277" contenteditable="true"><tp store="278" contenteditable="true">Hyperthyroidism followed by hypothyroidism (HH)</tp></td><td store="279" contenteditable="true" class=""><tp store="280" contenteditable="true"><i data-time="1584367655000" data-username="Annapoorni Swamynathan" contenteditable="true">De novo</i> hypothyroidism (DN)</tp></td></tr></thead><tbody store="281" contenteditable="true"><tr store="282" contenteditable="true"><td store="283" contenteditable="true"><tp store="284" contenteditable="true">Number of patients (<i data-time="1584367888000" data-username="Annapoorni Swamynathan" contenteditable="true">n</i> = 16)</tp></td><td store="285" contenteditable="true"><tp store="286" contenteditable="true">13</tp></td><td store="287" contenteditable="true"><tp store="288" contenteditable="true">3</tp></td><td store="289" contenteditable="true"><tp store="290" contenteditable="true">12</tp></td><td store="291" contenteditable="true"><tp store="292" contenteditable="true">4 </tp></td></tr><tr store="293" contenteditable="true"><td store="294" contenteditable="true"><tp store="295" contenteditable="true">Gender</tp></td><td store="296" contenteditable="true"><tp store="297" contenteditable="true"></tp></td><td store="298" contenteditable="true"><tp store="299" contenteditable="true"></tp></td><td store="300" contenteditable="true"><tp store="301" contenteditable="true"></tp></td><td store="302" contenteditable="true"><tp store="303" contenteditable="true"></tp></td></tr><tr store="304" contenteditable="true"><td store="305" contenteditable="true"><tp store="306" contenteditable="true"> Male (M)</tp></td><td store="307" contenteditable="true"><tp store="308" contenteditable="true">4</tp></td><td store="309" contenteditable="true"><tp store="310" contenteditable="true">1</tp></td><td store="311" contenteditable="true"><tp store="312" contenteditable="true">5</tp></td><td store="313" contenteditable="true"><tp store="314" contenteditable="true">0</tp></td></tr><tr store="315" contenteditable="true"><td store="316" contenteditable="true"><tp store="317" contenteditable="true"> Female (F)</tp></td><td store="318" contenteditable="true"><tp store="319" contenteditable="true">9 </tp></td><td store="320" contenteditable="true"><tp store="321" contenteditable="true">2</tp></td><td store="322" contenteditable="true"><tp store="323" contenteditable="true">7 </tp></td><td store="324" contenteditable="true"><tp store="325" contenteditable="true">4 </tp></td></tr><tr store="326" contenteditable="true"><td store="327" contenteditable="true"><tp store="328" contenteditable="true">Gender differential of total treatment population (<i data-time="1584367890000" data-username="Annapoorni Swamynathan" contenteditable="true">n</i> = 103)</tp></td><td store="329" contenteditable="true"><tp store="330" contenteditable="true">Males 57/103</tp><tp store="331" contenteditable="true">Females 46/103</tp></td><td store="332" contenteditable="true"><tp store="333" contenteditable="true">Males 57/103</tp><tp store="334" contenteditable="true">Females 46/103</tp></td><td store="335" contenteditable="true"><tp store="336" contenteditable="true">Males 57/103</tp><tp store="337" contenteditable="true">Females 46/103</tp></td><td store="338" contenteditable="true"><tp store="339" contenteditable="true">Males 57/103</tp><tp store="340" contenteditable="true">Females 46/103</tp></td></tr><tr store="341" contenteditable="true"><td store="342" contenteditable="true"><tp store="343" contenteditable="true">Age (years)</tp></td><td store="344" contenteditable="true"><tp store="345" contenteditable="true"></tp></td><td store="346" contenteditable="true"><tp store="347" contenteditable="true"></tp></td><td store="348" contenteditable="true"><tp store="349" contenteditable="true"></tp></td><td store="350" contenteditable="true"><tp store="351" contenteditable="true"></tp></td></tr><tr store="352" contenteditable="true"><td store="353" contenteditable="true"><tp store="354" contenteditable="true"> Mean</tp></td><td store="355" contenteditable="true"><tp store="356" contenteditable="true">58</tp></td><td store="357" contenteditable="true"><tp store="358" contenteditable="true">57</tp></td><td store="359" contenteditable="true"><tp store="360" contenteditable="true">56</tp></td><td store="361" contenteditable="true"><tp store="362" contenteditable="true">70.5</tp></td></tr><tr store="363" contenteditable="true"><td store="364" contenteditable="true"><tp store="365" contenteditable="true"> Range</tp></td><td store="366" contenteditable="true" class=""><tp store="367" contenteditable="true">29<span class="del cts-1" data-cid="113" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428222115" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:27pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="114" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428222190" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:27pm">–</span>74</tp></td><td store="368" contenteditable="true"><tp store="369" contenteditable="true">46<span class="del cts-1" data-cid="115" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428224341" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:27pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="116" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428224380" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:27pm">–</span>64</tp></td><td store="370" contenteditable="true"><tp store="371" contenteditable="true">29<span class="del cts-1" data-cid="117" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428226253" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:27pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="118" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428226294" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:27pm">–</span>64</tp></td><td store="372" contenteditable="true"><tp store="373" contenteditable="true">48<span class="del cts-1" data-cid="119" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428228780" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:27pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="120" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428228818" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:27pm">–</span>89</tp></td></tr><tr store="374" contenteditable="true"><td store="375" contenteditable="true" class=""><tp store="376" contenteditable="true">Ethnicity<span class="ins cts-1" data-cid="121" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428269704" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:27pm"><sup data-time="1584428272000" data-username="Annapoorni Swamynathan">a</sup></span><span class="del cts-1" data-cid="122" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428273744" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:27pm" contenteditable="false" style="display: inline;">*</span></tp></td><td store="377" contenteditable="true"><tp store="378" contenteditable="true"></tp></td><td store="379" contenteditable="true"><tp store="380" contenteditable="true"></tp></td><td store="381" contenteditable="true"><tp store="382" contenteditable="true"></tp></td><td store="383" contenteditable="true"><tp store="384" contenteditable="true"></tp></td></tr><tr store="385" contenteditable="true"><td store="386" contenteditable="true"><tp store="387" contenteditable="true"> White British</tp></td><td store="388" contenteditable="true"><tp store="389" contenteditable="true">13/13</tp></td><td store="390" contenteditable="true"><tp store="391" contenteditable="true">2/3</tp></td><td store="392" contenteditable="true"><tp store="393" contenteditable="true">11/12</tp></td><td store="394" contenteditable="true"><tp store="395" contenteditable="true">4/4</tp></td></tr><tr store="396" contenteditable="true"><td store="397" contenteditable="true"><tp store="398" contenteditable="true"> White Polish</tp></td><td store="399" contenteditable="true"><tp store="400" contenteditable="true">0/13</tp></td><td store="401" contenteditable="true"><tp store="402" contenteditable="true">1/3</tp></td><td store="403" contenteditable="true"><tp store="404" contenteditable="true">1/12</tp></td><td store="405" contenteditable="true"><tp store="406" contenteditable="true">0/4</tp></td></tr><tr store="407" contenteditable="true"><td store="408" contenteditable="true"><tp store="409" contenteditable="true"> Other</tp></td><td store="410" contenteditable="true"><tp store="411" contenteditable="true">0 /13</tp></td><td store="412" contenteditable="true"><tp store="413" contenteditable="true">0 </tp></td><td store="414" contenteditable="true"><tp store="415" contenteditable="true">0/12</tp></td><td store="416" contenteditable="true"><tp store="417" contenteditable="true">0/4</tp></td></tr><tr store="418" contenteditable="true"><td store="419" contenteditable="true"><tp store="420" contenteditable="true">Melanoma <span class="del cts-1" data-cid="127" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428310968" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:28pm" contenteditable="false" style="display: inline;">S</span><span class="ins cts-1" data-cid="128" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428310985" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:28pm">s</span>ubtype</tp></td><td store="421" contenteditable="true"><tp store="422" contenteditable="true"></tp></td><td store="423" contenteditable="true"><tp store="424" contenteditable="true"></tp></td><td store="425" contenteditable="true"><tp store="426" contenteditable="true"></tp></td><td store="427" contenteditable="true"><tp store="428" contenteditable="true"></tp></td></tr><tr store="429" contenteditable="true"><td store="430" contenteditable="true"><tp store="431" contenteditable="true"> Cutaneous</tp></td><td store="432" contenteditable="true"><tp store="433" contenteditable="true">11/13</tp></td><td store="434" contenteditable="true"><tp store="435" contenteditable="true">2/3</tp></td><td store="436" contenteditable="true"><tp store="437" contenteditable="true">8/12</tp></td><td store="438" contenteditable="true"><tp store="439" contenteditable="true">4/4</tp></td></tr><tr store="440" contenteditable="true"><td store="441" contenteditable="true"><tp store="442" contenteditable="true"> Uveal</tp></td><td store="443" contenteditable="true"><tp store="444" contenteditable="true">1/13</tp></td><td store="445" contenteditable="true"><tp store="446" contenteditable="true">1/3</tp></td><td store="447" contenteditable="true"><tp store="448" contenteditable="true">3/12</tp></td><td store="449" contenteditable="true"><tp store="450" contenteditable="true">0/4</tp></td></tr><tr store="451" contenteditable="true"><td store="452" contenteditable="true"><tp store="453" contenteditable="true"> Anal</tp></td><td store="454" contenteditable="true"><tp store="455" contenteditable="true">1/13</tp></td><td store="456" contenteditable="true"><tp store="457" contenteditable="true">0/3</tp></td><td store="458" contenteditable="true"><tp store="459" contenteditable="true">1/12</tp></td><td store="460" contenteditable="true"><tp store="461" contenteditable="true">0/4</tp></td></tr><tr store="462" contenteditable="true"><td store="463" contenteditable="true"><tp store="464" contenteditable="true">Number of metastatic sites</tp></td><td store="465" contenteditable="true"><tp store="466" contenteditable="true"></tp></td><td store="467" contenteditable="true"><tp store="468" contenteditable="true"></tp></td><td store="469" contenteditable="true"><tp store="470" contenteditable="true"></tp></td><td store="471" contenteditable="true"><tp store="472" contenteditable="true"></tp></td></tr><tr store="473" contenteditable="true"><td store="474" contenteditable="true"><tp store="475" contenteditable="true"> 1</tp></td><td store="476" contenteditable="true"><tp store="477" contenteditable="true">4/13</tp></td><td store="478" contenteditable="true"><tp store="479" contenteditable="true">1 (33.3%)</tp></td><td store="480" contenteditable="true"><tp store="481" contenteditable="true">3/12</tp></td><td store="482" contenteditable="true"><tp store="483" contenteditable="true">1/4</tp></td></tr><tr store="484" contenteditable="true"><td store="485" contenteditable="true"><tp store="486" contenteditable="true"> 2</tp></td><td store="487" contenteditable="true"><tp store="488" contenteditable="true">6/13</tp></td><td store="489" contenteditable="true"><tp store="490" contenteditable="true">1 (33.3%)</tp></td><td store="491" contenteditable="true"><tp store="492" contenteditable="true">6/12</tp></td><td store="493" contenteditable="true"><tp store="494" contenteditable="true">2/4</tp></td></tr><tr store="495" contenteditable="true"><td store="496" contenteditable="true"><tp store="497" contenteditable="true"> ≥3</tp></td><td store="498" contenteditable="true"><tp store="499" contenteditable="true">3/13</tp></td><td store="500" contenteditable="true"><tp store="501" contenteditable="true">1 (33.3%)</tp></td><td store="502" contenteditable="true"><tp store="503" contenteditable="true">3/12</tp></td><td store="504" contenteditable="true"><tp store="505" contenteditable="true">1 /4</tp></td></tr><tr store="506" contenteditable="true"><td store="507" contenteditable="true"><tp store="508" contenteditable="true">Line of treatment</tp></td><td store="509" contenteditable="true"><tp store="510" contenteditable="true"></tp></td><td store="511" contenteditable="true"><tp store="512" contenteditable="true"></tp></td><td store="513" contenteditable="true"><tp store="514" contenteditable="true"></tp></td><td store="515" contenteditable="true"><tp store="516" contenteditable="true"></tp></td></tr><tr store="517" contenteditable="true"><td store="518" contenteditable="true"><tp store="519" contenteditable="true"> 1</tp></td><td store="520" contenteditable="true"><tp store="521" contenteditable="true">5/13</tp></td><td store="522" contenteditable="true"><tp store="523" contenteditable="true">1/3</tp></td><td store="524" contenteditable="true"><tp store="525" contenteditable="true">5 /12</tp></td><td store="526" contenteditable="true"><tp store="527" contenteditable="true">3/4</tp></td></tr><tr store="528" contenteditable="true"><td store="529" contenteditable="true"><tp store="530" contenteditable="true"> 2</tp></td><td store="531" contenteditable="true"><tp store="532" contenteditable="true">6/13</tp></td><td store="533" contenteditable="true"><tp store="534" contenteditable="true">1/3</tp></td><td store="535" contenteditable="true"><tp store="536" contenteditable="true">6/12</tp></td><td store="537" contenteditable="true"><tp store="538" contenteditable="true">0/4</tp></td></tr><tr store="539" contenteditable="true"><td store="540" contenteditable="true"><tp store="541" contenteditable="true"> 3</tp></td><td store="542" contenteditable="true"><tp store="543" contenteditable="true">2/13</tp></td><td store="544" contenteditable="true"><tp store="545" contenteditable="true">1/3</tp></td><td store="546" contenteditable="true"><tp store="547" contenteditable="true">1/12 </tp></td><td store="548" contenteditable="true"><tp store="549" contenteditable="true">1/4</tp></td></tr><tr store="550" contenteditable="true"><td store="551" contenteditable="true"><tp store="552" contenteditable="true">Type of treatment</tp></td><td store="553" contenteditable="true"><tp store="554" contenteditable="true"></tp></td><td store="555" contenteditable="true"><tp store="556" contenteditable="true"></tp></td><td store="557" contenteditable="true"><tp store="558" contenteditable="true"></tp></td><td store="559" contenteditable="true"><tp store="560" contenteditable="true"></tp></td></tr><tr store="561" contenteditable="true"><td store="562" contenteditable="true"><tp store="563" contenteditable="true"> Monotherapy</tp></td><td store="564" contenteditable="true"><tp store="565" contenteditable="true">13/13</tp></td><td store="566" contenteditable="true"><tp store="567" contenteditable="true">3/3</tp></td><td store="568" contenteditable="true"><tp store="569" contenteditable="true">9/12</tp></td><td store="570" contenteditable="true"><tp store="571" contenteditable="true">4/4</tp></td></tr><tr store="572" contenteditable="true"><td store="573" contenteditable="true" class=" otherclass" style="background-color: rgb(155, 179, 218);"><tp store="574" contenteditable="true"> Combination <span class="del cts-1" data-cid="125" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428300278" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:28pm" contenteditable="false" style="display: inline;">T</span><span class="ins cts-1" data-cid="126" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428300301" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:28pm">t</span>herapy</tp></td><td store="575" contenteditable="true"><tp store="576" contenteditable="true">0/13</tp></td><td store="577" contenteditable="true"><tp store="578" contenteditable="true">0/3 </tp></td><td store="579" contenteditable="true"><tp store="580" contenteditable="true">3/12</tp></td><td store="581" contenteditable="true"><tp store="582" contenteditable="true">0/4</tp></td></tr></tbody></table><table-wrap-foot store="583" contenteditable="true"><fn id="fn1" store="584" contenteditable="true"><label1 store="585" contenteditable="true"></label1><pp1 store="586" contenteditable="true"><span class="ins cts-1" data-cid="123" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428278939" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:27pm"><sup data-time="1584428281000" data-username="Annapoorni Swamynathan">a</sup></span><span class="del cts-1" data-cid="124" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428281841" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:28pm" contenteditable="false" style="display: inline;">*</span>Likely to reflect the ethic mix of the local population.</pp1></fn></table-wrap-foot></table-wrap></pp1></sec><sec sec-type="H2" store="587" contenteditable="true"><title1 title="H2" store="588" contenteditable="true">Patterns of thyroid dysfunction and treatment</title1><pp1 store="589" contenteditable="true">Two clear patterns of thyroid dysfunction were identified (<xref ref-type="table" rid="T1" store="590" contenteditable="true">Table 1</xref>): hyperthyroidism followed by hypothyroidism (HH) in 12/16 of cases and <i store="591" contenteditable="true">de novo</i> (DN) hypothyroidism in 4/16 of cases.</pp1><pp1 store="592" contenteditable="true">With the HH pattern, there was an initial period of, minimally symptomatic or asymptomatic, hyperthyroidism followed by a decline in T4 and subsequent hypothyroidism. Where TSH was found to be low, both T4 and T3 were measured, but there were no cases of T3 elevation in the presence of a T4 within the normal range. The HH pattern was seen in 9/13 of patients receiving <xref ref-type="scheme" language="US" store="593" contenteditable="true"><xref ref-type="scheme" language="UK" store="594" contenteditable="true">monotherapy</xref></xref><span class="del cts-1" data-cid="129" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428356658" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:29pm" contenteditable="false" style="display: inline;">,</span> and in all patients receiving combination therapy (<xref ref-type="fig" rid="F1" store="595" contenteditable="true">Fig. 1A</xref>, <xref ref-type="fig" rid="F1" store="596" contenteditable="true">B</xref> and <xref ref-type="fig" rid="F1" store="597" contenteditable="true">C</xref>). The median time to onset was <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound0_regex_style51" common_tag="1584367806000_ifound0_regex_style51" contenteditable="false" style="display: inline;">9 weeks </span><span store="1584367806000_i0" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound0_regex_style51" common_tag="1584367806000_ifound0_regex_style51" contenteditable="true">9 weeks </span>(range 6<span class="del cts-1" data-cid="130" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428363175" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:29pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="131" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428363222" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:29pm">–</span>27; IQR 3) and <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound2_regex_style51" common_tag="1584367806000_ifound2_regex_style51" contenteditable="false" style="display: inline;">3 weeks </span><span store="1584367806000_i1" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound2_regex_style51" common_tag="1584367806000_ifound2_regex_style51" contenteditable="true">3 weeks </span>(range 3<span class="del cts-1" data-cid="132" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428368667" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:29pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="133" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428368709" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:29pm">–</span>6; IQR 3) with <xref ref-type="scheme" language="US" store="598" contenteditable="true"><xref ref-type="scheme" language="UK" store="599" contenteditable="true">monotherapy</xref></xref> ICI and combination therapy, respectively. The hyperthyroid phase duration was <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound1_regex_style51" common_tag="1584367806000_ifound1_regex_style51" contenteditable="false" style="display: inline;">9 weeks </span><span store="1584367806000_i2" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound1_regex_style51" common_tag="1584367806000_ifound1_regex_style51" contenteditable="true">9 weeks </span>(range 3<span class="del cts-1" data-cid="134" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428376570" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:29pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="135" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428376621" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:29pm">–</span>15; IQR 6) in patients receiving <xref ref-type="scheme" language="US" store="600" contenteditable="true"><xref ref-type="scheme" language="UK" store="601" contenteditable="true">monotherapy</xref></xref> and universally <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound3_regex_style51" common_tag="1584367806000_ifound3_regex_style51" contenteditable="false" style="display: inline;">6 weeks </span><span store="1584367806000_i3" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound3_regex_style51" common_tag="1584367806000_ifound3_regex_style51" contenteditable="true">6 weeks </span>(range 6; IQR 0 as) in those receiving combination therapy. The time to onset of thyroid dysfunction from the commencement of ICI therapy was significantly longer (<span class="del cts-1" data-cid="6" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367910369" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="false" style="display: inline;">p</span><span class="ins cts-1" data-cid="7" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367910409" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="true"><i data-time="1584367911000" data-username="Annapoorni Swamynathan" contenteditable="true">P</i></span> = 0.02) in the <xref ref-type="scheme" language="US" store="602" contenteditable="true"><xref ref-type="scheme" language="UK" store="603" contenteditable="true">monotherapy</xref></xref> group, but the duration of the hyperthyroid phase did not differ between <xref ref-type="scheme" language="US" store="604" contenteditable="true"><xref ref-type="scheme" language="UK" store="605" contenteditable="true">monotherapy</xref></xref> and combination therapy patients (<span class="del cts-1" data-cid="8" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367913520" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="false" style="display: inline;">p</span><span class="ins cts-1" data-cid="9" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367913559" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="true"><i data-time="1584367914000" data-username="Annapoorni Swamynathan" contenteditable="true">P</i></span> = 0.25). The T4 peak was 39.<span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367813000_dfound0_regex_style174" common_tag="1584367813000_ifound0_regex_style174" contenteditable="false" style="display: inline;">3 pmol/L </span><span store="1584367813000_i0" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367813000_ifound0_regex_style174" common_tag="1584367813000_ifound0_regex_style174" contenteditable="true">3 pmol/L </span>(95% CI 32.7<span class="del cts-1" data-cid="225" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430474456" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:04pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="226" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430474565" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:04pm">–</span>45.9 <xref ref-type="scheme" language="US" store="608" contenteditable="true"><xref ref-type="scheme" language="UK" store="609" contenteditable="true">pmol</xref></xref>/L) and lasted 6<span class="del cts-1" data-cid="136" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428396357" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:29pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="137" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428396408" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:29pm">–</span>21 days. All cases were associated with a trough TSH of &lt;0.1 <xref ref-type="scheme" language="US" store="610" contenteditable="true"><xref ref-type="scheme" language="UK" store="611" contenteditable="true">mU</xref></xref>/L. The mean trough T4 seen prior to thyroid replacement in the pooled analysis was 6.<span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367813000_dfound1_regex_style174" common_tag="1584367813000_ifound1_regex_style174" contenteditable="false" style="display: inline;">6 pmol/L </span><span store="1584367813000_i1" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367813000_ifound1_regex_style174" common_tag="1584367813000_ifound1_regex_style174" contenteditable="true">6 pmol/L </span>(95% CI 4.9<span class="del cts-1" data-cid="138" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428405703" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:30pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="139" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428405748" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:30pm">–</span>8.3 <xref ref-type="scheme" language="US" store="614" contenteditable="true"><xref ref-type="scheme" language="UK" store="615" contenteditable="true">pmol</xref></xref>/L)<span class="ins cts-1" data-cid="142" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428433530" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:30pm">,</span> associated with a mean peak TSH of 53.2 <xref ref-type="scheme" language="US" store="616" contenteditable="true"><xref ref-type="scheme" language="UK" store="617" contenteditable="true">mU</xref></xref>/L (95% CI 25.6<span class="del cts-1" data-cid="140" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428413556" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:30pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="141" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428413599" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:30pm">–</span>80.8 <xref ref-type="scheme" language="US" store="618" contenteditable="true"><xref ref-type="scheme" language="UK" store="619" contenteditable="true">mU</xref></xref>/L).<fig fig-type="figure" id="F1" position="float" store="620" contenteditable="true"><label1 store="621" contenteditable="true"><b store="622" contenteditable="true">Figure 1</b></label1><caption1 store="623" contenteditable="true"><p1 store="624" contenteditable="true"> Changes in TSH (Black) and T4 (grey) with the thyroid dysfunction characterised by an initial phase of hyperthyroidism followed by hypothyroidism (HH). (A) Changes in thyroid hormones over time. (B) Pattern of T4 changes from the point of dysfunction in patients receiving monotherapy immunotherapy. (C) Pattern of T4 changes from the point of dysfunction in patients receiving combination immunotherapy with ipilimumab and nivolumab.</p1></caption1><img src="http://78.137.168.31:8080/oxygenxml-web-author/plugins-dispatcher/webdav-server/xmlfiles/docbook/5914/11029/finaloutput/images/ECC_190473_f001.jpg" store="625" contenteditable="false"/></fig></pp1><pp1 store="626" contenteditable="true">The second pattern of thyroid dysfunction, DN hypothyroidism, did not have a preceding hyperthyroid phase (<xref ref-type="fig" rid="F2" store="627" contenteditable="true">Fig. 2A</xref> and <xref ref-type="fig" rid="F2" store="628" contenteditable="true">B</xref>). However, there were two patients who had TSH levels &lt;0.3 <xref ref-type="scheme" language="US" store="629" contenteditable="true"><xref ref-type="scheme" language="UK" store="630" contenteditable="true">mU</xref></xref>/L but with normal T3/T4 during therapy. TSH levels were within the normal range (4.38 <xref ref-type="scheme" language="US" store="631" contenteditable="true"><xref ref-type="scheme" language="UK" store="632" contenteditable="true">mU</xref></xref>/L; 3.63 <xref ref-type="scheme" language="US" store="633" contenteditable="true"><xref ref-type="scheme" language="UK" store="634" contenteditable="true">mU</xref></xref>/L) at baseline in these two patients. All patients with DN hypothyroidism were asymptomatic prior to the detection of the hypothyroid state, apart from grade 1 fatigue in <span class="del cts-1" data-cid="143" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428765661" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:36pm" contenteditable="false" style="display: inline;">4</span><span class="ins cts-1" data-cid="144" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428765702" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:36pm">four</span> patients. The median time to development of thyroid dysfunction after <xref ref-type="scheme" language="US" store="635" contenteditable="true"><xref ref-type="scheme" language="UK" store="636" contenteditable="true">monotherapy</xref></xref> ICI was <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound4_regex_style51" common_tag="1584367806000_ifound4_regex_style51" contenteditable="false" style="display: inline;">12 weeks </span><span store="1584367806000_i4" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound4_regex_style51" common_tag="1584367806000_ifound4_regex_style51" contenteditable="true">12 weeks </span>(range 6<span class="del cts-1" data-cid="148" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428771324" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:36pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="149" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428771367" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:36pm">–</span>18 weeks; IQR 6 weeks). The trough T4 prior to commencement of levothyroxine was 4.<span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367813000_dfound2_regex_style174" common_tag="1584367813000_ifound2_regex_style174" contenteditable="false" style="display: inline;">45 pmol/L </span><span store="1584367813000_i2" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367813000_ifound2_regex_style174" common_tag="1584367813000_ifound2_regex_style174" contenteditable="true">45 pmol/L </span>(95% CI 0.4<span class="del cts-1" data-cid="150" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428776719" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:36pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="151" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428776760" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:36pm">–</span>8.5 <xref ref-type="scheme" language="US" store="639" contenteditable="true"><xref ref-type="scheme" language="UK" store="640" contenteditable="true">pmol</xref></xref>/L)<span class="ins cts-1" data-cid="152" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428779373" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:36pm">,</span> with an associated peak TSH of 69.0 <xref ref-type="scheme" language="US" store="641" contenteditable="true"><xref ref-type="scheme" language="UK" store="642" contenteditable="true">mU</xref></xref>/L (95% CI 44.7<span class="del cts-1" data-cid="153" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428782333" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:36pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="154" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584428782378" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:36pm">–</span>93.2 <xref ref-type="scheme" language="US" store="643" contenteditable="true"><xref ref-type="scheme" language="UK" store="644" contenteditable="true">mU</xref></xref>/L).<fig fig-type="figure" id="F2" position="float" store="645" contenteditable="true"><label1 store="646" contenteditable="true"><b store="647" contenteditable="true">Figure 2</b></label1><caption1 store="648" contenteditable="true"><p1 store="649" contenteditable="true"> Changes of TSH (Black) and T4 (grey) changes with the <i contenteditable="true">de nov<span class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367670000" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:37pm" contenteditable="true">o</span></i> (DN) pattern of thyroid dysfunction. (A) Changes in thyroid hormones over time. (B) Pattern of T4 changes from the point of dysfunction in patients receiving monotherapy immunotherapy.</p1></caption1><img src="http://78.137.168.31:8080/oxygenxml-web-author/plugins-dispatcher/webdav-server/xmlfiles/docbook/5914/11029/finaloutput/images/ECC_190473_f002.jpg" store="650" contenteditable="false"/></fig></pp1><pp1 store="651" contenteditable="true">Only one patient developed clinical symptoms and had the highest observed T4 (T4 60 <xref ref-type="scheme" language="US" store="652" contenteditable="true"><xref ref-type="scheme" language="UK" store="653" contenteditable="true">pmol</xref></xref>/L) level<span class="del cts-1" data-cid="155" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429029666" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:40pm" contenteditable="false" style="display: inline;">,</span> and was the only patient to require symptomatic treatment with β-blockade. None of the other patients displayed any classic clinical symptoms of either hyper- or hypo<span class="del cts-1" data-cid="156" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429047426" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:40pm" contenteditable="false" style="display: inline;">- </span>thyroid dysfunction. Clinical examination did not reveal any signs of thyroid disease including <xref ref-type="scheme" language="US" store="654" contenteditable="true">goitre</xref>, exophthalmos, pretibial <xref ref-type="scheme" language="US" store="655" contenteditable="true">myxoedema</xref> or proximal myopathy.</pp1><pp1 store="656" contenteditable="true">The hyperthyroid phase in HH spontaneously terminated in all patients without pharmacological intervention with <xref ref-type="scheme" language="US" store="657" contenteditable="true"><xref ref-type="scheme" language="UK" store="658" contenteditable="true">thioamides</xref></xref>. Patients were monitored for resolution of their thyroid function<span class="ins cts-1" data-cid="157" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429078998" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:41pm">,</span> but no recovery was seen. All patients required long-term levothyroxine replacement. Following the management of thyroid dysfunction, all patients continued with ICI immunotherapy. However, thyroid dysfunction did result in a treatment break with ICIs, the longest of which was for <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound5_regex_style51" common_tag="1584367806000_ifound5_regex_style51" contenteditable="false" style="display: inline;">20 weeks </span><span store="1584367806000_i5" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound5_regex_style51" common_tag="1584367806000_ifound5_regex_style51" contenteditable="true">20 weeks </span>(mean 2; range 0<span class="del cts-1" data-cid="158" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429091777" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:41pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="159" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429091822" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:41pm">–</span>20).</pp1></sec><sec sec-type="H2" store="659" contenteditable="true"><title1 title="H2" store="660" contenteditable="true">Associations with thyroid dysfunction</title1><sec sec-type="H3" store="661" contenteditable="true"><title1 title="H3" store="662" contenteditable="true">Gender</title1><pp1 store="663" contenteditable="true">Females were more commonly affected than males, with 11/16 being women (<span class="del cts-1" data-cid="10" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367916728" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="false" style="display: inline;">p</span><span class="ins cts-1" data-cid="11" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367916775" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:41pm" contenteditable="true"><i data-time="1584367919000" data-username="Annapoorni Swamynathan" contenteditable="true">P</i></span> = 0.04)<span class="ins cts-1" data-cid="160" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429100896" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:41pm">,</span> but most notably all patients developing DN hypothyroidism without a preceding hyperthyroid phase were female in this series. Of note<span class="ins cts-1" data-cid="161" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429117429" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:41pm">,</span> within the total treated population<span class="ins cts-1" data-cid="162" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429120768" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:42pm">,</span> 57/103 were male and 46/103 were female<span class="ins cts-1" data-cid="163" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429142508" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:42pm">,</span> thus the female predominance of thyroid dysfunction did not reflect the gender split of the treated population overall.</pp1></sec><sec sec-type="H3" store="664" contenteditable="true"><title1 title="H3" store="665" contenteditable="true">Pre-treatment TSH levels</title1><pp1 store="666" contenteditable="true">The pre-treatment mean TSH level in the DN group (5.77 <xref ref-type="scheme" language="US" store="667" contenteditable="true"><xref ref-type="scheme" language="UK" store="668" contenteditable="true">mU</xref></xref>/L; 95% CI 2.45<span class="del cts-1" data-cid="164" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429164297" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:42pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="165" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429164358" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:42pm">–</span>9.09 <xref ref-type="scheme" language="US" store="669" contenteditable="true"><xref ref-type="scheme" language="UK" store="670" contenteditable="true">mU</xref></xref>/L) was higher (<span class="del cts-1" data-cid="12" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367921694" title="Deleted by Annapoorni Swamynathan - 03/16/2020 7:42pm" contenteditable="false" style="display: inline;">p</span><span class="ins cts-1" data-cid="13" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367921733" title="Inserted by Annapoorni Swamynathan - 03/16/2020 7:42pm" contenteditable="true"><i data-time="1584367922000" data-username="Annapoorni Swamynathan" contenteditable="true">P</i></span> = 0.009) than in the HH group (2.49 <xref ref-type="scheme" language="US" store="671" contenteditable="true"><xref ref-type="scheme" language="UK" store="672" contenteditable="true">mU</xref></xref>/L; 95% CI 1.78<span class="del cts-1" data-cid="166" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429169070" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:42pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="167" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429169115" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:42pm">–</span>3.22 <xref ref-type="scheme" language="US" store="673" contenteditable="true"><xref ref-type="scheme" language="UK" store="674" contenteditable="true">mU</xref></xref>/L) (Supplementary Fig. 1). Patients with a known diagnosis of thyroid dysfunction were excluded from evaluation but we did include patients (<i data-time="1584367892000" data-username="Annapoorni Swamynathan" contenteditable="true">n</i> = 2) with sub-clinically elevated TSH levels at baseline. Both of these patients went on to develop DN hypothyroidism without a hyperthyroid phase. It is unclear as to whether these patients would have gone on to develop clinical hypothyroidism with depressed T3/T4 levels in the absence of checkpoint blockade. All the patients included in this analysis had normal T4/T3 levels at baseline prior to treatment with immunotherapy.</pp1></sec><sec sec-type="H3" store="675" contenteditable="true"><title1 title="H3" store="676" contenteditable="true">Thyroid autoantibodies</title1><pp1 store="677" contenteditable="true">Of the 16 patients identified to have thyroid dysfunction, 12 had thyroid autoantibodies assessed. Five out of the 12 were found to have positive thyroid antibodies (anti-TPO, anti-<xref ref-type="scheme" language="US" store="678" contenteditable="true"><xref ref-type="scheme" language="UK" store="679" contenteditable="true">Tg</xref></xref> and anti-<xref ref-type="scheme" language="US" store="680" contenteditable="true"><xref ref-type="scheme" language="UK" store="681" contenteditable="true">TRAb</xref></xref>). One patient developed HH on <xref ref-type="scheme" language="US" store="682" contenteditable="true"><xref ref-type="scheme" language="UK" store="683" contenteditable="true">pembrolizumab</xref></xref> <xref ref-type="scheme" language="US" store="684" contenteditable="true"><xref ref-type="scheme" language="UK" store="685" contenteditable="true">monotherapy</xref></xref> and had a positive anti-TPO <xref ref-type="scheme" language="US" store="686" contenteditable="true">titre</xref> of 60.43 IU/<xref ref-type="scheme" language="US" store="687" contenteditable="true"><xref ref-type="scheme" language="UK" store="688" contenteditable="true">mL.</xref></xref> A second patient developed HH on combination immunotherapy and had a positive anti-TPO <xref ref-type="scheme" language="US" store="689" contenteditable="true">titre</xref> of 505 IU/mL and was anti-<xref ref-type="scheme" language="US" store="690" contenteditable="true"><xref ref-type="scheme" language="UK" store="691" contenteditable="true">Tg</xref></xref> Elisa positive with a concentration of 275.12 U/<xref ref-type="scheme" language="US" store="692" contenteditable="true"><xref ref-type="scheme" language="UK" store="693" contenteditable="true">mL.</xref></xref> A third patient who developed DN on <xref ref-type="scheme" language="US" store="694" contenteditable="true"><xref ref-type="scheme" language="UK" store="695" contenteditable="true">pembrolizumab</xref></xref> <xref ref-type="scheme" language="US" store="696" contenteditable="true"><xref ref-type="scheme" language="UK" store="697" contenteditable="true">monotherapy</xref></xref> had a positive anti-TPO <xref ref-type="scheme" language="US" store="698" contenteditable="true">titre</xref> of 183 IU/mL and a <xref ref-type="scheme" language="US" store="699" contenteditable="true"><xref ref-type="scheme" language="UK" store="700" contenteditable="true">TRAb</xref></xref> <xref ref-type="scheme" language="US" store="701" contenteditable="true">titre</xref> of 3.5 U/L despite being hypothyroid and requiring levothyroxine. A further two patients who both developed the HH pattern of dysfunction, one receiving <xref ref-type="scheme" language="US" store="702" contenteditable="true"><xref ref-type="scheme" language="UK" store="703" contenteditable="true">pembrolizumab</xref></xref> <xref ref-type="scheme" language="US" store="704" contenteditable="true"><xref ref-type="scheme" language="UK" store="705" contenteditable="true">monotherapy</xref></xref> and the other combination ICI, had positive anti-<xref ref-type="scheme" language="US" store="706" contenteditable="true"><xref ref-type="scheme" language="UK" store="707" contenteditable="true">Tg</xref></xref> antibodies with <xref ref-type="scheme" language="US" store="708" contenteditable="true">titres</xref> of 208.43 U/mL and 117.95 U/mL<span class="ins cts-1" data-cid="168" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429256451" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:44pm">,</span> respectively. <xref ref-type="scheme" language="US" store="709" contenteditable="true"><xref ref-type="scheme" language="UK" store="710" contenteditable="true">TRAb</xref></xref> and anti-TPO antibodies were not detected in these patients. The remaining <span class="del cts-1" data-cid="169" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429263312" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:44pm" contenteditable="false" style="display: inline;">7</span><span class="ins cts-1" data-cid="170" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429263356" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:44pm">seven</span> patients had negative <xref ref-type="scheme" language="US" store="711" contenteditable="true"><xref ref-type="scheme" language="UK" store="712" contenteditable="true">TRAb</xref></xref>, anti-TPO and anti-<xref ref-type="scheme" language="US" store="713" contenteditable="true"><xref ref-type="scheme" language="UK" store="714" contenteditable="true">Tg</xref></xref> antibodies. There was no correlation with the clinical pattern.</pp1></sec></sec></sec><sec sec-type="H1" store="715" contenteditable="true"><title1 title="H1" store="716" contenteditable="true">Discussion</title1><pp1 store="717" contenteditable="true"><query data-time="1584429615000" data-username="Annapoorni Swamynathan" id="1584429596000" title="AQ: Please check the edit made to the sentence &amp;#x0022;In this report of patients with metastatic malignant melanoma receiving...&amp;#x0022; and amend if necessary." contenteditable="false" class="fa fa-question-circle fa-1x" style="color: red; display: inline-block;" onclick="addQueryText(1584429596000);"></query>In this report of patients with metastatic malignant melanoma receiving ICI therapy, we have undertaken longitudinal <xref ref-type="scheme" language="US" store="718" contenteditable="true">characterisation</xref> of patients who developed thyroid dysfunction<span class="del cts-1" data-cid="175" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429298670" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:44pm" contenteditable="false" style="display: inline;">,</span> and show<span class="ins cts-1" data-cid="176" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429578024" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:49pm">n</span> two clinical patterns of thyroid dysfunction: hyperthyroidism followed by hypothyroidism and <i data-time="1584367675000" data-username="Annapoorni Swamynathan" contenteditable="true">de novo</i> development of hypothyroidism. We also showed an association with gender and variable presence of autoantibodies. A recent systematic review of 38 <xref ref-type="scheme" language="US" store="719" contenteditable="true">randomised</xref> clinical trials showed that the risk of thyroid dysfunction was highest with combination therapy, followed by PD1 inhibitors (<xref ref-type="bibr" rid="CIT00016" title="16. Barroso-SousaRBarryWTGarrido-CastroACHodiFSMinLKropIETolaneySM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncology 2018 4 173–182. (https://doi.org/10.1001/jamaoncol.2017.3064)" store="720" contenteditable="true">16</xref>). Our analysis shows that the time to onset may also be shorter with combination therapy when compared with <xref ref-type="scheme" language="US" store="721" contenteditable="true"><xref ref-type="scheme" language="UK" store="722" contenteditable="true">monotherapy</xref></xref>. The time to onset with <xref ref-type="scheme" language="US" store="723" contenteditable="true"><xref ref-type="scheme" language="UK" store="724" contenteditable="true">monotherapy</xref></xref> varies with the longest time interval to onset being <span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_dfound6_regex_style51" common_tag="1584367806000_ifound6_regex_style51" contenteditable="false" style="display: inline;">27 weeks </span><span store="1584367806000_i6" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367806000_ifound6_regex_style51" common_tag="1584367806000_ifound6_regex_style51" contenteditable="true">27 weeks </span>within our patient cohort. This highlights the need for continued vigilance throughout the treatment course. Whil<span class="del cts-1" data-cid="45" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427454306" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:14pm" contenteditable="false" style="display: inline;">st</span><span class="ins cts-1" data-cid="46" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427454348" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:14pm">e</span> in clinical trials (Supplementary Table 1) the predominant pattern of toxicity was hyperthyroidism transient thyroiditis has been previously identified (<xref ref-type="bibr" rid="CIT00013 CIT00017" store="725" contenteditable="true">13, 17</xref>)<span class="ins cts-1" data-cid="179" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429820712" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:53pm">;</span> however<span class="ins cts-1" data-cid="180" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429822893" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:53pm">,</span> with regular patient sampling throughout treatment with ICIs<span class="ins cts-1" data-cid="181" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429832231" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:53pm">,</span> we have illustrated that the majority of patients actually experience the transient hyperthyroidism with the HH pattern, with only a minority of patients developing DN hypothyroidism as the initial manifestation of thyroid toxicity.</pp1><pp1 store="726" contenteditable="true">Whil<span class="del cts-1" data-cid="47" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427458051" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:14pm" contenteditable="false" style="display: inline;">st</span><span class="ins cts-1" data-cid="48" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427458092" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:14pm">e</span> the effector mechanisms responsible for the efficacy of ICIs are becoming better understood, the pathophysiological mechanisms underlying <xref ref-type="scheme" language="US" store="727" contenteditable="true"><xref ref-type="scheme" language="UK" store="728" contenteditable="true">irAEs</xref></xref> remain to be fully <xref ref-type="scheme" language="US" store="729" contenteditable="true">characterised</xref>. Previous data has shown that the <xref ref-type="scheme" language="US" store="730" contenteditable="true"><xref ref-type="scheme" language="UK" store="731" contenteditable="true">thyrotoxic</xref></xref> pattern is associated with increased <sup store="732" contenteditable="true">18</sup>FDG uptake compatible with an inflammatory process (<xref ref-type="bibr" rid="CIT00018" title="18. de FiletteJJansenYSchreuerMEveraertHVelkeniersBNeynsBBravenboerB. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. Journal of Clinical Endocrinology and Metabolism 2016 101 4431–4439. (https://doi.org/10.1210/jc.2016-2300)" store="733" contenteditable="true">18</xref>). It is possible that the threshold for developing autoimmune thyroid disease (AITD) varies in the population<span class="del cts-1" data-cid="182" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429867291" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:54pm" contenteditable="false" style="display: inline;">,</span> and <span class="ins cts-1" data-cid="183" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429870019" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:54pm">that </span>the use of ICIs lowers the threshold further allowing those who are most susceptible to develop thyroid dysfunction while undergoing therapy. Consistent with this, there is considerable similarity between the thyroid dysfunction associated with ICI use and painless thyroiditis (PT), a subtype of AITD (<xref ref-type="bibr" rid="CIT00019 CIT00020" store="734" contenteditable="true">19, 20</xref>). The presentation can be variable; approximately 30% of patients manifest a <xref ref-type="scheme" language="US" store="735" contenteditable="true"><xref ref-type="scheme" language="UK" store="736" contenteditable="true">triphasic</xref></xref> pattern (hyper- followed by hypo-<span class="del cts-1" data-cid="188" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429894940" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:54pm" contenteditable="false" style="display: inline;">,</span> and then <xref ref-type="scheme" language="US" store="737" contenteditable="true"><xref ref-type="scheme" language="UK" store="738" contenteditable="true">euthyroidism</xref></xref>), while the remaining 70% manifest either the hyper- or hypo- phases in isolation prior to a return to <xref ref-type="scheme" language="US" store="739" contenteditable="true"><xref ref-type="scheme" language="UK" store="740" contenteditable="true">euthyroidism</xref></xref> (<xref ref-type="bibr" rid="CIT00021 CIT00022" store="741" contenteditable="true">21, 22</xref>). In our patients, we did not see a return to <xref ref-type="scheme" language="US" store="742" contenteditable="true"><xref ref-type="scheme" language="UK" store="743" contenteditable="true">euthyroidism</xref></xref>, although that has been reported to occur in a minority of patients (<xref ref-type="bibr" rid="CIT00023" title="23. ScottESLongGVGuminskiAClifton-BlighRJMenziesAMTsangVH. The spectrum, incidence, kinetics, and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European Journal of Endocrinology 2018 178 173–180. (https://doi.org/10.1530/EJE-17-0810)" store="744" contenteditable="true">23</xref>). The higher risk in women in our patients is consistent with the gender difference seen in painless thyroiditis. Whil<span class="del cts-1" data-cid="49" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427462206" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:14pm" contenteditable="false" style="display: inline;">st</span><span class="ins cts-1" data-cid="50" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427462250" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:14pm">e</span> baseline TSH does not appear predictive for ICI<span class="del cts-1" data-cid="67" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427665392" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:17pm" contenteditable="false" style="display: inline;"> </span><span class="ins cts-1" data-cid="68" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584427665433" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:17pm">-</span>induced thyroid dysfunction (<xref ref-type="bibr" rid="CIT00012" title="12. MorgansteinDLLaiZSpainLDiemSLevineDMaceCGoreMLarkinJ. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clinical Endocrinology 2017 86 614–620. (https://doi.org/10.1111/cen.13297)" store="745" contenteditable="true">12</xref>)<span class="ins cts-1" data-cid="192" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429974204" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:56pm">,</span> it may be indicative of which pattern of dysfunction occurs<span class="ins cts-1" data-cid="193" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429976314" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:56pm">,</span> since those who developed DN in our series had significantly higher baseline TSH levels than those with the HH pattern. This suggests that some patients may have subclinical thyroid dysfunction at baseline which is then exacerbated by ICI therapy. Although we observed this in <span class="del cts-1" data-cid="194" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429992069" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:56pm" contenteditable="false" style="display: inline;">2</span><span class="ins cts-1" data-cid="195" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584429992119" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:56pm">two</span> patients (50%), we acknowledge that our sample size is small, and further studies to determine whether baseline TSH levels are truly predictive will need to be prospectively evaluated in a larger patient population. It is likely that both HH and DN patterns of thyroid dysfunction result from a degree of thyroiditis with glandular destruction<span class="ins cts-1" data-cid="198" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430009521" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:56pm">;</span> however<span class="ins cts-1" data-cid="199" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430012059" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:56pm">,</span> within the DN cohort<span class="ins cts-1" data-cid="200" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430015694" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:56pm">,</span> the degree of inflammation does not appear to lead to significant <xref ref-type="scheme" language="US" store="746" contenteditable="true"><xref ref-type="scheme" language="UK" store="747" contenteditable="true">thyroxine</xref></xref> discharge. The reasons for this are unclear at this stage but may be due to existing subclinical glandular insufficiency, lower absolute levels of inflammation or different inflammatory mediators.</pp1><pp1 store="748" contenteditable="true">In painless thyroiditis, it is known that patients have very high levels of anti-TPO antibodies (<xref ref-type="bibr" rid="CIT00019" title="19. FaridNRHaweBSWalfishPG. Increased frequency of HLA-DR3 and 5 in the syndromes of painless thyroiditis with transient thyrotoxicosis: evidence for an autoimmune aetiology. Clinical Endocrinology 1983 19 699–704. (https://doi.org/10.1111/j.1365-2265.1983.tb00047.x)" store="749" contenteditable="true">19</xref>). By contrast, we did not find a consistent pattern of thyroid autoantibodies in the patients on ICI with thyroid dysfunction. While Osorio<span class="del cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367744000_dfound0_regex_style882" common_tag="1584367744000_ifound0_regex_style882" contenteditable="false" style="display: inline;"> et al </span><span store="1584367744000_i0" class="ins cts-1" data-cid="2" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584367744000_ifound0_regex_style882" common_tag="1584367744000_ifound0_regex_style882" contenteditable="true"><i data-time="1584367791000" data-username="Annapoorni Swamynathan" contenteditable="true"> et al</i>. </span>found that 8/10 patients in their cohort had positive thyroid autoantibodies (<xref ref-type="bibr" rid="CIT00013" title="13. OsorioJCNiAChaftJEPollinaRKaslerMKStephensDRodriguezCCambridgeLRizviHWolchokJD, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of Oncology 2017 28 583–589. (https://doi.org/10.1093/annonc/mdw640)" store="750" contenteditable="true">13</xref>), this has been less clear in other studies (<xref ref-type="bibr" rid="CIT00012 CIT00017" store="751" contenteditable="true">12, 17</xref>). Our case series reinforces the fact that the mechanism of thyroid dysfunction is not clearly related to autoantibodies<span class="del cts-1" data-cid="201" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430054473" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:57pm" contenteditable="false" style="display: inline;">,</span> and alternative, probably cellular-mediated mechanisms may be responsible. It is possible that the presence of autoantibodies is more likely to be a secondary effect of thyroid destruction, possibly by T cells, although this will need further study using tissue sections.</pp1><pp1 store="752" contenteditable="true">In conclusion, we have <xref ref-type="scheme" language="US" store="753" contenteditable="true">characterised</xref> the course of patients who developed thyroid dysfunction after receiving ICIs either as <xref ref-type="scheme" language="US" store="754" contenteditable="true"><xref ref-type="scheme" language="UK" store="755" contenteditable="true">monotherapy</xref></xref> or in combination. Despite the limitation of this study being a single <xref ref-type="scheme" language="US" store="756" contenteditable="true">centre</xref>, retrospective review of a small number of patients, there was robust and <xref ref-type="scheme" language="US" store="757" contenteditable="true">standardised</xref> measurement of biochemical thyroid function allowing consistent <xref ref-type="scheme" language="US" store="758" contenteditable="true">characterisation</xref>. This illustrates that, unlike the apparent clinical picture reported in clinical trials (<xref ref-type="bibr" rid="CIT00001 CIT00002 CIT00003 CIT00004 CIT00005 CIT00006 CIT00007 CIT00008 CIT00009 CIT00010" store="759" contenteditable="true">1, 2, 3, 4, 5, 6, 7, 8, 9, 10</xref>), the majority of patients develop a preceding hyperthyroidism prior to the hypothyroid phase. <query data-time="1584430156000" data-username="Annapoorni Swamynathan" id="1584430142000" title="AQ: Please check the edit made to the sentence &amp;#x0022;The levels of T4 can be significant but, despite this, treatment other...&amp;#x0022; and amend if necessary." contenteditable="false" class="fa fa-question-circle fa-1x" style="color: red; display: inline-block;" onclick="addQueryText(1584430142000);"></query>The levels of T4 can be significant but<span class="ins cts-1" data-cid="202" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430126689" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:58pm">,</span> despite this, treatment other than β-blockade for symptomatic control<span class="del cts-1" data-cid="203" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430129791" title="Deleted by Annapoorni Swamynathan - 03/17/2020 12:58pm" contenteditable="false" style="display: inline;">,</span> is not required. The hyperthyroid phase predictably self terminates with loss of thyroid capability. Furthermore, the natural course of the thyroid dysfunction seems to be permanent. Larger, <xref ref-type="scheme" language="US" store="760" contenteditable="true">multicentre</xref> studies are needed to further validate these findings. Irrespective of further studies, it seems clear that patients should be monitored for thyroid dysfunction throughout their course of therapy because of the variable temporal relationship<span class="ins cts-1" data-cid="204" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430176301" title="Inserted by Annapoorni Swamynathan - 03/17/2020 12:59pm">,</span> so that symptomatic management of the hyperthyroid phase and timely institution of hormone replacement in the hypothyroid phase can be achieved<span class="ins cts-1" data-cid="205" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430202933" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:00pm">,</span> <xref ref-type="scheme" language="US" store="761" contenteditable="true">optimising</xref> symptomatic management and limiting the patient impact of thyroid <xref ref-type="scheme" language="US" store="762" contenteditable="true"><xref ref-type="scheme" language="UK" store="763" contenteditable="true">irAEs</xref></xref>.</pp1><sec sec-type="H4" store="764" contenteditable="true"><title1 title="H4" store="765" contenteditable="true">Supplementary materials</title1><pp1 store="766" contenteditable="true">This is linked to the online version of the paper at <uri xlinkhref="https://doi.org/10.1530/EC-19-0473" store="767" contenteditable="true">https://doi.org/10.1530/EC-19-0473</uri>.</pp1></sec><sec sec-type="H4" store="768" contenteditable="true"><title1 title="H4" store="769" contenteditable="true">Declaration of interest</title1><pp1 store="770" contenteditable="true"><xref ref-type="scheme" language="US" store="771" contenteditable="true"><query data-time="1584430408000" data-username="Annapoorni Swamynathan" id="1584430379000" title="AQ: Please check the edits made to the &amp;#x0022;Declaration of interest&amp;#x0022; section and amend if necessary." contenteditable="false" class="fa fa-question-circle fa-1x" style="color: red; display: inline-block;" onclick="addQueryText(1584430379000);"></query>Dr</xref> Rosemary Lord has received honoraria from <xref ref-type="scheme" language="US" store="772" contenteditable="true"><xref ref-type="scheme" language="UK" store="773" contenteditable="true">Tezzaro</xref></xref> and AstraZeneca. <xref ref-type="scheme" language="US" store="774" contenteditable="true">Dr</xref> Joseph Sacco has received honoraria for speaking at educational events from Bristol-Myers<span class="del cts-1" data-cid="206" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430230560" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:00pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="207" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430230616" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:00pm"> </span>Squibb. He has received honoraria for attending Bristol-Myers<span class="del cts-1" data-cid="208" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430247387" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:00pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="209" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430247437" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:00pm"> </span>Squibb, <xref ref-type="scheme" language="US" store="775" contenteditable="true"><xref ref-type="scheme" language="UK" store="776" contenteditable="true">Immunocore</xref></xref> and Pierre Fabre advisory boards. <xref ref-type="scheme" language="US" store="777" contenteditable="true">Dr</xref> Jonathan Wagg is an employee of Roche <xref ref-type="scheme" language="US" store="778" contenteditable="true"><xref ref-type="scheme" language="UK" store="779" contenteditable="true">Pharma</xref></xref> and holds shares in the company. Prof Mark Coles has received educational honoraria from Roche <xref ref-type="scheme" language="US" store="780" contenteditable="true"><xref ref-type="scheme" language="UK" store="781" contenteditable="true">Pharma<span class="ins cts-1" data-cid="214" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430276369" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:01pm">.</span></xref></xref> Prof Sir <xref ref-type="scheme" language="US" store="782" contenteditable="true"><xref ref-type="scheme" language="UK" store="783" contenteditable="true">Pirmohamed</xref></xref> is the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics fellowship scheme leader. Prof Mark Coles has received educational honoraria from Roche <xref ref-type="scheme" language="US" store="784" contenteditable="true"><xref ref-type="scheme" language="UK" store="785" contenteditable="true">Pharma</xref></xref>.</pp1></sec><sec sec-type="H4" store="786" contenteditable="true"><title1 title="H4" store="787" contenteditable="true">Funding</title1><pp1 store="788" contenteditable="true"><query data-time="1584430426000" data-username="Annapoorni Swamynathan" id="1584430412000" title="AQ: Please check the edits made to the &amp;#x0022;Funding&amp;#x0022; section and amend if necessary." contenteditable="false" class="fa fa-question-circle fa-1x" style="color: red; display: inline-block;" onclick="addQueryText(1584430412000);"></query>Anna Olsson-Brown is an MRC <span class="del cts-1" data-cid="215" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430350479" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:02pm" contenteditable="false" style="display: inline;">C</span><span class="ins cts-1" data-cid="216" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430350531" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:02pm">c</span>linical <span class="del cts-1" data-cid="217" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430352910" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:02pm" contenteditable="false" style="display: inline;">T</span><span class="ins cts-1" data-cid="218" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430352961" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:02pm">t</span>raining <span class="del cts-1" data-cid="219" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430355602" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:02pm" contenteditable="false" style="display: inline;">F</span><span class="ins cts-1" data-cid="220" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430355654" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:02pm">f</span>ellow based at the University of Liverpool supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council (Award Ref. MR/N025989/1), Roche <xref ref-type="scheme" language="US" store="789" contenteditable="true"><xref ref-type="scheme" language="UK" store="790" contenteditable="true">Pharma</xref></xref>, Eli Lilly and Company Limited, UCB <xref ref-type="scheme" language="US" store="791" contenteditable="true"><xref ref-type="scheme" language="UK" store="792" contenteditable="true">Pharma</xref></xref>, Novartis, the University of Liverpool and the University of Manchester. She has received honoraria for speaking at educational events from Roche <xref ref-type="scheme" language="US" store="793" contenteditable="true"><xref ref-type="scheme" language="UK" store="794" contenteditable="true">Pharma</xref></xref>, Bristol-Myers<span class="del cts-1" data-cid="221" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430370184" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:02pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="222" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430370237" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:02pm"> </span>Squibb and MSD. She has received honoraria for attending Bristol-Myers<span class="del cts-1" data-cid="223" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430374168" title="Deleted by Annapoorni Swamynathan - 03/17/2020 1:02pm" contenteditable="false" style="display: inline;">-</span><span class="ins cts-1" data-cid="224" data-userid="11" data-username="Annapoorni Swamynathan" data-time="1584430374219" title="Inserted by Annapoorni Swamynathan - 03/17/2020 1:02pm"> </span>Squibb advisory boards.</pp1></sec></sec></body1><back store="795" contenteditable="true"><ref-list store="796" contenteditable="true"><title1 store="797" contenteditable="true">Referen<query title="We have been unable to find the DOI for these references; please provide if possible." data-time="1584108455" data-username="Editor" id="6" contenteditable="false" changetime="13/03/2020 19:37:29" store="798"><i class="fa fa-question-circle fa-1x fa-1x" style="color:red;" onclick="addQueryText(6);" contenteditable="true" store="799"></i></query>ces</title1><ref id="CIT00001" store="800" contenteditable="true"><label1 store="801" contenteditable="true">1. </label1><mixed-citation publication-type="journal" store="802" contenteditable="true"><person-group person-group-type="author" store="803" contenteditable="true"><name store="804" contenteditable="true"><surname store="805" contenteditable="true">Larkin</surname><!--punc--> <!--punc--><given-names store="806" contenteditable="true">J</given-names></name><!--punc-->, <!--punc--><name store="807" contenteditable="true"><surname store="808" contenteditable="true">Chiarion-Sileni</surname><!--punc--> <!--punc--><given-names store="809" contenteditable="true">V</given-names></name><!--punc-->, <!--punc--><name store="810" contenteditable="true"><surname store="811" contenteditable="true">Gonzalez</surname><!--punc--> <!--punc--><given-names store="812" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="813" contenteditable="true"><surname store="814" contenteditable="true">Grob</surname><!--punc--> <!--punc--><given-names store="815" contenteditable="true">JJ</given-names></name><!--punc-->, <!--punc--><name store="816" contenteditable="true"><surname store="817" contenteditable="true">Cowey</surname><!--punc--> <!--punc--><given-names store="818" contenteditable="true">CL</given-names></name><!--punc-->, <!--punc--><name store="819" contenteditable="true"><surname store="820" contenteditable="true">Lao</surname><!--punc--> <!--punc--><given-names store="821" contenteditable="true">CD</given-names></name><!--punc-->, <!--punc--><name store="822" contenteditable="true"><surname store="823" contenteditable="true">Schadendorf</surname><!--punc--> <!--punc--><given-names store="824" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="825" contenteditable="true"><surname store="826" contenteditable="true">Dummer</surname><!--punc--> <!--punc--><given-names store="827" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="828" contenteditable="true"><surname store="829" contenteditable="true">Smylie</surname><!--punc--> <!--punc--><given-names store="830" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="831" contenteditable="true"><surname store="832" contenteditable="true">Rutkowski</surname><!--punc--> <!--punc--><given-names store="833" contenteditable="true" style="" class="">P</given-names></name></person-group><delimiter store="834" contenteditable="true">, </delimiter><i store="835" contenteditable="true">et al</i><delimiter store="836" contenteditable="true">. </delimiter><article-title store="837" contenteditable="true">Combined nivolumab and ipilimumab or monotherapy in untreated melanoma</article-title><delimiter store="838" contenteditable="true">. </delimiter><source1 store="839" contenteditable="true"><i store="840" contenteditable="true">New England Journal of Medicine</i></source1><delimiter store="841" contenteditable="true"> </delimiter><year store="842" contenteditable="true">2015</year><delimiter store="843" contenteditable="true"> </delimiter><volume1 store="844" contenteditable="true"><!--punc--><b store="845" contenteditable="true"><!--punc-->373<!--punc--></b><!--punc--></volume1><delimiter store="846" contenteditable="true"> </delimiter><fpage1 store="847" contenteditable="true">23</fpage1><delimiter store="848" contenteditable="true">–</delimiter><lpage1 store="849" contenteditable="true">34</lpage1><delimiter store="850" contenteditable="true">. </delimiter><pub-id store="851" contenteditable="true">(https://doi.org/10.1056/NEJMoa1504030)</pub-id></mixed-citation></ref><ref id="CIT00002" store="852" contenteditable="true"><label1 store="853" contenteditable="true">2. </label1><mixed-citation publication-type="journal" store="854" contenteditable="true"><person-group person-group-type="author" store="855" contenteditable="true"><name store="856" contenteditable="true"><surname store="857" contenteditable="true">Postow</surname><!--punc--> <!--punc--><given-names store="858" contenteditable="true">MA</given-names></name><!--punc-->, <!--punc--><name store="859" contenteditable="true"><surname store="860" contenteditable="true">Chesney</surname><!--punc--> <!--punc--><given-names store="861" contenteditable="true">J</given-names></name><!--punc-->, <!--punc--><name store="862" contenteditable="true"><surname store="863" contenteditable="true">Pavlick</surname><!--punc--> <!--punc--><given-names store="864" contenteditable="true">AC</given-names></name><!--punc-->, <!--punc--><name store="865" contenteditable="true"><surname store="866" contenteditable="true">Robert</surname><!--punc--> <!--punc--><given-names store="867" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="868" contenteditable="true"><surname store="869" contenteditable="true">Grossmann</surname><!--punc--> <!--punc--><given-names store="870" contenteditable="true">K</given-names></name><!--punc-->, <!--punc--><name store="871" contenteditable="true"><surname store="872" contenteditable="true">McDermott</surname><!--punc--> <!--punc--><given-names store="873" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="874" contenteditable="true"><surname store="875" contenteditable="true">Linette</surname><!--punc--> <!--punc--><given-names store="876" contenteditable="true">GP</given-names></name><!--punc-->, <!--punc--><name store="877" contenteditable="true"><surname store="878" contenteditable="true">Meyer</surname><!--punc--> <!--punc--><given-names store="879" contenteditable="true" style="" class="">N</given-names></name><!--punc-->, <!--punc--><name store="880" contenteditable="true"><surname store="881" contenteditable="true">Giguere</surname><!--punc--> <!--punc--><given-names store="882" contenteditable="true">JK</given-names></name><!--punc-->, <!--punc--><name store="883" contenteditable="true"><surname store="884" contenteditable="true">Agarwala</surname><!--punc--> <!--punc--><given-names store="885" contenteditable="true">SS</given-names></name></person-group><delimiter store="886" contenteditable="true">, </delimiter><i store="887" contenteditable="true">et al</i><delimiter store="888" contenteditable="true">. </delimiter><article-title store="889" contenteditable="true">Nivolumab and ipilimumab versus ipilimumab in untreated melanoma</article-title><delimiter store="890" contenteditable="true">. </delimiter><source1 store="891" contenteditable="true"><i store="892" contenteditable="true">New England Journal of Medicine</i></source1><delimiter store="893" contenteditable="true"> </delimiter><year store="894" contenteditable="true">2015</year><delimiter store="895" contenteditable="true"> </delimiter><volume1 store="896" contenteditable="true"><!--punc--><b store="897" contenteditable="true"><!--punc-->372<!--punc--></b><!--punc--></volume1><delimiter store="898" contenteditable="true"> </delimiter><fpage1 store="899" contenteditable="true">2006</fpage1><delimiter store="900" contenteditable="true">–</delimiter><lpage1 store="901" contenteditable="true">2017</lpage1><delimiter store="902" contenteditable="true">. </delimiter><pub-id store="903" contenteditable="true">(https://doi.org/10.1056/NEJMoa1414428)</pub-id></mixed-citation></ref><ref id="CIT00003" store="904" contenteditable="true"><label1 store="905" contenteditable="true">3. </label1><mixed-citation publication-type="journal" store="906" contenteditable="true"><person-group person-group-type="author" store="907" contenteditable="true"><name store="908" contenteditable="true"><surname store="909" contenteditable="true">Robert</surname><!--punc--> <!--punc--><given-names store="910" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="911" contenteditable="true"><surname store="912" contenteditable="true">Long</surname><!--punc--> <!--punc--><given-names store="913" contenteditable="true">GV</given-names></name><!--punc-->, <!--punc--><name store="914" contenteditable="true"><surname store="915" contenteditable="true">Brady</surname><!--punc--> <!--punc--><given-names store="916" contenteditable="true">B</given-names></name><!--punc-->, <!--punc--><name store="917" contenteditable="true"><surname store="918" contenteditable="true">Dutriaux</surname><!--punc--> <!--punc--><given-names store="919" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="920" contenteditable="true"><surname store="921" contenteditable="true">Maio</surname><!--punc--> <!--punc--><given-names store="922" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="923" contenteditable="true"><surname store="924" contenteditable="true">Mortier</surname><!--punc--> <!--punc--><given-names store="925" contenteditable="true">L</given-names></name><!--punc-->, <!--punc--><name store="926" contenteditable="true"><surname store="927" contenteditable="true">Hassel</surname><!--punc--> <!--punc--><given-names store="928" contenteditable="true">JC</given-names></name><!--punc-->, <!--punc--><name store="929" contenteditable="true"><surname store="930" contenteditable="true">Rutkowski</surname><!--punc--> <!--punc--><given-names store="931" contenteditable="true" style="" class="">P</given-names></name><!--punc-->, <!--punc--><name store="932" contenteditable="true"><surname store="933" contenteditable="true">McNeil</surname><!--punc--> <!--punc--><given-names store="934" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="935" contenteditable="true"><surname store="936" contenteditable="true">Kalinka-Warzocha</surname><!--punc--> <!--punc--><given-names store="937" contenteditable="true">E</given-names></name></person-group><delimiter store="938" contenteditable="true">, </delimiter><i store="939" contenteditable="true">et al</i><delimiter store="940" contenteditable="true">. </delimiter><article-title store="941" contenteditable="true">Nivolumab in previously untreated melanoma without BRAF mutation</article-title><delimiter store="942" contenteditable="true">. </delimiter><source1 store="943" contenteditable="true"><i store="944" contenteditable="true">New England Journal of Medicine</i></source1><delimiter store="945" contenteditable="true"> </delimiter><year store="946" contenteditable="true">2015</year><delimiter store="947" contenteditable="true"> </delimiter><volume1 store="948" contenteditable="true"><!--punc--><b store="949" contenteditable="true"><!--punc-->372<!--punc--></b><!--punc--></volume1><delimiter store="950" contenteditable="true"> </delimiter><fpage1 store="951" contenteditable="true">320</fpage1><delimiter store="952" contenteditable="true">–</delimiter><lpage1 store="953" contenteditable="true">330</lpage1><delimiter store="954" contenteditable="true">. </delimiter><pub-id store="955" contenteditable="true">(https://doi.org/10.1056/NEJMoa1412082)</pub-id></mixed-citation></ref><ref id="CIT00004" store="956" contenteditable="true"><label1 store="957" contenteditable="true">4. </label1><mixed-citation publication-type="journal" store="958" contenteditable="true"><person-group person-group-type="author" store="959" contenteditable="true"><name store="960" contenteditable="true"><surname store="961" contenteditable="true">Hodi</surname><!--punc--> <!--punc--><given-names store="962" contenteditable="true">FS</given-names></name><!--punc-->, <!--punc--><name store="963" contenteditable="true"><surname store="964" contenteditable="true">O’Day</surname><!--punc--> <!--punc--><given-names store="965" contenteditable="true">SJ</given-names></name><!--punc-->, <!--punc--><name store="966" contenteditable="true"><surname store="967" contenteditable="true">McDermott</surname><!--punc--> <!--punc--><given-names store="968" contenteditable="true">DF</given-names></name><!--punc-->, <!--punc--><name store="969" contenteditable="true"><surname store="970" contenteditable="true">Weber</surname><!--punc--> <!--punc--><given-names store="971" contenteditable="true">RW</given-names></name><!--punc-->, <!--punc--><name store="972" contenteditable="true"><surname store="973" contenteditable="true">Sosman</surname><!--punc--> <!--punc--><given-names store="974" contenteditable="true">JA</given-names></name><!--punc-->, <!--punc--><name store="975" contenteditable="true"><surname store="976" contenteditable="true">Haanen</surname><!--punc--> <!--punc--><given-names store="977" contenteditable="true">JB</given-names></name><!--punc-->, <!--punc--><name store="978" contenteditable="true"><surname store="979" contenteditable="true">Gonzalez</surname><!--punc--> <!--punc--><given-names store="980" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="981" contenteditable="true"><surname store="982" contenteditable="true">Robert</surname><!--punc--> <!--punc--><given-names store="983" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="984" contenteditable="true"><surname store="985" contenteditable="true">Schadendorf</surname><!--punc--> <!--punc--><given-names store="986" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="987" contenteditable="true"><surname store="988" contenteditable="true">Hassel</surname><!--punc--> <!--punc--><given-names store="989" contenteditable="true">JC</given-names></name></person-group><delimiter store="990" contenteditable="true">, </delimiter><i store="991" contenteditable="true">et al</i><delimiter store="992" contenteditable="true">. </delimiter><article-title store="993" contenteditable="true">Improved survival with ipilimumab in patients with metastatic melanoma</article-title><delimiter store="994" contenteditable="true">. </delimiter><source1 store="995" contenteditable="true"><i store="996" contenteditable="true">New England Journal of Medicine</i></source1><delimiter store="997" contenteditable="true"> </delimiter><year store="998" contenteditable="true">2010</year><delimiter store="999" contenteditable="true"> </delimiter><volume1 store="1000" contenteditable="true"><!--punc--><b store="1001" contenteditable="true"><!--punc-->363<!--punc--></b><!--punc--></volume1><delimiter store="1002" contenteditable="true"> </delimiter><fpage1 store="1003" contenteditable="true">711</fpage1><delimiter store="1004" contenteditable="true">–</delimiter><lpage1 store="1005" contenteditable="true">723</lpage1><delimiter store="1006" contenteditable="true">. </delimiter><pub-id store="1007" contenteditable="true">(https://doi.org/10.1056/NEJMoa1003466)</pub-id></mixed-citation></ref><ref id="CIT00005" store="1008" contenteditable="true"><label1 store="1009" contenteditable="true">5. </label1><mixed-citation publication-type="journal" store="1010" contenteditable="true"><person-group person-group-type="author" store="1011" contenteditable="true"><name store="1012" contenteditable="true"><surname store="1013" contenteditable="true">Weber</surname><!--punc--> <!--punc--><given-names store="1014" contenteditable="true">JS</given-names></name><!--punc-->, <!--punc--><name store="1015" contenteditable="true"><surname store="1016" contenteditable="true">D’Angelo</surname><!--punc--> <!--punc--><given-names store="1017" contenteditable="true">SP</given-names></name><!--punc-->, <!--punc--><name store="1018" contenteditable="true"><surname store="1019" contenteditable="true">Minor</surname><!--punc--> <!--punc--><given-names store="1020" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="1021" contenteditable="true"><surname store="1022" contenteditable="true">Hodi</surname><!--punc--> <!--punc--><given-names store="1023" contenteditable="true">FS</given-names></name><!--punc-->, <!--punc--><name store="1024" contenteditable="true"><surname store="1025" contenteditable="true">Gutzmer</surname><!--punc--> <!--punc--><given-names store="1026" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="1027" contenteditable="true"><surname store="1028" contenteditable="true">Neyns</surname><!--punc--> <!--punc--><given-names store="1029" contenteditable="true">B</given-names></name><!--punc-->, <!--punc--><name store="1030" contenteditable="true"><surname store="1031" contenteditable="true">Hoeller</surname><!--punc--> <!--punc--><given-names store="1032" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="1033" contenteditable="true"><surname store="1034" contenteditable="true">Khushalani</surname><!--punc--> <!--punc--><given-names store="1035" contenteditable="true">NI</given-names></name><!--punc-->, <!--punc--><name store="1036" contenteditable="true"><surname store="1037" contenteditable="true">Miller</surname><!--punc--> <!--punc--><suffix store="1038" contenteditable="true">Jr</suffix><!--punc--> <!--punc--><given-names store="1039" contenteditable="true">WH</given-names></name><!--punc-->, <!--punc--><name store="1040" contenteditable="true"><surname store="1041" contenteditable="true">Lao</surname><!--punc--> <!--punc--><given-names store="1042" contenteditable="true">CD</given-names></name></person-group><delimiter store="1043" contenteditable="true">, </delimiter><i store="1044" contenteditable="true">et al</i><delimiter store="1045" contenteditable="true">. </delimiter><article-title store="1046" contenteditable="true">Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial</article-title><delimiter store="1047" contenteditable="true">. </delimiter><source1 store="1048" contenteditable="true"><i store="1049" contenteditable="true">Lancet: Oncology</i></source1><delimiter store="1050" contenteditable="true"> </delimiter><year store="1051" contenteditable="true">2015</year><delimiter store="1052" contenteditable="true"> </delimiter><volume1 store="1053" contenteditable="true"><!--punc--><b store="1054" contenteditable="true"><!--punc-->16<!--punc--></b><!--punc--></volume1><delimiter store="1055" contenteditable="true"> </delimiter><fpage1 store="1056" contenteditable="true">375</fpage1><delimiter store="1057" contenteditable="true">–</delimiter><lpage1 store="1058" contenteditable="true">384</lpage1><delimiter store="1059" contenteditable="true">. </delimiter><pub-id store="1060" contenteditable="true">(https://doi.org/10.1016/S1470-2045(15)70076-8)</pub-id></mixed-citation></ref><ref id="CIT00006" store="1061" contenteditable="true"><label1 store="1062" contenteditable="true">6. </label1><mixed-citation publication-type="journal" store="1063" contenteditable="true"><person-group person-group-type="author" store="1064" contenteditable="true"><name store="1065" contenteditable="true"><surname store="1066" contenteditable="true">Long</surname><!--punc--> <!--punc--><given-names store="1067" contenteditable="true">GV</given-names></name><!--punc-->, <!--punc--><name store="1068" contenteditable="true"><surname store="1069" contenteditable="true">Atkinson</surname><!--punc--> <!--punc--><given-names store="1070" contenteditable="true">V</given-names></name><!--punc-->, <!--punc--><name store="1071" contenteditable="true"><surname store="1072" contenteditable="true">Cebon</surname><!--punc--> <!--punc--><given-names store="1073" contenteditable="true">JS</given-names></name><!--punc-->, <!--punc--><name store="1074" contenteditable="true"><surname store="1075" contenteditable="true">Jameson</surname><!--punc--> <!--punc--><given-names store="1076" contenteditable="true">MB</given-names></name><!--punc-->, <!--punc--><name store="1077" contenteditable="true"><surname store="1078" contenteditable="true">Fitzharris</surname><!--punc--> <!--punc--><given-names store="1079" contenteditable="true">BM</given-names></name><!--punc-->, <!--punc--><name store="1080" contenteditable="true"><surname store="1081" contenteditable="true">McNeil</surname><!--punc--> <!--punc--><given-names store="1082" contenteditable="true">CM</given-names></name><!--punc-->, <!--punc--><name store="1083" contenteditable="true"><surname store="1084" contenteditable="true">Hill</surname><!--punc--> <!--punc--><given-names store="1085" contenteditable="true">AG</given-names></name><!--punc-->, <!--punc--><name store="1086" contenteditable="true"><surname store="1087" contenteditable="true">Ribas</surname><!--punc--> <!--punc--><given-names store="1088" contenteditable="true">A</given-names></name><!--punc-->, <!--punc--><name store="1089" contenteditable="true"><surname store="1090" contenteditable="true">Atkins</surname><!--punc--> <!--punc--><given-names store="1091" contenteditable="true">MB</given-names></name><!--punc-->, <!--punc--><name store="1092" contenteditable="true"><surname store="1093" contenteditable="true">Thompson</surname><!--punc--> <!--punc--><given-names store="1094" contenteditable="true">JA</given-names></name></person-group><delimiter store="1095" contenteditable="true">, </delimiter><i store="1096" contenteditable="true">et al</i><delimiter store="1097" contenteditable="true">. </delimiter><article-title store="1098" contenteditable="true">Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial</article-title><delimiter store="1099" contenteditable="true">. </delimiter><source1 store="1100" contenteditable="true"><i store="1101" contenteditable="true">Lancet: Oncology</i></source1><delimiter store="1102" contenteditable="true"> </delimiter><year store="1103" contenteditable="true">2017</year><delimiter store="1104" contenteditable="true"> </delimiter><volume1 store="1105" contenteditable="true"><!--punc--><b store="1106" contenteditable="true"><!--punc-->18<!--punc--></b><!--punc--></volume1><delimiter store="1107" contenteditable="true"> </delimiter><fpage1 store="1108" contenteditable="true">1202</fpage1><delimiter store="1109" contenteditable="true">–</delimiter><lpage1 store="1110" contenteditable="true">1210</lpage1><delimiter store="1111" contenteditable="true">. </delimiter><pub-id store="1112" contenteditable="true">(https://doi.org/10.1016/S1470-2045(17)30428-X)</pub-id></mixed-citation></ref><ref id="CIT00007" store="1113" contenteditable="true"><label1 store="1114" contenteditable="true">7. </label1><mixed-citation publication-type="journal" store="1115" contenteditable="true"><person-group person-group-type="author" store="1116" contenteditable="true"><name store="1117" contenteditable="true"><surname store="1118" contenteditable="true">Motzer</surname><!--punc--> <!--punc--><given-names store="1119" contenteditable="true">RJ</given-names></name><!--punc-->, <!--punc--><name store="1120" contenteditable="true"><surname store="1121" contenteditable="true">Escudier</surname><!--punc--> <!--punc--><given-names store="1122" contenteditable="true">B</given-names></name><!--punc-->, <!--punc--><name store="1123" contenteditable="true"><surname store="1124" contenteditable="true">McDermott</surname><!--punc--> <!--punc--><given-names store="1125" contenteditable="true">DF</given-names></name><!--punc-->, <!--punc--><name store="1126" contenteditable="true"><surname store="1127" contenteditable="true">George</surname><!--punc--> <!--punc--><given-names store="1128" contenteditable="true">S</given-names></name><!--punc-->, <!--punc--><name store="1129" contenteditable="true"><surname store="1130" contenteditable="true">Hammers</surname><!--punc--> <!--punc--><given-names store="1131" contenteditable="true">HJ</given-names></name><!--punc-->, <!--punc--><name store="1132" contenteditable="true"><surname store="1133" contenteditable="true">Srinivas</surname><!--punc--> <!--punc--><given-names store="1134" contenteditable="true">S</given-names></name><!--punc-->, <!--punc--><name store="1135" contenteditable="true"><surname store="1136" contenteditable="true">Tykodi</surname><!--punc--> <!--punc--><given-names store="1137" contenteditable="true">SS</given-names></name><!--punc-->, <!--punc--><name store="1138" contenteditable="true"><surname store="1139" contenteditable="true">Sosman</surname><!--punc--> <!--punc--><given-names store="1140" contenteditable="true">JA</given-names></name><!--punc-->, <!--punc--><name store="1141" contenteditable="true"><surname store="1142" contenteditable="true">Procopio</surname><!--punc--> <!--punc--><given-names store="1143" contenteditable="true">G</given-names></name><!--punc-->, <!--punc--><name store="1144" contenteditable="true"><surname store="1145" contenteditable="true">Plimack</surname><!--punc--> <!--punc--><given-names store="1146" contenteditable="true">ER</given-names></name></person-group><delimiter store="1147" contenteditable="true">, </delimiter><i store="1148" contenteditable="true">et al</i><delimiter store="1149" contenteditable="true">. </delimiter><article-title store="1150" contenteditable="true">Nivolumab versus everolimus in advanced renal-cell carcinoma</article-title><delimiter store="1151" contenteditable="true">. </delimiter><source1 store="1152" contenteditable="true"><i store="1153" contenteditable="true">New England Journal of Medicine</i></source1><delimiter store="1154" contenteditable="true"> </delimiter><year store="1155" contenteditable="true">2015</year><delimiter store="1156" contenteditable="true"> </delimiter><volume1 store="1157" contenteditable="true"><!--punc--><b store="1158" contenteditable="true"><!--punc-->373<!--punc--></b><!--punc--></volume1><delimiter store="1159" contenteditable="true"> </delimiter><fpage1 store="1160" contenteditable="true">1803</fpage1><delimiter store="1161" contenteditable="true">–</delimiter><lpage1 store="1162" contenteditable="true">1813</lpage1><delimiter store="1163" contenteditable="true">. </delimiter><pub-id store="1164" contenteditable="true">(https://doi.org/10.1056/NEJMoa1510665)</pub-id></mixed-citation></ref><ref id="CIT00008" store="1165" contenteditable="true"><label1 store="1166" contenteditable="true">8. </label1><mixed-citation publication-type="journal" store="1167" contenteditable="true"><person-group person-group-type="author" store="1168" contenteditable="true"><name store="1169" contenteditable="true"><surname store="1170" contenteditable="true">Herbst</surname><!--punc--> <!--punc--><given-names store="1171" contenteditable="true">RS</given-names></name><!--punc-->, <!--punc--><name store="1172" contenteditable="true"><surname store="1173" contenteditable="true">Baas</surname><!--punc--> <!--punc--><given-names store="1174" contenteditable="true" style="" class="">P</given-names></name><!--punc-->, <!--punc--><name store="1175" contenteditable="true"><surname store="1176" contenteditable="true">Kim</surname><!--punc--> <!--punc--><given-names store="1177" contenteditable="true">DW</given-names></name><!--punc-->, <!--punc--><name store="1178" contenteditable="true"><surname store="1179" contenteditable="true">Felip</surname><!--punc--> <!--punc--><given-names store="1180" contenteditable="true">E</given-names></name><!--punc-->, <!--punc--><name store="1181" contenteditable="true"><surname store="1182" contenteditable="true">Pérez-Gracia</surname><!--punc--> <!--punc--><given-names store="1183" contenteditable="true">JL</given-names></name><!--punc-->, <!--punc--><name store="1184" contenteditable="true"><surname store="1185" contenteditable="true">Han</surname><!--punc--> <!--punc--><given-names store="1186" contenteditable="true">JY</given-names></name><!--punc-->, <!--punc--><name store="1187" contenteditable="true"><surname store="1188" contenteditable="true">Molina</surname><!--punc--> <!--punc--><given-names store="1189" contenteditable="true">J</given-names></name><!--punc-->, <!--punc--><name store="1190" contenteditable="true"><surname store="1191" contenteditable="true">Kim</surname><!--punc--> <!--punc--><given-names store="1192" contenteditable="true">JH</given-names></name><!--punc-->, <!--punc--><name store="1193" contenteditable="true"><surname store="1194" contenteditable="true">Arvis</surname><!--punc--> <!--punc--><given-names store="1195" contenteditable="true">CD</given-names></name><!--punc-->, <!--punc--><name store="1196" contenteditable="true"><surname store="1197" contenteditable="true">Ahn</surname><!--punc--> <!--punc--><given-names store="1198" contenteditable="true">MJ</given-names></name></person-group><delimiter store="1199" contenteditable="true">, </delimiter><i store="1200" contenteditable="true">et al</i><delimiter store="1201" contenteditable="true">. </delimiter><article-title store="1202" contenteditable="true">Pembrolizumab versus docetaxel for previous PD-L1 positive, advanced non-small cell lung cancer (Keynote-010): a randomised control trial</article-title><delimiter store="1203" contenteditable="true">. </delimiter><source1 store="1204" contenteditable="true"><i store="1205" contenteditable="true">Lancet</i></source1><delimiter store="1206" contenteditable="true"> </delimiter><year store="1207" contenteditable="true">2016</year><delimiter store="1208" contenteditable="true"> </delimiter><volume1 store="1209" contenteditable="true"><!--punc--><b store="1210" contenteditable="true"><!--punc-->387<!--punc--></b><!--punc--></volume1><delimiter store="1211" contenteditable="true"> </delimiter><fpage1 store="1212" contenteditable="true">1440</fpage1><delimiter store="1213" contenteditable="true">–</delimiter><lpage1 store="1214" contenteditable="true">1450</lpage1><delimiter store="1215" contenteditable="true">.</delimiter></mixed-citation></ref><ref id="CIT00009" store="1216" contenteditable="true"><label1 store="1217" contenteditable="true">9. </label1><mixed-citation publication-type="journal" store="1218" contenteditable="true"><person-group person-group-type="author" store="1219" contenteditable="true"><name store="1220" contenteditable="true"><surname store="1221" contenteditable="true">Robert</surname><!--punc--> <!--punc--><given-names store="1222" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="1223" contenteditable="true"><surname store="1224" contenteditable="true">Ribas</surname><!--punc--> <!--punc--><given-names store="1225" contenteditable="true">A</given-names></name><!--punc-->, <!--punc--><name store="1226" contenteditable="true"><surname store="1227" contenteditable="true">Wolchok</surname><!--punc--> <!--punc--><given-names store="1228" contenteditable="true">JD</given-names></name><!--punc-->, <!--punc--><name store="1229" contenteditable="true"><surname store="1230" contenteditable="true">Hodi</surname><!--punc--> <!--punc--><given-names store="1231" contenteditable="true">FS</given-names></name><!--punc-->, <!--punc--><name store="1232" contenteditable="true"><surname store="1233" contenteditable="true">Hamid</surname><!--punc--> <!--punc--><given-names store="1234" contenteditable="true">O</given-names></name><!--punc-->, <!--punc--><name store="1235" contenteditable="true"><surname store="1236" contenteditable="true">Kefford</surname><!--punc--> <!--punc--><given-names store="1237" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="1238" contenteditable="true"><surname store="1239" contenteditable="true">Weber</surname><!--punc--> <!--punc--><given-names store="1240" contenteditable="true">JS</given-names></name><!--punc-->, <!--punc--><name store="1241" contenteditable="true"><surname store="1242" contenteditable="true">Joshua</surname><!--punc--> <!--punc--><given-names store="1243" contenteditable="true">AM</given-names></name><!--punc-->, <!--punc--><name store="1244" contenteditable="true"><surname store="1245" contenteditable="true">Hwu</surname><!--punc--> <!--punc--><given-names store="1246" contenteditable="true">WJ</given-names></name><!--punc-->, <!--punc--><name store="1247" contenteditable="true"><surname store="1248" contenteditable="true">Gangadhar</surname><!--punc--> <!--punc--><given-names store="1249" contenteditable="true">TC</given-names></name></person-group><delimiter store="1250" contenteditable="true">, </delimiter><i store="1251" contenteditable="true">et al</i><delimiter store="1252" contenteditable="true">. </delimiter><article-title store="1253" contenteditable="true">Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial</article-title><delimiter store="1254" contenteditable="true">. </delimiter><source1 store="1255" contenteditable="true"><i store="1256" contenteditable="true">Lancet</i></source1><delimiter store="1257" contenteditable="true"> </delimiter><year store="1258" contenteditable="true">2014</year><delimiter store="1259" contenteditable="true"> </delimiter><volume1 store="1260" contenteditable="true"><!--punc--><b store="1261" contenteditable="true"><!--punc-->384<!--punc--></b><!--punc--></volume1><delimiter store="1262" contenteditable="true"> </delimiter><fpage1 store="1263" contenteditable="true">1109</fpage1><delimiter store="1264" contenteditable="true">–</delimiter><lpage1 store="1265" contenteditable="true">1117</lpage1><delimiter store="1266" contenteditable="true">. </delimiter><pub-id store="1267" contenteditable="true">(https://doi.org/10.1016/S0140-6736(14)60958-2)</pub-id></mixed-citation></ref><ref id="CIT00010" store="1268" contenteditable="true"><label1 store="1269" contenteditable="true">10. </label1><mixed-citation publication-type="journal" store="1270" contenteditable="true"><person-group person-group-type="author" store="1271" contenteditable="true"><name store="1272" contenteditable="true"><surname store="1273" contenteditable="true">Ribas</surname><!--punc--> <!--punc--><given-names store="1274" contenteditable="true">A</given-names></name><!--punc-->, <!--punc--><name store="1275" contenteditable="true"><surname store="1276" contenteditable="true">Puzanov</surname><!--punc--> <!--punc--><given-names store="1277" contenteditable="true">I</given-names></name><!--punc-->, <!--punc--><name store="1278" contenteditable="true"><surname store="1279" contenteditable="true">Dummer</surname><!--punc--> <!--punc--><given-names store="1280" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="1281" contenteditable="true"><surname store="1282" contenteditable="true">Schadendorf</surname><!--punc--> <!--punc--><given-names store="1283" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="1284" contenteditable="true"><surname store="1285" contenteditable="true">Hamid</surname><!--punc--> <!--punc--><given-names store="1286" contenteditable="true">O</given-names></name><!--punc-->, <!--punc--><name store="1287" contenteditable="true"><surname store="1288" contenteditable="true">Robert</surname><!--punc--> <!--punc--><given-names store="1289" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="1290" contenteditable="true"><surname store="1291" contenteditable="true">Hodi</surname><!--punc--> <!--punc--><given-names store="1292" contenteditable="true">FS</given-names></name><!--punc-->, <!--punc--><name store="1293" contenteditable="true"><surname store="1294" contenteditable="true">Schachter</surname><!--punc--> <!--punc--><given-names store="1295" contenteditable="true">J</given-names></name><!--punc-->, <!--punc--><name store="1296" contenteditable="true"><surname store="1297" contenteditable="true">Pavlick</surname><!--punc--> <!--punc--><given-names store="1298" contenteditable="true">AC</given-names></name><!--punc-->, <!--punc--><name store="1299" contenteditable="true"><surname store="1300" contenteditable="true">Lewis</surname><!--punc--> <!--punc--><given-names store="1301" contenteditable="true">KD</given-names></name></person-group><delimiter store="1302" contenteditable="true">, </delimiter><i store="1303" contenteditable="true">et al</i><delimiter store="1304" contenteditable="true">. </delimiter><article-title store="1305" contenteditable="true">Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial</article-title><delimiter store="1306" contenteditable="true">. </delimiter><source1 store="1307" contenteditable="true"><i store="1308" contenteditable="true">Lancet: Oncology</i></source1><delimiter store="1309" contenteditable="true"> </delimiter><year store="1310" contenteditable="true">2015</year><delimiter store="1311" contenteditable="true"> </delimiter><volume1 store="1312" contenteditable="true"><!--punc--><b store="1313" contenteditable="true"><!--punc-->16<!--punc--></b><!--punc--></volume1><delimiter store="1314" contenteditable="true"> </delimiter><fpage1 store="1315" contenteditable="true">908</fpage1><delimiter store="1316" contenteditable="true">–</delimiter><lpage1 store="1317" contenteditable="true">918</lpage1><delimiter store="1318" contenteditable="true">. </delimiter><pub-id store="1319" contenteditable="true">(https://doi.org/10.1016/S1470-2045(15)00083-2)</pub-id></mixed-citation></ref><ref id="CIT00011" store="1320" contenteditable="true"><label1 store="1321" contenteditable="true">11. </label1><mixed-citation publication-type="journal" store="1322" contenteditable="true"><person-group person-group-type="author" store="1323" contenteditable="true"><name store="1324" contenteditable="true"><surname store="1325" contenteditable="true">Bertrand</surname><!--punc--> <!--punc--><given-names store="1326" contenteditable="true">A</given-names></name><!--punc-->, <!--punc--><name store="1327" contenteditable="true"><surname store="1328" contenteditable="true">Kostine</surname><!--punc--> <!--punc--><given-names store="1329" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="1330" contenteditable="true"><surname store="1331" contenteditable="true">Barnetche</surname><!--punc--> <!--punc--><given-names store="1332" contenteditable="true">T</given-names></name><!--punc-->, <!--punc--><name store="1333" contenteditable="true"><surname store="1334" contenteditable="true">Truchetet</surname><!--punc--> <!--punc--><given-names store="1335" contenteditable="true">ME</given-names></name><!--punc--> &amp; <!--punc--><name store="1336" contenteditable="true"><surname store="1337" contenteditable="true">Schaeverbeke</surname><!--punc--> <!--punc--><given-names store="1338" contenteditable="true">T</given-names></name></person-group><delimiter store="1339" contenteditable="true">. </delimiter><article-title store="1340" contenteditable="true">Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis</article-title><delimiter store="1341" contenteditable="true">. </delimiter><source1 store="1342" contenteditable="true"><i store="1343" contenteditable="true">BMC Medicine</i></source1><delimiter store="1344" contenteditable="true"> </delimiter><year store="1345" contenteditable="true">2015</year><delimiter store="1346" contenteditable="true"> </delimiter><volume1 store="1347" contenteditable="true"><!--punc--><b store="1348" contenteditable="true"><!--punc-->13<!--punc--></b><!--punc--></volume1><delimiter store="1349" contenteditable="true"> </delimiter><fpage1 store="1350" contenteditable="true">211</fpage1><delimiter store="1351" contenteditable="true">. </delimiter><pub-id store="1352" contenteditable="true">(https://doi.org/10.1186/s12916-015-0455-8)</pub-id></mixed-citation></ref><ref id="CIT00012" store="1353" contenteditable="true"><label1 store="1354" contenteditable="true">12. </label1><mixed-citation publication-type="journal" store="1355" contenteditable="true"><person-group person-group-type="author" store="1356" contenteditable="true"><name store="1357" contenteditable="true"><surname store="1358" contenteditable="true">Morganstein</surname><!--punc--> <!--punc--><given-names store="1359" contenteditable="true">DL</given-names></name><!--punc-->, <!--punc--><name store="1360" contenteditable="true"><surname store="1361" contenteditable="true">Lai</surname><!--punc--> <!--punc--><given-names store="1362" contenteditable="true">Z</given-names></name><!--punc-->, <!--punc--><name store="1363" contenteditable="true"><surname store="1364" contenteditable="true">Spain</surname><!--punc--> <!--punc--><given-names store="1365" contenteditable="true">L</given-names></name><!--punc-->, <!--punc--><name store="1366" contenteditable="true"><surname store="1367" contenteditable="true">Diem</surname><!--punc--> <!--punc--><given-names store="1368" contenteditable="true">S</given-names></name><!--punc-->, <!--punc--><name store="1369" contenteditable="true"><surname store="1370" contenteditable="true">Levine</surname><!--punc--> <!--punc--><given-names store="1371" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="1372" contenteditable="true"><surname store="1373" contenteditable="true">Mace</surname><!--punc--> <!--punc--><given-names store="1374" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="1375" contenteditable="true"><surname store="1376" contenteditable="true">Gore</surname><!--punc--> <!--punc--><given-names store="1377" contenteditable="true">M</given-names></name><!--punc--> &amp; <!--punc--><name store="1378" contenteditable="true"><surname store="1379" contenteditable="true">Larkin</surname><!--punc--> <!--punc--><given-names store="1380" contenteditable="true">J</given-names></name></person-group><delimiter store="1381" contenteditable="true">. </delimiter><article-title store="1382" contenteditable="true">Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma</article-title><delimiter store="1383" contenteditable="true">. </delimiter><source1 store="1384" contenteditable="true"><i store="1385" contenteditable="true">Clinical Endocrinology</i></source1><delimiter store="1386" contenteditable="true"> </delimiter><year store="1387" contenteditable="true">2017</year><delimiter store="1388" contenteditable="true"> </delimiter><volume1 store="1389" contenteditable="true"><!--punc--><b store="1390" contenteditable="true"><!--punc-->86<!--punc--></b><!--punc--></volume1><delimiter store="1391" contenteditable="true"> </delimiter><fpage1 store="1392" contenteditable="true">614</fpage1><delimiter store="1393" contenteditable="true">–</delimiter><lpage1 store="1394" contenteditable="true">620</lpage1><delimiter store="1395" contenteditable="true">. </delimiter><pub-id store="1396" contenteditable="true">(https://doi.org/10.1111/cen.13297)</pub-id></mixed-citation></ref><ref id="CIT00013" store="1397" contenteditable="true"><label1 store="1398" contenteditable="true">13. </label1><mixed-citation publication-type="journal" store="1399" contenteditable="true"><person-group person-group-type="author" store="1400" contenteditable="true"><name store="1401" contenteditable="true"><surname store="1402" contenteditable="true">Osorio</surname><!--punc--> <!--punc--><given-names store="1403" contenteditable="true">JC</given-names></name><!--punc-->, <!--punc--><name store="1404" contenteditable="true"><surname store="1405" contenteditable="true">Ni</surname><!--punc--> <!--punc--><given-names store="1406" contenteditable="true">A</given-names></name><!--punc-->, <!--punc--><name store="1407" contenteditable="true"><surname store="1408" contenteditable="true">Chaft</surname><!--punc--> <!--punc--><given-names store="1409" contenteditable="true">JE</given-names></name><!--punc-->, <!--punc--><name store="1410" contenteditable="true"><surname store="1411" contenteditable="true">Pollina</surname><!--punc--> <!--punc--><given-names store="1412" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="1413" contenteditable="true"><surname store="1414" contenteditable="true">Kasler</surname><!--punc--> <!--punc--><given-names store="1415" contenteditable="true">MK</given-names></name><!--punc-->, <!--punc--><name store="1416" contenteditable="true"><surname store="1417" contenteditable="true">Stephens</surname><!--punc--> <!--punc--><given-names store="1418" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="1419" contenteditable="true"><surname store="1420" contenteditable="true">Rodriguez</surname><!--punc--> <!--punc--><given-names store="1421" contenteditable="true">C</given-names></name><!--punc-->, <!--punc--><name store="1422" contenteditable="true"><surname store="1423" contenteditable="true">Cambridge</surname><!--punc--> <!--punc--><given-names store="1424" contenteditable="true">L</given-names></name><!--punc-->, <!--punc--><name store="1425" contenteditable="true"><surname store="1426" contenteditable="true">Rizvi</surname><!--punc--> <!--punc--><given-names store="1427" contenteditable="true">H</given-names></name><!--punc-->, <!--punc--><name store="1428" contenteditable="true"><surname store="1429" contenteditable="true">Wolchok</surname><!--punc--> <!--punc--><given-names store="1430" contenteditable="true">JD</given-names></name></person-group><delimiter store="1431" contenteditable="true">, </delimiter><i store="1432" contenteditable="true">et al</i><delimiter store="1433" contenteditable="true">. </delimiter><article-title store="1434" contenteditable="true">Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer</article-title><delimiter store="1435" contenteditable="true">. </delimiter><source1 store="1436" contenteditable="true"><i store="1437" contenteditable="true">Annals of Oncology</i></source1><delimiter store="1438" contenteditable="true"> </delimiter><year store="1439" contenteditable="true">2017</year><delimiter store="1440" contenteditable="true"> </delimiter><volume1 store="1441" contenteditable="true"><!--punc--><b store="1442" contenteditable="true"><!--punc-->28<!--punc--></b><!--punc--></volume1><delimiter store="1443" contenteditable="true"> </delimiter><fpage1 store="1444" contenteditable="true">583</fpage1><delimiter store="1445" contenteditable="true">–</delimiter><lpage1 store="1446" contenteditable="true">589</lpage1><delimiter store="1447" contenteditable="true">. </delimiter><pub-id store="1448" contenteditable="true">(https://doi.org/10.1093/annonc/mdw640)</pub-id></mixed-citation></ref><ref id="CIT00014" store="1449" contenteditable="true"><label1 store="1450" contenteditable="true">14. </label1><mixed-citation publication-type="journal" store="1451" contenteditable="true"><person-group person-group-type="author" store="1452" contenteditable="true"><name store="1453" contenteditable="true"><surname store="1454" contenteditable="true">Sznol</surname><!--punc--> <!--punc--><given-names store="1455" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="1456" contenteditable="true"><surname store="1457" contenteditable="true">Postow</surname><!--punc--> <!--punc--><given-names store="1458" contenteditable="true">MA</given-names></name><!--punc-->, <!--punc--><name store="1459" contenteditable="true"><surname store="1460" contenteditable="true">Davies</surname><!--punc--> <!--punc--><given-names store="1461" contenteditable="true">MJ</given-names></name><!--punc-->, <!--punc--><name store="1462" contenteditable="true"><surname store="1463" contenteditable="true">Pavlick</surname><!--punc--> <!--punc--><given-names store="1464" contenteditable="true">AC</given-names></name><!--punc-->, <!--punc--><name store="1465" contenteditable="true"><surname store="1466" contenteditable="true">Plimack</surname><!--punc--> <!--punc--><given-names store="1467" contenteditable="true">ER</given-names></name><!--punc-->, <!--punc--><name store="1468" contenteditable="true"><surname store="1469" contenteditable="true">Shaheen</surname><!--punc--> <!--punc--><given-names store="1470" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="1471" contenteditable="true"><surname store="1472" contenteditable="true">Veloski</surname><!--punc--> <!--punc--><given-names store="1473" contenteditable="true">C</given-names></name><!--punc--> &amp; <!--punc--><name store="1474" contenteditable="true"><surname store="1475" contenteditable="true">Robert</surname><!--punc--> <!--punc--><given-names store="1476" contenteditable="true">C</given-names></name></person-group><delimiter store="1477" contenteditable="true">. </delimiter><article-title store="1478" contenteditable="true">Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management</article-title><delimiter store="1479" contenteditable="true">. </delimiter><source1 store="1480" contenteditable="true"><i store="1481" contenteditable="true">Cancer Treatment Reviews</i></source1><delimiter store="1482" contenteditable="true"> </delimiter><year store="1483" contenteditable="true">2017</year><delimiter store="1484" contenteditable="true"> </delimiter><volume1 store="1485" contenteditable="true"><!--punc--><b store="1486" contenteditable="true"><!--punc-->58<!--punc--></b><!--punc--></volume1><delimiter store="1487" contenteditable="true"> </delimiter><fpage1 store="1488" contenteditable="true">70</fpage1><delimiter store="1489" contenteditable="true">–</delimiter><lpage1 store="1490" contenteditable="true">76</lpage1><delimiter store="1491" contenteditable="true">. </delimiter><pub-id store="1492" contenteditable="true">(https://doi.org/10.1016/j.ctrv.2017.06.002)</pub-id></mixed-citation></ref><ref id="CIT00015" store="1493" contenteditable="true"><label1 store="1494" contenteditable="true">15. </label1><mixed-citation publication-type="journal" store="1495" contenteditable="true"><person-group person-group-type="author" store="1496" contenteditable="true"><name store="1497" contenteditable="true"><surname store="1498" contenteditable="true">Yamauchi</surname><!--punc--> <!--punc--><given-names store="1499" contenteditable="true">I</given-names></name><!--punc-->, <!--punc--><name store="1500" contenteditable="true"><surname store="1501" contenteditable="true">Sakane</surname><!--punc--> <!--punc--><given-names store="1502" contenteditable="true">Y</given-names></name><!--punc-->, <!--punc--><name store="1503" contenteditable="true"><surname store="1504" contenteditable="true">Fukuda</surname><!--punc--> <!--punc--><given-names store="1505" contenteditable="true">Y</given-names></name><!--punc-->, <!--punc--><name store="1506" contenteditable="true"><surname store="1507" contenteditable="true">Fujii</surname><!--punc--> <!--punc--><given-names store="1508" contenteditable="true">T</given-names></name><!--punc-->, <!--punc--><name store="1509" contenteditable="true"><surname store="1510" contenteditable="true">Taura</surname><!--punc--> <!--punc--><given-names store="1511" contenteditable="true">D</given-names></name><!--punc-->, <!--punc--><name store="1512" contenteditable="true"><surname store="1513" contenteditable="true">Hirata</surname><!--punc--> <!--punc--><given-names store="1514" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="1515" contenteditable="true"><surname store="1516" contenteditable="true">Hirota</surname><!--punc--> <!--punc--><given-names store="1517" contenteditable="true">K</given-names></name><!--punc-->, <!--punc--><name store="1518" contenteditable="true"><surname store="1519" contenteditable="true">Ueda</surname><!--punc--> <!--punc--><given-names store="1520" contenteditable="true">Y</given-names></name><!--punc-->, <!--punc--><name store="1521" contenteditable="true"><surname store="1522" contenteditable="true">Kanai</surname><!--punc--> <!--punc--><given-names store="1523" contenteditable="true">Y</given-names></name><!--punc-->, <!--punc--><name store="1524" contenteditable="true"><surname store="1525" contenteditable="true">Yamashita</surname><!--punc--> <!--punc--><given-names store="1526" contenteditable="true">Y</given-names></name></person-group><delimiter store="1527" contenteditable="true">, </delimiter><i store="1528" contenteditable="true">et al</i><delimiter store="1529" contenteditable="true">. </delimiter><article-title store="1530" contenteditable="true">Clinical features of Nivolumab-induced thyroiditis: a case series study</article-title><delimiter store="1531" contenteditable="true">. </delimiter><source1 store="1532" contenteditable="true"><i store="1533" contenteditable="true">Thyroid</i></source1><delimiter store="1534" contenteditable="true"> </delimiter><year store="1535" contenteditable="true">2017</year><delimiter store="1536" contenteditable="true"> </delimiter><volume1 store="1537" contenteditable="true"><!--punc--><b store="1538" contenteditable="true"><!--punc-->27<!--punc--></b><!--punc--></volume1><delimiter store="1539" contenteditable="true"> </delimiter><fpage1 store="1540" contenteditable="true">894</fpage1><delimiter store="1541" contenteditable="true">–</delimiter><lpage1 store="1542" contenteditable="true">901</lpage1><delimiter store="1543" contenteditable="true">. </delimiter><pub-id store="1544" contenteditable="true">(https://doi.org/10.1089/thy.2016.0562)</pub-id></mixed-citation></ref><ref id="CIT00016" store="1545" contenteditable="true"><label1 store="1546" contenteditable="true">16. </label1><mixed-citation publication-type="journal" store="1547" contenteditable="true"><person-group person-group-type="author" store="1548" contenteditable="true"><name store="1549" contenteditable="true"><surname store="1550" contenteditable="true">Barroso-Sousa</surname><!--punc--> <!--punc--><given-names store="1551" contenteditable="true">R</given-names></name><!--punc-->, <!--punc--><name store="1552" contenteditable="true"><surname store="1553" contenteditable="true">Barry</surname><!--punc--> <!--punc--><given-names store="1554" contenteditable="true">WT</given-names></name><!--punc-->, <!--punc--><name store="1555" contenteditable="true"><surname store="1556" contenteditable="true">Garrido-Castro</surname><!--punc--> <!--punc--><given-names store="1557" contenteditable="true">AC</given-names></name><!--punc-->, <!--punc--><name store="1558" contenteditable="true"><surname store="1559" contenteditable="true">Hodi</surname><!--punc--> <!--punc--><given-names store="1560" contenteditable="true">FS</given-names></name><!--punc-->, <!--punc--><name store="1561" contenteditable="true"><surname store="1562" contenteditable="true">Min</surname><!--punc--> <!--punc--><given-names store="1563" contenteditable="true">L</given-names></name><!--punc-->, <!--punc--><name store="1564" contenteditable="true"><surname store="1565" contenteditable="true">Krop</surname><!--punc--> <!--punc--><given-names store="1566" contenteditable="true">IE</given-names></name><!--punc--> &amp; <!--punc--><name store="1567" contenteditable="true"><surname store="1568" contenteditable="true">Tolaney</surname><!--punc--> <!--punc--><given-names store="1569" contenteditable="true">SM</given-names></name></person-group><delimiter store="1570" contenteditable="true">. </delimiter><article-title store="1571" contenteditable="true">Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis</article-title><delimiter store="1572" contenteditable="true">. </delimiter><source1 store="1573" contenteditable="true"><i store="1574" contenteditable="true">JAMA Oncology</i></source1><delimiter store="1575" contenteditable="true"> </delimiter><year store="1576" contenteditable="true">2018</year><delimiter store="1577" contenteditable="true"> </delimiter><volume1 store="1578" contenteditable="true"><!--punc--><b store="1579" contenteditable="true"><!--punc-->4<!--punc--></b><!--punc--></volume1><delimiter store="1580" contenteditable="true"> </delimiter><fpage1 store="1581" contenteditable="true">173</fpage1><delimiter store="1582" contenteditable="true">–</delimiter><lpage1 store="1583" contenteditable="true">182</lpage1><delimiter store="1584" contenteditable="true">. </delimiter><pub-id store="1585" contenteditable="true">(https://doi.org/10.1001/jamaoncol.2017.3064)</pub-id></mixed-citation></ref><ref id="CIT00017" store="1586" contenteditable="true"><label1 store="1587" contenteditable="true">17. </label1><mixed-citation publication-type="journal" store="1588" contenteditable="true"><person-group person-group-type="author" store="1589" contenteditable="true"><name store="1590" contenteditable="true"><surname store="1591" contenteditable="true">O’Malley</surname><!--punc--> <!--punc--><given-names store="1592" contenteditable="true">G</given-names></name><!--punc-->, <!--punc--><name store="1593" contenteditable="true"><surname store="1594" contenteditable="true">Lee</surname><!--punc--> <!--punc--><given-names store="1595" contenteditable="true">HJ</given-names></name><!--punc-->, <!--punc--><name store="1596" contenteditable="true"><surname store="1597" contenteditable="true">Parekl</surname><!--punc--> <!--punc--><given-names store="1598" contenteditable="true">S</given-names></name><!--punc-->, <!--punc--><name store="1599" contenteditable="true"><surname store="1600" contenteditable="true">Galsky</surname><!--punc--> <!--punc--><given-names store="1601" contenteditable="true">MD</given-names></name><!--punc-->, <!--punc--><name store="1602" contenteditable="true"><surname store="1603" contenteditable="true">Smith</surname><!--punc--> <!--punc--><given-names store="1604" contenteditable="true">CB</given-names></name><!--punc-->, <!--punc--><name store="1605" contenteditable="true"><surname store="1606" contenteditable="true">Friedlander</surname><!--punc--> <!--punc--><given-names store="1607" contenteditable="true" style="" class="">P</given-names></name><!--punc-->, <!--punc--><name store="1608" contenteditable="true"><surname store="1609" contenteditable="true">Yanagisawa</surname><!--punc--> <!--punc--><given-names store="1610" contenteditable="true">RT</given-names></name><!--punc--> &amp; <!--punc--><name store="1611" contenteditable="true"><surname store="1612" contenteditable="true">Gallagher</surname><!--punc--> <!--punc--><given-names store="1613" contenteditable="true">EJ</given-names></name></person-group><delimiter store="1614" contenteditable="true">. </delimiter><article-title store="1615" contenteditable="true">Rapid evolution of thyroid dysfunction in patinets treated with nivoluab</article-title><delimiter store="1616" contenteditable="true">. </delimiter><source1 store="1617" contenteditable="true"><i store="1618" contenteditable="true">Endocrine Practice</i></source1><delimiter store="1619" contenteditable="true"> </delimiter><year store="1620" contenteditable="true">2017</year><delimiter store="1621" contenteditable="true"> </delimiter><volume1 store="1622" contenteditable="true"><!--punc--><b store="1623" contenteditable="true"><!--punc-->23<!--punc--></b><!--punc--></volume1><delimiter store="1624" contenteditable="true"> </delimiter><fpage1 store="1625" contenteditable="true">1223</fpage1><delimiter store="1626" contenteditable="true">–</delimiter><lpage1 store="1627" contenteditable="true">1231</lpage1><delimiter store="1628" contenteditable="true">. </delimiter><pub-id store="1629" contenteditable="true">(https://doi.org/10.4158/EP171832.OR)</pub-id></mixed-citation></ref><ref id="CIT00018" store="1630" contenteditable="true"><label1 store="1631" contenteditable="true">18. </label1><mixed-citation publication-type="journal" store="1632" contenteditable="true"><person-group person-group-type="author" store="1633" contenteditable="true"><name store="1634" contenteditable="true"><surname store="1635" contenteditable="true">de Filette</surname><!--punc--> <!--punc--><given-names store="1636" contenteditable="true">J</given-names></name><!--punc-->, <!--punc--><name store="1637" contenteditable="true"><surname store="1638" contenteditable="true">Jansen</surname><!--punc--> <!--punc--><given-names store="1639" contenteditable="true">Y</given-names></name><!--punc-->, <!--punc--><name store="1640" contenteditable="true"><surname store="1641" contenteditable="true">Schreuer</surname><!--punc--> <!--punc--><given-names store="1642" contenteditable="true">M</given-names></name><!--punc-->, <!--punc--><name store="1643" contenteditable="true"><surname store="1644" contenteditable="true">Everaert</surname><!--punc--> <!--punc--><given-names store="1645" contenteditable="true">H</given-names></name><!--punc-->, <!--punc--><name store="1646" contenteditable="true"><surname store="1647" contenteditable="true">Velkeniers</surname><!--punc--> <!--punc--><given-names store="1648" contenteditable="true">B</given-names></name><!--punc-->, <!--punc--><name store="1649" contenteditable="true"><surname store="1650" contenteditable="true">Neyns</surname><!--punc--> <!--punc--><given-names store="1651" contenteditable="true">B</given-names></name><!--punc--> &amp; <!--punc--><name store="1652" contenteditable="true"><surname store="1653" contenteditable="true">Bravenboer</surname><!--punc--> <!--punc--><given-names store="1654" contenteditable="true">B</given-names></name></person-group><delimiter store="1655" contenteditable="true">. </delimiter><article-title store="1656" contenteditable="true">Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab</article-title><delimiter store="1657" contenteditable="true">. </delimiter><source1 store="1658" contenteditable="true"><i store="1659" contenteditable="true">Journal of Clinical Endocrinology and Metabolism</i></source1><delimiter store="1660" contenteditable="true"> </delimiter><year store="1661" contenteditable="true">2016</year><delimiter store="1662" contenteditable="true"> </delimiter><volume1 store="1663" contenteditable="true"><!--punc--><b store="1664" contenteditable="true"><!--punc-->101<!--punc--></b><!--punc--></volume1><delimiter store="1665" contenteditable="true"> </delimiter><fpage1 store="1666" contenteditable="true">4431</fpage1><delimiter store="1667" contenteditable="true">–</delimiter><lpage1 store="1668" contenteditable="true">4439</lpage1><delimiter store="1669" contenteditable="true">. </delimiter><pub-id store="1670" contenteditable="true">(https://doi.org/10.1210/jc.2016-2300)</pub-id></mixed-citation></ref><ref id="CIT00019" store="1671" contenteditable="true"><label1 store="1672" contenteditable="true">19. </label1><mixed-citation publication-type="journal" store="1673" contenteditable="true"><person-group person-group-type="author" store="1674" contenteditable="true"><name store="1675" contenteditable="true"><surname store="1676" contenteditable="true">Farid</surname><!--punc--> <!--punc--><given-names store="1677" contenteditable="true">NR</given-names></name><!--punc-->, <!--punc--><name store="1678" contenteditable="true"><surname store="1679" contenteditable="true">Hawe</surname><!--punc--> <!--punc--><given-names store="1680" contenteditable="true">BS</given-names></name><!--punc--> &amp; <!--punc--><name store="1681" contenteditable="true"><surname store="1682" contenteditable="true">Walfish</surname><!--punc--> <!--punc--><given-names store="1683" contenteditable="true">PG</given-names></name></person-group><delimiter store="1684" contenteditable="true">. </delimiter><article-title store="1685" contenteditable="true">Increased frequency of HLA-DR3 and 5 in the syndromes of painless thyroiditis with transient thyrotoxicosis: evidence for an autoimmune aetiology</article-title><delimiter store="1686" contenteditable="true">. </delimiter><source1 store="1687" contenteditable="true"><i store="1688" contenteditable="true">Clinical Endocrinology</i></source1><delimiter store="1689" contenteditable="true"> </delimiter><year store="1690" contenteditable="true">1983</year><delimiter store="1691" contenteditable="true"> </delimiter><volume1 store="1692" contenteditable="true"><!--punc--><b store="1693" contenteditable="true"><!--punc-->19<!--punc--></b><!--punc--></volume1><delimiter store="1694" contenteditable="true"> </delimiter><fpage1 store="1695" contenteditable="true">699</fpage1><delimiter store="1696" contenteditable="true">–</delimiter><lpage1 store="1697" contenteditable="true">704</lpage1><delimiter store="1698" contenteditable="true">. </delimiter><pub-id store="1699" contenteditable="true">(https://doi.org/10.1111/j.1365-2265.1983.tb00047.x)</pub-id></mixed-citation></ref><ref id="CIT00020" store="1700" contenteditable="true"><label1 store="1701" contenteditable="true">20. </label1><mixed-citation publication-type="journal" store="1702" contenteditable="true"><person-group person-group-type="author" store="1703" contenteditable="true"><name store="1704" contenteditable="true"><surname store="1705" contenteditable="true">Pearce</surname><!--punc--> <!--punc--><given-names store="1706" contenteditable="true">EN</given-names></name><!--punc-->, <!--punc--><name store="1707" contenteditable="true"><surname store="1708" contenteditable="true">Farwell</surname><!--punc--> <!--punc--><given-names store="1709" contenteditable="true">AP</given-names></name><!--punc--> &amp; <!--punc--><name store="1710" contenteditable="true"><surname store="1711" contenteditable="true">Braverman</surname><!--punc--> <!--punc--><given-names store="1712" contenteditable="true">LE</given-names></name></person-group><delimiter store="1713" contenteditable="true">. </delimiter><article-title store="1714" contenteditable="true">Thyroiditis</article-title><delimiter store="1715" contenteditable="true">. </delimiter><source1 store="1716" contenteditable="true"><i store="1717" contenteditable="true">New England Journal of Medicine</i></source1><delimiter store="1718" contenteditable="true"> </delimiter><year store="1719" contenteditable="true">2003</year><delimiter store="1720" contenteditable="true"> </delimiter><volume1 store="1721" contenteditable="true"><!--punc--><b store="1722" contenteditable="true"><!--punc-->348<!--punc--></b><!--punc--></volume1><delimiter store="1723" contenteditable="true"> </delimiter><fpage1 store="1724" contenteditable="true">2646</fpage1><delimiter store="1725" contenteditable="true">–</delimiter><lpage1 store="1726" contenteditable="true">2655</lpage1><delimiter store="1727" contenteditable="true">. </delimiter><pub-id store="1728" contenteditable="true">(https://doi.org/10.1056/NEJMra021194)</pub-id></mixed-citation></ref><ref id="CIT00021" store="1729" contenteditable="true"><label1 store="1730" contenteditable="true">21. </label1><mixed-citation publication-type="journal" store="1731" contenteditable="true"><person-group person-group-type="author" store="1732" contenteditable="true"><name store="1733" contenteditable="true"><surname store="1734" contenteditable="true">Caturegli</surname><!--punc--> <!--punc--><given-names store="1735" contenteditable="true" style="" class="">P</given-names></name><!--punc-->, <!--punc--><name store="1736" contenteditable="true"><surname store="1737" contenteditable="true">De Remigis</surname><!--punc--> <!--punc--><given-names store="1738" contenteditable="true">A</given-names></name><!--punc--> &amp; <!--punc--><name store="1739" contenteditable="true"><surname store="1740" contenteditable="true">Rose</surname><!--punc--> <!--punc--><given-names store="1741" contenteditable="true">NR</given-names></name></person-group><delimiter store="1742" contenteditable="true">. </delimiter><article-title store="1743" contenteditable="true">Hashimoto thyroiditis: clinical and diagnostic criteria</article-title><delimiter store="1744" contenteditable="true">. </delimiter><source1 store="1745" contenteditable="true"><i store="1746" contenteditable="true">Autoimmunity Reviews</i></source1><delimiter store="1747" contenteditable="true"> </delimiter><year store="1748" contenteditable="true">2014</year><delimiter store="1749" contenteditable="true"> </delimiter><volume1 store="1750" contenteditable="true"><!--punc--><b store="1751" contenteditable="true"><!--punc-->13<!--punc--></b><!--punc--></volume1><delimiter store="1752" contenteditable="true"> </delimiter><fpage1 store="1753" contenteditable="true">391</fpage1><delimiter store="1754" contenteditable="true">–</delimiter><lpage1 store="1755" contenteditable="true">397</lpage1><delimiter store="1756" contenteditable="true">. </delimiter><pub-id store="1757" contenteditable="true">(https://doi.org/10.1016/j.autrev.2014.01.007)</pub-id></mixed-citation></ref><ref id="CIT00022" store="1758" contenteditable="true"><label1 store="1759" contenteditable="true">22. </label1><mixed-citation publication-type="journal" store="1760" contenteditable="true"><person-group person-group-type="author" store="1761" contenteditable="true"><name store="1762" contenteditable="true"><surname store="1763" contenteditable="true">Woolf</surname><!--punc--> <!--punc--><given-names store="1764" contenteditable="true">PD</given-names></name></person-group><delimiter store="1765" contenteditable="true">. </delimiter><article-title store="1766" contenteditable="true">Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis?</article-title><delimiter store="1767" contenteditable="true"> </delimiter><source1 store="1768" contenteditable="true"><i store="1769" contenteditable="true">Endocrine Reviews</i></source1><delimiter store="1770" contenteditable="true"> </delimiter><year store="1771" contenteditable="true">1980</year><delimiter store="1772" contenteditable="true"> </delimiter><volume1 store="1773" contenteditable="true"><!--punc--><b store="1774" contenteditable="true"><!--punc-->1<!--punc--></b><!--punc--></volume1><delimiter store="1775" contenteditable="true"> </delimiter><fpage1 store="1776" contenteditable="true">411</fpage1><delimiter store="1777" contenteditable="true">–</delimiter><lpage1 store="1778" contenteditable="true">420</lpage1><delimiter store="1779" contenteditable="true">. </delimiter><pub-id store="1780" contenteditable="true">(https://doi.org/10.1210/edrv-1-4-411)</pub-id></mixed-citation></ref><ref id="CIT00023" store="1781" contenteditable="true"><label1 store="1782" contenteditable="true">23. </label1><mixed-citation publication-type="journal" store="1783" contenteditable="true"><person-group person-group-type="author" store="1784" contenteditable="true"><name store="1785" contenteditable="true"><surname store="1786" contenteditable="true">Scott</surname><!--punc--> <!--punc--><given-names store="1787" contenteditable="true">ES</given-names></name><!--punc-->, <!--punc--><name store="1788" contenteditable="true"><surname store="1789" contenteditable="true">Long</surname><!--punc--> <!--punc--><given-names store="1790" contenteditable="true">GV</given-names></name><!--punc-->, <!--punc--><name store="1791" contenteditable="true"><surname store="1792" contenteditable="true">Guminski</surname><!--punc--> <!--punc--><given-names store="1793" contenteditable="true">A</given-names></name><!--punc-->, <!--punc--><name store="1794" contenteditable="true"><surname store="1795" contenteditable="true">Clifton-Bligh</surname><!--punc--> <!--punc--><given-names store="1796" contenteditable="true">RJ</given-names></name><!--punc-->, <!--punc--><name store="1797" contenteditable="true"><surname store="1798" contenteditable="true">Menzies</surname><!--punc--> <!--punc--><given-names store="1799" contenteditable="true">AM</given-names></name><!--punc--> &amp; <!--punc--><name store="1800" contenteditable="true"><surname store="1801" contenteditable="true">Tsang</surname><!--punc--> <!--punc--><given-names store="1802" contenteditable="true">VH</given-names></name></person-group><delimiter store="1803" contenteditable="true">. </delimiter><article-title store="1804" contenteditable="true">The spectrum, incidence, kinetics, and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma</article-title><delimiter store="1805" contenteditable="true">. </delimiter><source1 store="1806" contenteditable="true"><i store="1807" contenteditable="true">European Journal of Endocrinology</i></source1><delimiter store="1808" contenteditable="true"> </delimiter><year store="1809" contenteditable="true">2018</year><delimiter store="1810" contenteditable="true"> </delimiter><volume1 store="1811" contenteditable="true"><!--punc--><b store="1812" contenteditable="true"><!--punc-->178<!--punc--></b><!--punc--></volume1><delimiter store="1813" contenteditable="true"> </delimiter><fpage1 store="1814" contenteditable="true">173</fpage1><delimiter store="1815" contenteditable="true">–</delimiter><lpage1 store="1816" contenteditable="true">180</lpage1><delimiter store="1817" contenteditable="true">. </delimiter><pub-id store="1818" contenteditable="true">(https://doi.org/10.1530/EJE-17-0810)</pub-id></mixed-citation></ref></ref-list></back><spellingerrors store="1819" contenteditable="true"><spellingerror language="US" store="1820" contenteditable="true"><word store="1821" contenteditable="true"><text store="1822" contenteditable="true">ipilimumab</text><suggestions store="1823" contenteditable="true"></suggestions></word><word store="1824" contenteditable="true"><text store="1825" contenteditable="true">Yervoy</text><suggestions store="1826" contenteditable="true"><suggestion store="1827" contenteditable="true">Hervey</suggestion><suggestion store="1828" contenteditable="true">Envoy</suggestion><suggestion store="1829" contenteditable="true">Leroy</suggestion><suggestion store="1830" contenteditable="true">Servo</suggestion><suggestion store="1831" contenteditable="true">Nervy</suggestion><suggestion store="1832" contenteditable="true">Fervor</suggestion><suggestion store="1833" contenteditable="true">Servos</suggestion><suggestion store="1834" contenteditable="true">Fermoy</suggestion></suggestions></word><word store="1835" contenteditable="true"><text store="1836" contenteditable="true">nivolumab</text><suggestions store="1837" contenteditable="true"></suggestions></word><word store="1838" contenteditable="true"><text store="1839" contenteditable="true">Opidivo</text><suggestions store="1840" contenteditable="true"></suggestions></word><word store="1841" contenteditable="true"><text store="1842" contenteditable="true">pembrolizumab</text><suggestions store="1843" contenteditable="true"></suggestions></word><word store="1844" contenteditable="true"><text store="1845" contenteditable="true">Keytruda</text><suggestions store="1846" contenteditable="true"></suggestions></word><word store="1847" contenteditable="true"><text store="1848" contenteditable="true">nivolumab</text><suggestions store="1849" contenteditable="true"></suggestions></word><word store="1850" contenteditable="true"><text store="1851" contenteditable="true">ipilimumab</text><suggestions store="1852" contenteditable="true"></suggestions></word><word store="1853" contenteditable="true"><text store="1854" contenteditable="true">urothelial</text><suggestions store="1855" contenteditable="true"></suggestions></word><word store="1856" contenteditable="true"><text store="1857" contenteditable="true">Nivolumab</text><suggestions store="1858" contenteditable="true"></suggestions></word><word store="1859" contenteditable="true"><text store="1860" contenteditable="true">pembrolizumab</text><suggestions store="1861" contenteditable="true"></suggestions></word><word store="1862" contenteditable="true"><text store="1863" contenteditable="true">licences</text><suggestions store="1864" contenteditable="true"><suggestion store="1865" contenteditable="true">licenses</suggestion><suggestion store="1866" contenteditable="true">license's</suggestion><suggestion store="1867" contenteditable="true">licensees</suggestion><suggestion store="1868" contenteditable="true">licenses'</suggestion></suggestions></word><word store="1869" contenteditable="true"><text store="1870" contenteditable="true">oesophageal</text><suggestions store="1871" contenteditable="true"><suggestion store="1872" contenteditable="true">esophageal</suggestion></suggestions></word><word store="1873" contenteditable="true"><text store="1874" contenteditable="true">irAE</text><suggestions store="1875" contenteditable="true"><suggestion store="1876" contenteditable="true">ire</suggestion><suggestion store="1877" contenteditable="true">irate</suggestion><suggestion store="1878" contenteditable="true">irater</suggestion></suggestions></word><word store="1879" contenteditable="true"><text store="1880" contenteditable="true">irAEs</text><suggestions store="1881" contenteditable="true"><suggestion store="1882" contenteditable="true">iris</suggestion><suggestion store="1883" contenteditable="true">eras</suggestion><suggestion store="1884" contenteditable="true">irises</suggestion><suggestion store="1885" contenteditable="true">iratest</suggestion><suggestion store="1886" contenteditable="true">erases</suggestion><suggestion store="1887" contenteditable="true">ire</suggestion></suggestions></word><word store="1888" contenteditable="true"><text store="1889" contenteditable="true">ipilimumab</text><suggestions store="1890" contenteditable="true"></suggestions></word><word store="1891" contenteditable="true"><text store="1892" contenteditable="true">irAE</text><suggestions store="1893" contenteditable="true"><suggestion store="1894" contenteditable="true">ire</suggestion><suggestion store="1895" contenteditable="true">irate</suggestion><suggestion store="1896" contenteditable="true">irater</suggestion></suggestions></word><word store="1897" contenteditable="true"><text store="1898" contenteditable="true">ipilimumab</text><suggestions store="1899" contenteditable="true"></suggestions></word><word store="1900" contenteditable="true"><text store="1901" contenteditable="true">hypophysitis</text><suggestions store="1902" contenteditable="true"></suggestions></word><word store="1903" contenteditable="true"><text store="1904" contenteditable="true">monotherapy</text><suggestions store="1905" contenteditable="true"><suggestion store="1906" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="1907" contenteditable="true"><text store="1908" contenteditable="true">irAEs</text><suggestions store="1909" contenteditable="true"><suggestion store="1910" contenteditable="true">iris</suggestion><suggestion store="1911" contenteditable="true">eras</suggestion><suggestion store="1912" contenteditable="true">irises</suggestion><suggestion store="1913" contenteditable="true">iratest</suggestion><suggestion store="1914" contenteditable="true">erases</suggestion><suggestion store="1915" contenteditable="true">ire</suggestion></suggestions></word><word store="1916" contenteditable="true"><text store="1917" contenteditable="true">irAEs</text><suggestions store="1918" contenteditable="true"><suggestion store="1919" contenteditable="true">iris</suggestion><suggestion store="1920" contenteditable="true">eras</suggestion><suggestion store="1921" contenteditable="true">irises</suggestion><suggestion store="1922" contenteditable="true">iratest</suggestion><suggestion store="1923" contenteditable="true">erases</suggestion><suggestion store="1924" contenteditable="true">ire</suggestion></suggestions></word><word store="1925" contenteditable="true"><text store="1926" contenteditable="true">irAEs</text><suggestions store="1927" contenteditable="true"><suggestion store="1928" contenteditable="true">iris</suggestion><suggestion store="1929" contenteditable="true">eras</suggestion><suggestion store="1930" contenteditable="true">irises</suggestion><suggestion store="1931" contenteditable="true">iratest</suggestion><suggestion store="1932" contenteditable="true">erases</suggestion><suggestion store="1933" contenteditable="true">ire</suggestion></suggestions></word><word store="1934" contenteditable="true"><text store="1935" contenteditable="true">ipilimumab</text><suggestions store="1936" contenteditable="true"></suggestions></word><word store="1937" contenteditable="true"><text store="1938" contenteditable="true">irAEs</text><suggestions store="1939" contenteditable="true"><suggestion store="1940" contenteditable="true">iris</suggestion><suggestion store="1941" contenteditable="true">eras</suggestion><suggestion store="1942" contenteditable="true">irises</suggestion><suggestion store="1943" contenteditable="true">iratest</suggestion><suggestion store="1944" contenteditable="true">erases</suggestion><suggestion store="1945" contenteditable="true">ire</suggestion></suggestions></word><word store="1946" contenteditable="true"><text store="1947" contenteditable="true">endocrinopathies</text><suggestions store="1948" contenteditable="true"></suggestions></word><word store="1949" contenteditable="true"><text store="1950" contenteditable="true">irAEs</text><suggestions store="1951" contenteditable="true"><suggestion store="1952" contenteditable="true">iris</suggestion><suggestion store="1953" contenteditable="true">eras</suggestion><suggestion store="1954" contenteditable="true">irises</suggestion><suggestion store="1955" contenteditable="true">iratest</suggestion><suggestion store="1956" contenteditable="true">erases</suggestion><suggestion store="1957" contenteditable="true">ire</suggestion></suggestions></word><word store="1958" contenteditable="true"><text store="1959" contenteditable="true">characterise</text><suggestions store="1960" contenteditable="true"><suggestion store="1961" contenteditable="true">characterize</suggestion><suggestion store="1962" contenteditable="true">characterized</suggestion><suggestion store="1963" contenteditable="true">characterizes</suggestion></suggestions></word><word store="1964" contenteditable="true"><text store="1965" contenteditable="true">centre</text><suggestions store="1966" contenteditable="true"><suggestion store="1967" contenteditable="true">center</suggestion><suggestion store="1968" contenteditable="true">Centre</suggestion><suggestion store="1969" contenteditable="true">canter</suggestion></suggestions></word><word store="1970" contenteditable="true"><text store="1971" contenteditable="true">Clatterbridge</text><suggestions store="1972" contenteditable="true"><suggestion store="1973" contenteditable="true">Clatter bridge</suggestion></suggestions></word><word store="1974" contenteditable="true"><text store="1975" contenteditable="true">monotherapy</text><suggestions store="1976" contenteditable="true"><suggestion store="1977" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="1978" contenteditable="true"><text store="1979" contenteditable="true">pembrolizumab</text><suggestions store="1980" contenteditable="true"></suggestions></word><word store="1981" contenteditable="true"><text store="1982" contenteditable="true">nivolumab</text><suggestions store="1983" contenteditable="true"></suggestions></word><word store="1984" contenteditable="true"><text store="1985" contenteditable="true">nivolumab</text><suggestions store="1986" contenteditable="true"></suggestions></word><word store="1987" contenteditable="true"><text store="1988" contenteditable="true">ipilimumab</text><suggestions store="1989" contenteditable="true"></suggestions></word><word store="1990" contenteditable="true"><text store="1991" contenteditable="true">titres</text><suggestions store="1992" contenteditable="true"><suggestion store="1993" contenteditable="true">titers</suggestion><suggestion store="1994" contenteditable="true">tires</suggestion><suggestion store="1995" contenteditable="true">titters</suggestion><suggestion store="1996" contenteditable="true">tithes</suggestion><suggestion store="1997" contenteditable="true">titles</suggestion><suggestion store="1998" contenteditable="true">titer's</suggestion><suggestion store="1999" contenteditable="true">tetras</suggestion><suggestion store="2000" contenteditable="true">titers'</suggestion><suggestion store="2001" contenteditable="true">tortes</suggestion></suggestions></word><word store="2002" contenteditable="true"><text store="2003" contenteditable="true">TRAb</text><suggestions store="2004" contenteditable="true"><suggestion store="2005" contenteditable="true">Tab</suggestion><suggestion store="2006" contenteditable="true">Tribe</suggestion><suggestion store="2007" contenteditable="true">Tar</suggestion><suggestion store="2008" contenteditable="true">Throb</suggestion><suggestion store="2009" contenteditable="true">Traps</suggestion><suggestion store="2010" contenteditable="true">Trobe</suggestion><suggestion store="2011" contenteditable="true">Trap</suggestion></suggestions></word><word store="2012" contenteditable="true"><text store="2013" contenteditable="true">thyroidism</text><suggestions store="2014" contenteditable="true"><suggestion store="2015" contenteditable="true">thyroids</suggestion><suggestion store="2016" contenteditable="true">thyroids'</suggestion><suggestion store="2017" contenteditable="true">thyroid's</suggestion></suggestions></word><word store="2018" contenteditable="true"><text store="2019" contenteditable="true">eg</text><suggestions store="2020" contenteditable="true"><suggestion store="2021" contenteditable="true">egg</suggestion><suggestion store="2022" contenteditable="true">ego</suggestion><suggestion store="2023" contenteditable="true">e.g.</suggestion><suggestion store="2024" contenteditable="true">erg</suggestion><suggestion store="2025" contenteditable="true">eggs</suggestion><suggestion store="2026" contenteditable="true">beg</suggestion></suggestions></word><word store="2027" contenteditable="true"><text store="2028" contenteditable="true">pmol</text><suggestions store="2029" contenteditable="true"><suggestion store="2030" contenteditable="true">pool</suggestion><suggestion store="2031" contenteditable="true">poll</suggestion><suggestion store="2032" contenteditable="true">pole</suggestion><suggestion store="2033" contenteditable="true">polo</suggestion><suggestion store="2034" contenteditable="true">pomp</suggestion><suggestion store="2035" contenteditable="true">moll</suggestion><suggestion store="2036" contenteditable="true">pools</suggestion><suggestion store="2037" contenteditable="true">mold</suggestion><suggestion store="2038" contenteditable="true">mole</suggestion><suggestion store="2039" contenteditable="true">prowl</suggestion></suggestions></word><word store="2040" contenteditable="true"><text store="2041" contenteditable="true">mU</text><suggestions store="2042" contenteditable="true"><suggestion store="2043" contenteditable="true">mud</suggestion><suggestion store="2044" contenteditable="true">mug</suggestion><suggestion store="2045" contenteditable="true">mum</suggestion><suggestion store="2046" contenteditable="true">mo.</suggestion><suggestion store="2047" contenteditable="true">mi.</suggestion><suggestion store="2048" contenteditable="true">mow</suggestion><suggestion store="2049" contenteditable="true">much</suggestion><suggestion store="2050" contenteditable="true">must</suggestion><suggestion store="2051" contenteditable="true">mob</suggestion><suggestion store="2052" contenteditable="true">mom</suggestion></suggestions></word><word store="2053" contenteditable="true"><text store="2054" contenteditable="true">pmol</text><suggestions store="2055" contenteditable="true"><suggestion store="2056" contenteditable="true">pool</suggestion><suggestion store="2057" contenteditable="true">poll</suggestion><suggestion store="2058" contenteditable="true">pole</suggestion><suggestion store="2059" contenteditable="true">polo</suggestion><suggestion store="2060" contenteditable="true">pomp</suggestion><suggestion store="2061" contenteditable="true">moll</suggestion><suggestion store="2062" contenteditable="true">pools</suggestion><suggestion store="2063" contenteditable="true">mold</suggestion><suggestion store="2064" contenteditable="true">mole</suggestion><suggestion store="2065" contenteditable="true">prowl</suggestion></suggestions></word><word store="2066" contenteditable="true"><text store="2067" contenteditable="true">TRAb</text><suggestions store="2068" contenteditable="true"><suggestion store="2069" contenteditable="true">Tab</suggestion><suggestion store="2070" contenteditable="true">Tribe</suggestion><suggestion store="2071" contenteditable="true">Tar</suggestion><suggestion store="2072" contenteditable="true">Throb</suggestion><suggestion store="2073" contenteditable="true">Traps</suggestion><suggestion store="2074" contenteditable="true">Trobe</suggestion><suggestion store="2075" contenteditable="true">Trap</suggestion></suggestions></word><word store="2076" contenteditable="true"><text store="2077" contenteditable="true">mL.</text><suggestions store="2078" contenteditable="true"><suggestion store="2079" contenteditable="true">Mr.</suggestion><suggestion store="2080" contenteditable="true">Ms.</suggestion><suggestion store="2081" contenteditable="true">mall</suggestion><suggestion store="2082" contenteditable="true">malt</suggestion><suggestion store="2083" contenteditable="true">meld</suggestion><suggestion store="2084" contenteditable="true">melt</suggestion><suggestion store="2085" contenteditable="true">mild</suggestion><suggestion store="2086" contenteditable="true">mile</suggestion><suggestion store="2087" contenteditable="true">milk</suggestion><suggestion store="2088" contenteditable="true">mill</suggestion></suggestions></word><word store="2089" contenteditable="true"><text store="2090" contenteditable="true">Clatterbridge</text><suggestions store="2091" contenteditable="true"><suggestion store="2092" contenteditable="true">Clatter bridge</suggestion></suggestions></word><word store="2093" contenteditable="true"><text store="2094" contenteditable="true">standardised</text><suggestions store="2095" contenteditable="true"><suggestion store="2096" contenteditable="true">standardized</suggestion></suggestions></word><word store="2097" contenteditable="true"><text store="2098" contenteditable="true">analysed</text><suggestions store="2099" contenteditable="true"><suggestion store="2100" contenteditable="true">analyzed</suggestion><suggestion store="2101" contenteditable="true">analyses</suggestion></suggestions></word><word store="2102" contenteditable="true"><text store="2103" contenteditable="true">Clatterbridge</text><suggestions store="2104" contenteditable="true"><suggestion store="2105" contenteditable="true">Clatter bridge</suggestion></suggestions></word><word store="2106" contenteditable="true"><text store="2107" contenteditable="true">Biobank</text><suggestions store="2108" contenteditable="true"><suggestion store="2109" contenteditable="true">Bio bank</suggestion><suggestion store="2110" contenteditable="true">Burbank</suggestion></suggestions></word><word store="2111" contenteditable="true"><text store="2112" contenteditable="true">Tg</text><suggestions store="2113" contenteditable="true"><suggestion store="2114" contenteditable="true">Tag</suggestion><suggestion store="2115" contenteditable="true">Tog</suggestion><suggestion store="2116" contenteditable="true">Tug</suggestion><suggestion store="2117" contenteditable="true">To</suggestion><suggestion store="2118" contenteditable="true">Tw</suggestion></suggestions></word><word store="2119" contenteditable="true"><text store="2120" contenteditable="true">analysed</text><suggestions store="2121" contenteditable="true"><suggestion store="2122" contenteditable="true">analyzed</suggestion><suggestion store="2123" contenteditable="true">analyses</suggestion></suggestions></word><word store="2124" contenteditable="true"><text store="2125" contenteditable="true">utilised</text><suggestions store="2126" contenteditable="true"><suggestion store="2127" contenteditable="true">utilized</suggestion></suggestions></word><word store="2128" contenteditable="true"><text store="2129" contenteditable="true">Kruskal</text><suggestions store="2130" contenteditable="true"><suggestion store="2131" contenteditable="true">Kreskas</suggestion><suggestion store="2132" contenteditable="true">Kristal</suggestion><suggestion store="2133" contenteditable="true">Crustal</suggestion><suggestion store="2134" contenteditable="true">Ruska</suggestion><suggestion store="2135" contenteditable="true">Krystal</suggestion><suggestion store="2136" contenteditable="true">Rascal</suggestion><suggestion store="2137" contenteditable="true">Kuala</suggestion></suggestions></word><word store="2138" contenteditable="true"><text store="2139" contenteditable="true">utilised</text><suggestions store="2140" contenteditable="true"><suggestion store="2141" contenteditable="true">utilized</suggestion></suggestions></word><word store="2142" contenteditable="true"><text store="2143" contenteditable="true">monotherapy</text><suggestions store="2144" contenteditable="true"><suggestion store="2145" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2146" contenteditable="true"><text store="2147" contenteditable="true">monotherapy</text><suggestions store="2148" contenteditable="true"><suggestion store="2149" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2150" contenteditable="true"><text store="2151" contenteditable="true">monotherapy</text><suggestions store="2152" contenteditable="true"><suggestion store="2153" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2154" contenteditable="true"><text store="2155" contenteditable="true">monotherapy</text><suggestions store="2156" contenteditable="true"><suggestion store="2157" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2158" contenteditable="true"><text store="2159" contenteditable="true">monotherapy</text><suggestions store="2160" contenteditable="true"><suggestion store="2161" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2162" contenteditable="true"><text store="2163" contenteditable="true">monotherapy</text><suggestions store="2164" contenteditable="true"><suggestion store="2165" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2166" contenteditable="true"><text store="2167" contenteditable="true">monotherapy</text><suggestions store="2168" contenteditable="true"><suggestion store="2169" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2170" contenteditable="true"><text store="2171" contenteditable="true">pmol</text><suggestions store="2172" contenteditable="true"><suggestion store="2173" contenteditable="true">pool</suggestion><suggestion store="2174" contenteditable="true">poll</suggestion><suggestion store="2175" contenteditable="true">pole</suggestion><suggestion store="2176" contenteditable="true">polo</suggestion><suggestion store="2177" contenteditable="true">pomp</suggestion><suggestion store="2178" contenteditable="true">moll</suggestion><suggestion store="2179" contenteditable="true">pools</suggestion><suggestion store="2180" contenteditable="true">mold</suggestion><suggestion store="2181" contenteditable="true">mole</suggestion><suggestion store="2182" contenteditable="true">prowl</suggestion></suggestions></word><word store="2183" contenteditable="true"><text store="2184" contenteditable="true">pmol</text><suggestions store="2185" contenteditable="true"><suggestion store="2186" contenteditable="true">pool</suggestion><suggestion store="2187" contenteditable="true">poll</suggestion><suggestion store="2188" contenteditable="true">pole</suggestion><suggestion store="2189" contenteditable="true">polo</suggestion><suggestion store="2190" contenteditable="true">pomp</suggestion><suggestion store="2191" contenteditable="true">moll</suggestion><suggestion store="2192" contenteditable="true">pools</suggestion><suggestion store="2193" contenteditable="true">mold</suggestion><suggestion store="2194" contenteditable="true">mole</suggestion><suggestion store="2195" contenteditable="true">prowl</suggestion></suggestions></word><word store="2196" contenteditable="true"><text store="2197" contenteditable="true">mU</text><suggestions store="2198" contenteditable="true"><suggestion store="2199" contenteditable="true">mud</suggestion><suggestion store="2200" contenteditable="true">mug</suggestion><suggestion store="2201" contenteditable="true">mum</suggestion><suggestion store="2202" contenteditable="true">mo.</suggestion><suggestion store="2203" contenteditable="true">mi.</suggestion><suggestion store="2204" contenteditable="true">mow</suggestion><suggestion store="2205" contenteditable="true">much</suggestion><suggestion store="2206" contenteditable="true">must</suggestion><suggestion store="2207" contenteditable="true">mob</suggestion><suggestion store="2208" contenteditable="true">mom</suggestion></suggestions></word><word store="2209" contenteditable="true"><text store="2210" contenteditable="true">pmol</text><suggestions store="2211" contenteditable="true"><suggestion store="2212" contenteditable="true">pool</suggestion><suggestion store="2213" contenteditable="true">poll</suggestion><suggestion store="2214" contenteditable="true">pole</suggestion><suggestion store="2215" contenteditable="true">polo</suggestion><suggestion store="2216" contenteditable="true">pomp</suggestion><suggestion store="2217" contenteditable="true">moll</suggestion><suggestion store="2218" contenteditable="true">pools</suggestion><suggestion store="2219" contenteditable="true">mold</suggestion><suggestion store="2220" contenteditable="true">mole</suggestion><suggestion store="2221" contenteditable="true">prowl</suggestion></suggestions></word><word store="2222" contenteditable="true"><text store="2223" contenteditable="true">pmol</text><suggestions store="2224" contenteditable="true"><suggestion store="2225" contenteditable="true">pool</suggestion><suggestion store="2226" contenteditable="true">poll</suggestion><suggestion store="2227" contenteditable="true">pole</suggestion><suggestion store="2228" contenteditable="true">polo</suggestion><suggestion store="2229" contenteditable="true">pomp</suggestion><suggestion store="2230" contenteditable="true">moll</suggestion><suggestion store="2231" contenteditable="true">pools</suggestion><suggestion store="2232" contenteditable="true">mold</suggestion><suggestion store="2233" contenteditable="true">mole</suggestion><suggestion store="2234" contenteditable="true">prowl</suggestion></suggestions></word><word store="2235" contenteditable="true"><text store="2236" contenteditable="true">mU</text><suggestions store="2237" contenteditable="true"><suggestion store="2238" contenteditable="true">mud</suggestion><suggestion store="2239" contenteditable="true">mug</suggestion><suggestion store="2240" contenteditable="true">mum</suggestion><suggestion store="2241" contenteditable="true">mo.</suggestion><suggestion store="2242" contenteditable="true">mi.</suggestion><suggestion store="2243" contenteditable="true">mow</suggestion><suggestion store="2244" contenteditable="true">much</suggestion><suggestion store="2245" contenteditable="true">must</suggestion><suggestion store="2246" contenteditable="true">mob</suggestion><suggestion store="2247" contenteditable="true">mom</suggestion></suggestions></word><word store="2248" contenteditable="true"><text store="2249" contenteditable="true">mU</text><suggestions store="2250" contenteditable="true"><suggestion store="2251" contenteditable="true">mud</suggestion><suggestion store="2252" contenteditable="true">mug</suggestion><suggestion store="2253" contenteditable="true">mum</suggestion><suggestion store="2254" contenteditable="true">mo.</suggestion><suggestion store="2255" contenteditable="true">mi.</suggestion><suggestion store="2256" contenteditable="true">mow</suggestion><suggestion store="2257" contenteditable="true">much</suggestion><suggestion store="2258" contenteditable="true">must</suggestion><suggestion store="2259" contenteditable="true">mob</suggestion><suggestion store="2260" contenteditable="true">mom</suggestion></suggestions></word><word store="2261" contenteditable="true"><text store="2262" contenteditable="true">mU</text><suggestions store="2263" contenteditable="true"><suggestion store="2264" contenteditable="true">mud</suggestion><suggestion store="2265" contenteditable="true">mug</suggestion><suggestion store="2266" contenteditable="true">mum</suggestion><suggestion store="2267" contenteditable="true">mo.</suggestion><suggestion store="2268" contenteditable="true">mi.</suggestion><suggestion store="2269" contenteditable="true">mow</suggestion><suggestion store="2270" contenteditable="true">much</suggestion><suggestion store="2271" contenteditable="true">must</suggestion><suggestion store="2272" contenteditable="true">mob</suggestion><suggestion store="2273" contenteditable="true">mom</suggestion></suggestions></word><word store="2274" contenteditable="true"><text store="2275" contenteditable="true">mU</text><suggestions store="2276" contenteditable="true"><suggestion store="2277" contenteditable="true">mud</suggestion><suggestion store="2278" contenteditable="true">mug</suggestion><suggestion store="2279" contenteditable="true">mum</suggestion><suggestion store="2280" contenteditable="true">mo.</suggestion><suggestion store="2281" contenteditable="true">mi.</suggestion><suggestion store="2282" contenteditable="true">mow</suggestion><suggestion store="2283" contenteditable="true">much</suggestion><suggestion store="2284" contenteditable="true">must</suggestion><suggestion store="2285" contenteditable="true">mob</suggestion><suggestion store="2286" contenteditable="true">mom</suggestion></suggestions></word><word store="2287" contenteditable="true"><text store="2288" contenteditable="true">mU</text><suggestions store="2289" contenteditable="true"><suggestion store="2290" contenteditable="true">mud</suggestion><suggestion store="2291" contenteditable="true">mug</suggestion><suggestion store="2292" contenteditable="true">mum</suggestion><suggestion store="2293" contenteditable="true">mo.</suggestion><suggestion store="2294" contenteditable="true">mi.</suggestion><suggestion store="2295" contenteditable="true">mow</suggestion><suggestion store="2296" contenteditable="true">much</suggestion><suggestion store="2297" contenteditable="true">must</suggestion><suggestion store="2298" contenteditable="true">mob</suggestion><suggestion store="2299" contenteditable="true">mom</suggestion></suggestions></word><word store="2300" contenteditable="true"><text store="2301" contenteditable="true">monotherapy</text><suggestions store="2302" contenteditable="true"><suggestion store="2303" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2304" contenteditable="true"><text store="2305" contenteditable="true">pmol</text><suggestions store="2306" contenteditable="true"><suggestion store="2307" contenteditable="true">pool</suggestion><suggestion store="2308" contenteditable="true">poll</suggestion><suggestion store="2309" contenteditable="true">pole</suggestion><suggestion store="2310" contenteditable="true">polo</suggestion><suggestion store="2311" contenteditable="true">pomp</suggestion><suggestion store="2312" contenteditable="true">moll</suggestion><suggestion store="2313" contenteditable="true">pools</suggestion><suggestion store="2314" contenteditable="true">mold</suggestion><suggestion store="2315" contenteditable="true">mole</suggestion><suggestion store="2316" contenteditable="true">prowl</suggestion></suggestions></word><word store="2317" contenteditable="true"><text store="2318" contenteditable="true">pmol</text><suggestions store="2319" contenteditable="true"><suggestion store="2320" contenteditable="true">pool</suggestion><suggestion store="2321" contenteditable="true">poll</suggestion><suggestion store="2322" contenteditable="true">pole</suggestion><suggestion store="2323" contenteditable="true">polo</suggestion><suggestion store="2324" contenteditable="true">pomp</suggestion><suggestion store="2325" contenteditable="true">moll</suggestion><suggestion store="2326" contenteditable="true">pools</suggestion><suggestion store="2327" contenteditable="true">mold</suggestion><suggestion store="2328" contenteditable="true">mole</suggestion><suggestion store="2329" contenteditable="true">prowl</suggestion></suggestions></word><word store="2330" contenteditable="true"><text store="2331" contenteditable="true">mU</text><suggestions store="2332" contenteditable="true"><suggestion store="2333" contenteditable="true">mud</suggestion><suggestion store="2334" contenteditable="true">mug</suggestion><suggestion store="2335" contenteditable="true">mum</suggestion><suggestion store="2336" contenteditable="true">mo.</suggestion><suggestion store="2337" contenteditable="true">mi.</suggestion><suggestion store="2338" contenteditable="true">mow</suggestion><suggestion store="2339" contenteditable="true">much</suggestion><suggestion store="2340" contenteditable="true">must</suggestion><suggestion store="2341" contenteditable="true">mob</suggestion><suggestion store="2342" contenteditable="true">mom</suggestion></suggestions></word><word store="2343" contenteditable="true"><text store="2344" contenteditable="true">mU</text><suggestions store="2345" contenteditable="true"><suggestion store="2346" contenteditable="true">mud</suggestion><suggestion store="2347" contenteditable="true">mug</suggestion><suggestion store="2348" contenteditable="true">mum</suggestion><suggestion store="2349" contenteditable="true">mo.</suggestion><suggestion store="2350" contenteditable="true">mi.</suggestion><suggestion store="2351" contenteditable="true">mow</suggestion><suggestion store="2352" contenteditable="true">much</suggestion><suggestion store="2353" contenteditable="true">must</suggestion><suggestion store="2354" contenteditable="true">mob</suggestion><suggestion store="2355" contenteditable="true">mom</suggestion></suggestions></word><word store="2356" contenteditable="true"><text store="2357" contenteditable="true">pmol</text><suggestions store="2358" contenteditable="true"><suggestion store="2359" contenteditable="true">pool</suggestion><suggestion store="2360" contenteditable="true">poll</suggestion><suggestion store="2361" contenteditable="true">pole</suggestion><suggestion store="2362" contenteditable="true">polo</suggestion><suggestion store="2363" contenteditable="true">pomp</suggestion><suggestion store="2364" contenteditable="true">moll</suggestion><suggestion store="2365" contenteditable="true">pools</suggestion><suggestion store="2366" contenteditable="true">mold</suggestion><suggestion store="2367" contenteditable="true">mole</suggestion><suggestion store="2368" contenteditable="true">prowl</suggestion></suggestions></word><word store="2369" contenteditable="true"><text store="2370" contenteditable="true">goitre</text><suggestions store="2371" contenteditable="true"><suggestion store="2372" contenteditable="true">goiter</suggestion><suggestion store="2373" contenteditable="true">goiters</suggestion><suggestion store="2374" contenteditable="true">gaiter</suggestion></suggestions></word><word store="2375" contenteditable="true"><text store="2376" contenteditable="true">myxoedema</text><suggestions store="2377" contenteditable="true"><suggestion store="2378" contenteditable="true">myxedema</suggestion></suggestions></word><word store="2379" contenteditable="true"><text store="2380" contenteditable="true">thioamides</text><suggestions store="2381" contenteditable="true"><suggestion store="2382" contenteditable="true">thiazides</suggestion></suggestions></word><word store="2383" contenteditable="true"><text store="2384" contenteditable="true">mU</text><suggestions store="2385" contenteditable="true"><suggestion store="2386" contenteditable="true">mud</suggestion><suggestion store="2387" contenteditable="true">mug</suggestion><suggestion store="2388" contenteditable="true">mum</suggestion><suggestion store="2389" contenteditable="true">mo.</suggestion><suggestion store="2390" contenteditable="true">mi.</suggestion><suggestion store="2391" contenteditable="true">mow</suggestion><suggestion store="2392" contenteditable="true">much</suggestion><suggestion store="2393" contenteditable="true">must</suggestion><suggestion store="2394" contenteditable="true">mob</suggestion><suggestion store="2395" contenteditable="true">mom</suggestion></suggestions></word><word store="2396" contenteditable="true"><text store="2397" contenteditable="true">mU</text><suggestions store="2398" contenteditable="true"><suggestion store="2399" contenteditable="true">mud</suggestion><suggestion store="2400" contenteditable="true">mug</suggestion><suggestion store="2401" contenteditable="true">mum</suggestion><suggestion store="2402" contenteditable="true">mo.</suggestion><suggestion store="2403" contenteditable="true">mi.</suggestion><suggestion store="2404" contenteditable="true">mow</suggestion><suggestion store="2405" contenteditable="true">much</suggestion><suggestion store="2406" contenteditable="true">must</suggestion><suggestion store="2407" contenteditable="true">mob</suggestion><suggestion store="2408" contenteditable="true">mom</suggestion></suggestions></word><word store="2409" contenteditable="true"><text store="2410" contenteditable="true">mU</text><suggestions store="2411" contenteditable="true"><suggestion store="2412" contenteditable="true">mud</suggestion><suggestion store="2413" contenteditable="true">mug</suggestion><suggestion store="2414" contenteditable="true">mum</suggestion><suggestion store="2415" contenteditable="true">mo.</suggestion><suggestion store="2416" contenteditable="true">mi.</suggestion><suggestion store="2417" contenteditable="true">mow</suggestion><suggestion store="2418" contenteditable="true">much</suggestion><suggestion store="2419" contenteditable="true">must</suggestion><suggestion store="2420" contenteditable="true">mob</suggestion><suggestion store="2421" contenteditable="true">mom</suggestion></suggestions></word><word store="2422" contenteditable="true"><text store="2423" contenteditable="true">mU</text><suggestions store="2424" contenteditable="true"><suggestion store="2425" contenteditable="true">mud</suggestion><suggestion store="2426" contenteditable="true">mug</suggestion><suggestion store="2427" contenteditable="true">mum</suggestion><suggestion store="2428" contenteditable="true">mo.</suggestion><suggestion store="2429" contenteditable="true">mi.</suggestion><suggestion store="2430" contenteditable="true">mow</suggestion><suggestion store="2431" contenteditable="true">much</suggestion><suggestion store="2432" contenteditable="true">must</suggestion><suggestion store="2433" contenteditable="true">mob</suggestion><suggestion store="2434" contenteditable="true">mom</suggestion></suggestions></word><word store="2435" contenteditable="true"><text store="2436" contenteditable="true">Tg</text><suggestions store="2437" contenteditable="true"><suggestion store="2438" contenteditable="true">Tag</suggestion><suggestion store="2439" contenteditable="true">Tog</suggestion><suggestion store="2440" contenteditable="true">Tug</suggestion><suggestion store="2441" contenteditable="true">To</suggestion><suggestion store="2442" contenteditable="true">Tw</suggestion></suggestions></word><word store="2443" contenteditable="true"><text store="2444" contenteditable="true">TRAb</text><suggestions store="2445" contenteditable="true"><suggestion store="2446" contenteditable="true">Tab</suggestion><suggestion store="2447" contenteditable="true">Tribe</suggestion><suggestion store="2448" contenteditable="true">Tar</suggestion><suggestion store="2449" contenteditable="true">Throb</suggestion><suggestion store="2450" contenteditable="true">Traps</suggestion><suggestion store="2451" contenteditable="true">Trobe</suggestion><suggestion store="2452" contenteditable="true">Trap</suggestion></suggestions></word><word store="2453" contenteditable="true"><text store="2454" contenteditable="true">pembrolizumab</text><suggestions store="2455" contenteditable="true"></suggestions></word><word store="2456" contenteditable="true"><text store="2457" contenteditable="true">monotherapy</text><suggestions store="2458" contenteditable="true"><suggestion store="2459" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2460" contenteditable="true"><text store="2461" contenteditable="true">titre</text><suggestions store="2462" contenteditable="true"><suggestion store="2463" contenteditable="true">titer</suggestion><suggestion store="2464" contenteditable="true">titter</suggestion><suggestion store="2465" contenteditable="true">tire</suggestion><suggestion store="2466" contenteditable="true">tithe</suggestion><suggestion store="2467" contenteditable="true">title</suggestion><suggestion store="2468" contenteditable="true">titers</suggestion><suggestion store="2469" contenteditable="true">tetra</suggestion><suggestion store="2470" contenteditable="true">trite</suggestion><suggestion store="2471" contenteditable="true">torte</suggestion></suggestions></word><word store="2472" contenteditable="true"><text store="2473" contenteditable="true">mL.</text><suggestions store="2474" contenteditable="true"><suggestion store="2475" contenteditable="true">Mr.</suggestion><suggestion store="2476" contenteditable="true">Ms.</suggestion><suggestion store="2477" contenteditable="true">mall</suggestion><suggestion store="2478" contenteditable="true">malt</suggestion><suggestion store="2479" contenteditable="true">meld</suggestion><suggestion store="2480" contenteditable="true">melt</suggestion><suggestion store="2481" contenteditable="true">mild</suggestion><suggestion store="2482" contenteditable="true">mile</suggestion><suggestion store="2483" contenteditable="true">milk</suggestion><suggestion store="2484" contenteditable="true">mill</suggestion></suggestions></word><word store="2485" contenteditable="true"><text store="2486" contenteditable="true">titre</text><suggestions store="2487" contenteditable="true"><suggestion store="2488" contenteditable="true">titer</suggestion><suggestion store="2489" contenteditable="true">titter</suggestion><suggestion store="2490" contenteditable="true">tire</suggestion><suggestion store="2491" contenteditable="true">tithe</suggestion><suggestion store="2492" contenteditable="true">title</suggestion><suggestion store="2493" contenteditable="true">titers</suggestion><suggestion store="2494" contenteditable="true">tetra</suggestion><suggestion store="2495" contenteditable="true">trite</suggestion><suggestion store="2496" contenteditable="true">torte</suggestion></suggestions></word><word store="2497" contenteditable="true"><text store="2498" contenteditable="true">Tg</text><suggestions store="2499" contenteditable="true"><suggestion store="2500" contenteditable="true">Tag</suggestion><suggestion store="2501" contenteditable="true">Tog</suggestion><suggestion store="2502" contenteditable="true">Tug</suggestion><suggestion store="2503" contenteditable="true">To</suggestion><suggestion store="2504" contenteditable="true">Tw</suggestion></suggestions></word><word store="2505" contenteditable="true"><text store="2506" contenteditable="true">mL.</text><suggestions store="2507" contenteditable="true"><suggestion store="2508" contenteditable="true">Mr.</suggestion><suggestion store="2509" contenteditable="true">Ms.</suggestion><suggestion store="2510" contenteditable="true">mall</suggestion><suggestion store="2511" contenteditable="true">malt</suggestion><suggestion store="2512" contenteditable="true">meld</suggestion><suggestion store="2513" contenteditable="true">melt</suggestion><suggestion store="2514" contenteditable="true">mild</suggestion><suggestion store="2515" contenteditable="true">mile</suggestion><suggestion store="2516" contenteditable="true">milk</suggestion><suggestion store="2517" contenteditable="true">mill</suggestion></suggestions></word><word store="2518" contenteditable="true"><text store="2519" contenteditable="true">pembrolizumab</text><suggestions store="2520" contenteditable="true"></suggestions></word><word store="2521" contenteditable="true"><text store="2522" contenteditable="true">monotherapy</text><suggestions store="2523" contenteditable="true"><suggestion store="2524" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2525" contenteditable="true"><text store="2526" contenteditable="true">titre</text><suggestions store="2527" contenteditable="true"><suggestion store="2528" contenteditable="true">titer</suggestion><suggestion store="2529" contenteditable="true">titter</suggestion><suggestion store="2530" contenteditable="true">tire</suggestion><suggestion store="2531" contenteditable="true">tithe</suggestion><suggestion store="2532" contenteditable="true">title</suggestion><suggestion store="2533" contenteditable="true">titers</suggestion><suggestion store="2534" contenteditable="true">tetra</suggestion><suggestion store="2535" contenteditable="true">trite</suggestion><suggestion store="2536" contenteditable="true">torte</suggestion></suggestions></word><word store="2537" contenteditable="true"><text store="2538" contenteditable="true">TRAb</text><suggestions store="2539" contenteditable="true"><suggestion store="2540" contenteditable="true">Tab</suggestion><suggestion store="2541" contenteditable="true">Tribe</suggestion><suggestion store="2542" contenteditable="true">Tar</suggestion><suggestion store="2543" contenteditable="true">Throb</suggestion><suggestion store="2544" contenteditable="true">Traps</suggestion><suggestion store="2545" contenteditable="true">Trobe</suggestion><suggestion store="2546" contenteditable="true">Trap</suggestion></suggestions></word><word store="2547" contenteditable="true"><text store="2548" contenteditable="true">titre</text><suggestions store="2549" contenteditable="true"><suggestion store="2550" contenteditable="true">titer</suggestion><suggestion store="2551" contenteditable="true">titter</suggestion><suggestion store="2552" contenteditable="true">tire</suggestion><suggestion store="2553" contenteditable="true">tithe</suggestion><suggestion store="2554" contenteditable="true">title</suggestion><suggestion store="2555" contenteditable="true">titers</suggestion><suggestion store="2556" contenteditable="true">tetra</suggestion><suggestion store="2557" contenteditable="true">trite</suggestion><suggestion store="2558" contenteditable="true">torte</suggestion></suggestions></word><word store="2559" contenteditable="true"><text store="2560" contenteditable="true">pembrolizumab</text><suggestions store="2561" contenteditable="true"></suggestions></word><word store="2562" contenteditable="true"><text store="2563" contenteditable="true">monotherapy</text><suggestions store="2564" contenteditable="true"><suggestion store="2565" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2566" contenteditable="true"><text store="2567" contenteditable="true">Tg</text><suggestions store="2568" contenteditable="true"><suggestion store="2569" contenteditable="true">Tag</suggestion><suggestion store="2570" contenteditable="true">Tog</suggestion><suggestion store="2571" contenteditable="true">Tug</suggestion><suggestion store="2572" contenteditable="true">To</suggestion><suggestion store="2573" contenteditable="true">Tw</suggestion></suggestions></word><word store="2574" contenteditable="true"><text store="2575" contenteditable="true">titres</text><suggestions store="2576" contenteditable="true"><suggestion store="2577" contenteditable="true">titers</suggestion><suggestion store="2578" contenteditable="true">tires</suggestion><suggestion store="2579" contenteditable="true">titters</suggestion><suggestion store="2580" contenteditable="true">tithes</suggestion><suggestion store="2581" contenteditable="true">titles</suggestion><suggestion store="2582" contenteditable="true">titer's</suggestion><suggestion store="2583" contenteditable="true">tetras</suggestion><suggestion store="2584" contenteditable="true">titers'</suggestion><suggestion store="2585" contenteditable="true">tortes</suggestion></suggestions></word><word store="2586" contenteditable="true"><text store="2587" contenteditable="true">TRAb</text><suggestions store="2588" contenteditable="true"><suggestion store="2589" contenteditable="true">Tab</suggestion><suggestion store="2590" contenteditable="true">Tribe</suggestion><suggestion store="2591" contenteditable="true">Tar</suggestion><suggestion store="2592" contenteditable="true">Throb</suggestion><suggestion store="2593" contenteditable="true">Traps</suggestion><suggestion store="2594" contenteditable="true">Trobe</suggestion><suggestion store="2595" contenteditable="true">Trap</suggestion></suggestions></word><word store="2596" contenteditable="true"><text store="2597" contenteditable="true">TRAb</text><suggestions store="2598" contenteditable="true"><suggestion store="2599" contenteditable="true">Tab</suggestion><suggestion store="2600" contenteditable="true">Tribe</suggestion><suggestion store="2601" contenteditable="true">Tar</suggestion><suggestion store="2602" contenteditable="true">Throb</suggestion><suggestion store="2603" contenteditable="true">Traps</suggestion><suggestion store="2604" contenteditable="true">Trobe</suggestion><suggestion store="2605" contenteditable="true">Trap</suggestion></suggestions></word><word store="2606" contenteditable="true"><text store="2607" contenteditable="true">Tg</text><suggestions store="2608" contenteditable="true"><suggestion store="2609" contenteditable="true">Tag</suggestion><suggestion store="2610" contenteditable="true">Tog</suggestion><suggestion store="2611" contenteditable="true">Tug</suggestion><suggestion store="2612" contenteditable="true">To</suggestion><suggestion store="2613" contenteditable="true">Tw</suggestion></suggestions></word><word store="2614" contenteditable="true"><text store="2615" contenteditable="true">characterisation</text><suggestions store="2616" contenteditable="true"><suggestion store="2617" contenteditable="true">characterization</suggestion><suggestion store="2618" contenteditable="true">characterizations</suggestion></suggestions></word><word store="2619" contenteditable="true"><text store="2620" contenteditable="true">randomised</text><suggestions store="2621" contenteditable="true"><suggestion store="2622" contenteditable="true">randomized</suggestion></suggestions></word><word store="2623" contenteditable="true"><text store="2624" contenteditable="true">monotherapy</text><suggestions store="2625" contenteditable="true"><suggestion store="2626" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2627" contenteditable="true"><text store="2628" contenteditable="true">monotherapy</text><suggestions store="2629" contenteditable="true"><suggestion store="2630" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2631" contenteditable="true"><text store="2632" contenteditable="true">irAEs</text><suggestions store="2633" contenteditable="true"><suggestion store="2634" contenteditable="true">iris</suggestion><suggestion store="2635" contenteditable="true">eras</suggestion><suggestion store="2636" contenteditable="true">irises</suggestion><suggestion store="2637" contenteditable="true">iratest</suggestion><suggestion store="2638" contenteditable="true">erases</suggestion><suggestion store="2639" contenteditable="true">ire</suggestion></suggestions></word><word store="2640" contenteditable="true"><text store="2641" contenteditable="true">characterised</text><suggestions store="2642" contenteditable="true"><suggestion store="2643" contenteditable="true">characterized</suggestion></suggestions></word><word store="2644" contenteditable="true"><text store="2645" contenteditable="true">thyrotoxic</text><suggestions store="2646" contenteditable="true"><suggestion store="2647" contenteditable="true">phytotoxic</suggestion><suggestion store="2648" contenteditable="true">thyrotoxicosis</suggestion></suggestions></word><word store="2649" contenteditable="true"><text store="2650" contenteditable="true">triphasic</text><suggestions store="2651" contenteditable="true"><suggestion store="2652" contenteditable="true">diphasic</suggestion></suggestions></word><word store="2653" contenteditable="true"><text store="2654" contenteditable="true">euthyroidism</text><suggestions store="2655" contenteditable="true"></suggestions></word><word store="2656" contenteditable="true"><text store="2657" contenteditable="true">euthyroidism</text><suggestions store="2658" contenteditable="true"></suggestions></word><word store="2659" contenteditable="true"><text store="2660" contenteditable="true">euthyroidism</text><suggestions store="2661" contenteditable="true"></suggestions></word><word store="2662" contenteditable="true"><text store="2663" contenteditable="true">thyroxine</text><suggestions store="2664" contenteditable="true"><suggestion store="2665" contenteditable="true">thyroxin</suggestion></suggestions></word><word store="2666" contenteditable="true"><text store="2667" contenteditable="true">characterised</text><suggestions store="2668" contenteditable="true"><suggestion store="2669" contenteditable="true">characterized</suggestion></suggestions></word><word store="2670" contenteditable="true"><text store="2671" contenteditable="true">monotherapy</text><suggestions store="2672" contenteditable="true"><suggestion store="2673" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2674" contenteditable="true"><text store="2675" contenteditable="true">centre</text><suggestions store="2676" contenteditable="true"><suggestion store="2677" contenteditable="true">center</suggestion><suggestion store="2678" contenteditable="true">Centre</suggestion><suggestion store="2679" contenteditable="true">canter</suggestion></suggestions></word><word store="2680" contenteditable="true"><text store="2681" contenteditable="true">standardised</text><suggestions store="2682" contenteditable="true"><suggestion store="2683" contenteditable="true">standardized</suggestion></suggestions></word><word store="2684" contenteditable="true"><text store="2685" contenteditable="true">characterisation</text><suggestions store="2686" contenteditable="true"><suggestion store="2687" contenteditable="true">characterization</suggestion><suggestion store="2688" contenteditable="true">characterizations</suggestion></suggestions></word><word store="2689" contenteditable="true"><text store="2690" contenteditable="true">multicentre</text><suggestions store="2691" contenteditable="true"><suggestion store="2692" contenteditable="true">multicenter</suggestion></suggestions></word><word store="2693" contenteditable="true"><text store="2694" contenteditable="true">optimising</text><suggestions store="2695" contenteditable="true"><suggestion store="2696" contenteditable="true">optimizing</suggestion></suggestions></word><word store="2697" contenteditable="true"><text store="2698" contenteditable="true">irAEs</text><suggestions store="2699" contenteditable="true"><suggestion store="2700" contenteditable="true">iris</suggestion><suggestion store="2701" contenteditable="true">eras</suggestion><suggestion store="2702" contenteditable="true">irises</suggestion><suggestion store="2703" contenteditable="true">iratest</suggestion><suggestion store="2704" contenteditable="true">erases</suggestion><suggestion store="2705" contenteditable="true">ire</suggestion></suggestions></word><word store="2706" contenteditable="true"><text store="2707" contenteditable="true">Dr</text><suggestions store="2708" contenteditable="true"><suggestion store="2709" contenteditable="true">Dry</suggestion><suggestion store="2710" contenteditable="true">Rd.</suggestion><suggestion store="2711" contenteditable="true">Do</suggestion><suggestion store="2712" contenteditable="true">Ds</suggestion><suggestion store="2713" contenteditable="true">Dir.</suggestion><suggestion store="2714" contenteditable="true">R</suggestion><suggestion store="2715" contenteditable="true">Drab</suggestion><suggestion store="2716" contenteditable="true">Drag</suggestion><suggestion store="2717" contenteditable="true">Dram</suggestion><suggestion store="2718" contenteditable="true">Drat</suggestion></suggestions></word><word store="2719" contenteditable="true"><text store="2720" contenteditable="true">Tezzaro</text><suggestions store="2721" contenteditable="true"><suggestion store="2722" contenteditable="true">Tesoro</suggestion></suggestions></word><word store="2723" contenteditable="true"><text store="2724" contenteditable="true">Dr</text><suggestions store="2725" contenteditable="true"><suggestion store="2726" contenteditable="true">Dry</suggestion><suggestion store="2727" contenteditable="true">Rd.</suggestion><suggestion store="2728" contenteditable="true">Do</suggestion><suggestion store="2729" contenteditable="true">Ds</suggestion><suggestion store="2730" contenteditable="true">Dir.</suggestion><suggestion store="2731" contenteditable="true">R</suggestion><suggestion store="2732" contenteditable="true">Drab</suggestion><suggestion store="2733" contenteditable="true">Drag</suggestion><suggestion store="2734" contenteditable="true">Dram</suggestion><suggestion store="2735" contenteditable="true">Drat</suggestion></suggestions></word><word store="2736" contenteditable="true"><text store="2737" contenteditable="true">Immunocore</text><suggestions store="2738" contenteditable="true"></suggestions></word><word store="2739" contenteditable="true"><text store="2740" contenteditable="true">Dr</text><suggestions store="2741" contenteditable="true"><suggestion store="2742" contenteditable="true">Dry</suggestion><suggestion store="2743" contenteditable="true">Rd.</suggestion><suggestion store="2744" contenteditable="true">Do</suggestion><suggestion store="2745" contenteditable="true">Ds</suggestion><suggestion store="2746" contenteditable="true">Dir.</suggestion><suggestion store="2747" contenteditable="true">R</suggestion><suggestion store="2748" contenteditable="true">Drab</suggestion><suggestion store="2749" contenteditable="true">Drag</suggestion><suggestion store="2750" contenteditable="true">Dram</suggestion><suggestion store="2751" contenteditable="true">Drat</suggestion></suggestions></word><word store="2752" contenteditable="true"><text store="2753" contenteditable="true">Pharma</text><suggestions store="2754" contenteditable="true"><suggestion store="2755" contenteditable="true">Parma</suggestion><suggestion store="2756" contenteditable="true">Pharm</suggestion><suggestion store="2757" contenteditable="true">Pharms</suggestion><suggestion store="2758" contenteditable="true">Pharmacy</suggestion><suggestion store="2759" contenteditable="true">Pharmed</suggestion><suggestion store="2760" contenteditable="true">Pharm a</suggestion><suggestion store="2761" contenteditable="true">Dharma</suggestion><suggestion store="2762" contenteditable="true">Sharma</suggestion></suggestions></word><word store="2763" contenteditable="true"><text store="2764" contenteditable="true">Pharma</text><suggestions store="2765" contenteditable="true"><suggestion store="2766" contenteditable="true">Parma</suggestion><suggestion store="2767" contenteditable="true">Pharm</suggestion><suggestion store="2768" contenteditable="true">Pharms</suggestion><suggestion store="2769" contenteditable="true">Pharmacy</suggestion><suggestion store="2770" contenteditable="true">Pharmed</suggestion><suggestion store="2771" contenteditable="true">Pharm a</suggestion><suggestion store="2772" contenteditable="true">Dharma</suggestion><suggestion store="2773" contenteditable="true">Sharma</suggestion></suggestions></word><word store="2774" contenteditable="true"><text store="2775" contenteditable="true">Pirmohamed</text><suggestions store="2776" contenteditable="true"></suggestions></word><word store="2777" contenteditable="true"><text store="2778" contenteditable="true">Pharma</text><suggestions store="2779" contenteditable="true"><suggestion store="2780" contenteditable="true">Parma</suggestion><suggestion store="2781" contenteditable="true">Pharm</suggestion><suggestion store="2782" contenteditable="true">Pharms</suggestion><suggestion store="2783" contenteditable="true">Pharmacy</suggestion><suggestion store="2784" contenteditable="true">Pharmed</suggestion><suggestion store="2785" contenteditable="true">Pharm a</suggestion><suggestion store="2786" contenteditable="true">Dharma</suggestion><suggestion store="2787" contenteditable="true">Sharma</suggestion></suggestions></word><word store="2788" contenteditable="true"><text store="2789" contenteditable="true">Pharma</text><suggestions store="2790" contenteditable="true"><suggestion store="2791" contenteditable="true">Parma</suggestion><suggestion store="2792" contenteditable="true">Pharm</suggestion><suggestion store="2793" contenteditable="true">Pharms</suggestion><suggestion store="2794" contenteditable="true">Pharmacy</suggestion><suggestion store="2795" contenteditable="true">Pharmed</suggestion><suggestion store="2796" contenteditable="true">Pharm a</suggestion><suggestion store="2797" contenteditable="true">Dharma</suggestion><suggestion store="2798" contenteditable="true">Sharma</suggestion></suggestions></word><word store="2799" contenteditable="true"><text store="2800" contenteditable="true">Pharma</text><suggestions store="2801" contenteditable="true"><suggestion store="2802" contenteditable="true">Parma</suggestion><suggestion store="2803" contenteditable="true">Pharm</suggestion><suggestion store="2804" contenteditable="true">Pharms</suggestion><suggestion store="2805" contenteditable="true">Pharmacy</suggestion><suggestion store="2806" contenteditable="true">Pharmed</suggestion><suggestion store="2807" contenteditable="true">Pharm a</suggestion><suggestion store="2808" contenteditable="true">Dharma</suggestion><suggestion store="2809" contenteditable="true">Sharma</suggestion></suggestions></word><word store="2810" contenteditable="true"><text store="2811" contenteditable="true">Pharma</text><suggestions store="2812" contenteditable="true"><suggestion store="2813" contenteditable="true">Parma</suggestion><suggestion store="2814" contenteditable="true">Pharm</suggestion><suggestion store="2815" contenteditable="true">Pharms</suggestion><suggestion store="2816" contenteditable="true">Pharmacy</suggestion><suggestion store="2817" contenteditable="true">Pharmed</suggestion><suggestion store="2818" contenteditable="true">Pharm a</suggestion><suggestion store="2819" contenteditable="true">Dharma</suggestion><suggestion store="2820" contenteditable="true">Sharma</suggestion></suggestions></word></spellingerror><spellingerror language="UK" store="2821" contenteditable="true"><word store="2822" contenteditable="true"><text store="2823" contenteditable="true">ipilimumab</text><suggestions store="2824" contenteditable="true"></suggestions></word><word store="2825" contenteditable="true"><text store="2826" contenteditable="true">Yervoy</text><suggestions store="2827" contenteditable="true"></suggestions></word><word store="2828" contenteditable="true"><text store="2829" contenteditable="true">nivolumab</text><suggestions store="2830" contenteditable="true"></suggestions></word><word store="2831" contenteditable="true"><text store="2832" contenteditable="true">Opidivo</text><suggestions store="2833" contenteditable="true"></suggestions></word><word store="2834" contenteditable="true"><text store="2835" contenteditable="true">pembrolizumab</text><suggestions store="2836" contenteditable="true"></suggestions></word><word store="2837" contenteditable="true"><text store="2838" contenteditable="true">Keytruda</text><suggestions store="2839" contenteditable="true"></suggestions></word><word store="2840" contenteditable="true"><text store="2841" contenteditable="true">nivolumab</text><suggestions store="2842" contenteditable="true"></suggestions></word><word store="2843" contenteditable="true"><text store="2844" contenteditable="true">ipilimumab</text><suggestions store="2845" contenteditable="true"></suggestions></word><word store="2846" contenteditable="true"><text store="2847" contenteditable="true">urothelial</text><suggestions store="2848" contenteditable="true"></suggestions></word><word store="2849" contenteditable="true"><text store="2850" contenteditable="true">Nivolumab</text><suggestions store="2851" contenteditable="true"></suggestions></word><word store="2852" contenteditable="true"><text store="2853" contenteditable="true">pembrolizumab</text><suggestions store="2854" contenteditable="true"></suggestions></word><word store="2855" contenteditable="true"><text store="2856" contenteditable="true">irAE</text><suggestions store="2857" contenteditable="true"></suggestions></word><word store="2858" contenteditable="true"><text store="2859" contenteditable="true">irAEs</text><suggestions store="2860" contenteditable="true"><suggestion store="2861" contenteditable="true">iris</suggestion><suggestion store="2862" contenteditable="true">eras</suggestion><suggestion store="2863" contenteditable="true">irises</suggestion><suggestion store="2864" contenteditable="true">iratest</suggestion><suggestion store="2865" contenteditable="true">erases</suggestion><suggestion store="2866" contenteditable="true">ire</suggestion></suggestions></word><word store="2867" contenteditable="true"><text store="2868" contenteditable="true">ipilimumab</text><suggestions store="2869" contenteditable="true"></suggestions></word><word store="2870" contenteditable="true"><text store="2871" contenteditable="true">irAE</text><suggestions store="2872" contenteditable="true"><suggestion store="2873" contenteditable="true">ire</suggestion><suggestion store="2874" contenteditable="true">irate</suggestion><suggestion store="2875" contenteditable="true">irater</suggestion></suggestions></word><word store="2876" contenteditable="true"><text store="2877" contenteditable="true">ipilimumab</text><suggestions store="2878" contenteditable="true"></suggestions></word><word store="2879" contenteditable="true"><text store="2880" contenteditable="true">hypophysitis</text><suggestions store="2881" contenteditable="true"></suggestions></word><word store="2882" contenteditable="true"><text store="2883" contenteditable="true">monotherapy</text><suggestions store="2884" contenteditable="true"><suggestion store="2885" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2886" contenteditable="true"><text store="2887" contenteditable="true">irAEs</text><suggestions store="2888" contenteditable="true"><suggestion store="2889" contenteditable="true">iris</suggestion><suggestion store="2890" contenteditable="true">eras</suggestion><suggestion store="2891" contenteditable="true">irises</suggestion><suggestion store="2892" contenteditable="true">iratest</suggestion><suggestion store="2893" contenteditable="true">erases</suggestion><suggestion store="2894" contenteditable="true">ire</suggestion></suggestions></word><word store="2895" contenteditable="true"><text store="2896" contenteditable="true">irAEs</text><suggestions store="2897" contenteditable="true"><suggestion store="2898" contenteditable="true">iris</suggestion><suggestion store="2899" contenteditable="true">eras</suggestion><suggestion store="2900" contenteditable="true">irises</suggestion><suggestion store="2901" contenteditable="true">iratest</suggestion><suggestion store="2902" contenteditable="true">erases</suggestion><suggestion store="2903" contenteditable="true">ire</suggestion></suggestions></word><word store="2904" contenteditable="true"><text store="2905" contenteditable="true">irAEs</text><suggestions store="2906" contenteditable="true"><suggestion store="2907" contenteditable="true">iris</suggestion><suggestion store="2908" contenteditable="true">eras</suggestion><suggestion store="2909" contenteditable="true">irises</suggestion><suggestion store="2910" contenteditable="true">iratest</suggestion><suggestion store="2911" contenteditable="true">erases</suggestion><suggestion store="2912" contenteditable="true">ire</suggestion></suggestions></word><word store="2913" contenteditable="true"><text store="2914" contenteditable="true">ipilimumab</text><suggestions store="2915" contenteditable="true"></suggestions></word><word store="2916" contenteditable="true"><text store="2917" contenteditable="true">irAEs</text><suggestions store="2918" contenteditable="true"><suggestion store="2919" contenteditable="true">iris</suggestion><suggestion store="2920" contenteditable="true">eras</suggestion><suggestion store="2921" contenteditable="true">irises</suggestion><suggestion store="2922" contenteditable="true">iratest</suggestion><suggestion store="2923" contenteditable="true">erases</suggestion><suggestion store="2924" contenteditable="true">ire</suggestion></suggestions></word><word store="2925" contenteditable="true"><text store="2926" contenteditable="true">endocrinopathies</text><suggestions store="2927" contenteditable="true"></suggestions></word><word store="2928" contenteditable="true"><text store="2929" contenteditable="true">irAEs</text><suggestions store="2930" contenteditable="true"><suggestion store="2931" contenteditable="true">iris</suggestion><suggestion store="2932" contenteditable="true">eras</suggestion><suggestion store="2933" contenteditable="true">irises</suggestion><suggestion store="2934" contenteditable="true">iratest</suggestion><suggestion store="2935" contenteditable="true">erases</suggestion><suggestion store="2936" contenteditable="true">ire</suggestion></suggestions></word><word store="2937" contenteditable="true"><text store="2938" contenteditable="true">Clatterbridge</text><suggestions store="2939" contenteditable="true"><suggestion store="2940" contenteditable="true">Clatter bridge</suggestion></suggestions></word><word store="2941" contenteditable="true"><text store="2942" contenteditable="true">monotherapy</text><suggestions store="2943" contenteditable="true"><suggestion store="2944" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="2945" contenteditable="true"><text store="2946" contenteditable="true">pembrolizumab</text><suggestions store="2947" contenteditable="true"></suggestions></word><word store="2948" contenteditable="true"><text store="2949" contenteditable="true">nivolumab</text><suggestions store="2950" contenteditable="true"></suggestions></word><word store="2951" contenteditable="true"><text store="2952" contenteditable="true">nivolumab</text><suggestions store="2953" contenteditable="true"></suggestions></word><word store="2954" contenteditable="true"><text store="2955" contenteditable="true">ipilimumab</text><suggestions store="2956" contenteditable="true"></suggestions></word><word store="2957" contenteditable="true"><text store="2958" contenteditable="true">TRAb</text><suggestions store="2959" contenteditable="true"></suggestions></word><word store="2960" contenteditable="true"><text store="2961" contenteditable="true">thyroidism</text><suggestions store="2962" contenteditable="true"><suggestion store="2963" contenteditable="true">thyroids</suggestion><suggestion store="2964" contenteditable="true">thyroids'</suggestion><suggestion store="2965" contenteditable="true">thyroid's</suggestion></suggestions></word><word store="2966" contenteditable="true"><text store="2967" contenteditable="true">eg</text><suggestions store="2968" contenteditable="true"></suggestions></word><word store="2969" contenteditable="true"><text store="2970" contenteditable="true">pmol</text><suggestions store="2971" contenteditable="true"><suggestion store="2972" contenteditable="true">pool</suggestion><suggestion store="2973" contenteditable="true">poll</suggestion><suggestion store="2974" contenteditable="true">pole</suggestion><suggestion store="2975" contenteditable="true">polo</suggestion><suggestion store="2976" contenteditable="true">pomp</suggestion><suggestion store="2977" contenteditable="true">moll</suggestion><suggestion store="2978" contenteditable="true">pools</suggestion><suggestion store="2979" contenteditable="true">mole</suggestion><suggestion store="2980" contenteditable="true">prowl</suggestion><suggestion store="2981" contenteditable="true">pop</suggestion></suggestions></word><word store="2982" contenteditable="true"><text store="2983" contenteditable="true">mU</text><suggestions store="2984" contenteditable="true"><suggestion store="2985" contenteditable="true">mud</suggestion><suggestion store="2986" contenteditable="true">mug</suggestion><suggestion store="2987" contenteditable="true">mum</suggestion><suggestion store="2988" contenteditable="true">mo.</suggestion><suggestion store="2989" contenteditable="true">mi.</suggestion><suggestion store="2990" contenteditable="true">mow</suggestion><suggestion store="2991" contenteditable="true">much</suggestion><suggestion store="2992" contenteditable="true">must</suggestion><suggestion store="2993" contenteditable="true">mob</suggestion><suggestion store="2994" contenteditable="true">mom</suggestion></suggestions></word><word store="2995" contenteditable="true"><text store="2996" contenteditable="true">pmol</text><suggestions store="2997" contenteditable="true"><suggestion store="2998" contenteditable="true">pool</suggestion><suggestion store="2999" contenteditable="true">poll</suggestion><suggestion store="3000" contenteditable="true">pole</suggestion><suggestion store="3001" contenteditable="true">polo</suggestion><suggestion store="3002" contenteditable="true">pomp</suggestion><suggestion store="3003" contenteditable="true">moll</suggestion><suggestion store="3004" contenteditable="true">pools</suggestion><suggestion store="3005" contenteditable="true">mole</suggestion><suggestion store="3006" contenteditable="true">prowl</suggestion><suggestion store="3007" contenteditable="true">pop</suggestion></suggestions></word><word store="3008" contenteditable="true"><text store="3009" contenteditable="true">TRAb</text><suggestions store="3010" contenteditable="true"><suggestion store="3011" contenteditable="true">Tab</suggestion><suggestion store="3012" contenteditable="true">Tribe</suggestion><suggestion store="3013" contenteditable="true">Tar</suggestion><suggestion store="3014" contenteditable="true">Throb</suggestion><suggestion store="3015" contenteditable="true">Traps</suggestion><suggestion store="3016" contenteditable="true">Trobe</suggestion><suggestion store="3017" contenteditable="true">Trap</suggestion></suggestions></word><word store="3018" contenteditable="true"><text store="3019" contenteditable="true">mL.</text><suggestions store="3020" contenteditable="true"></suggestions></word><word store="3021" contenteditable="true"><text store="3022" contenteditable="true">Clatterbridge</text><suggestions store="3023" contenteditable="true"><suggestion store="3024" contenteditable="true">Clatter bridge</suggestion></suggestions></word><word store="3025" contenteditable="true"><text store="3026" contenteditable="true">Clatterbridge</text><suggestions store="3027" contenteditable="true"><suggestion store="3028" contenteditable="true">Clatter bridge</suggestion></suggestions></word><word store="3029" contenteditable="true"><text store="3030" contenteditable="true">Biobank</text><suggestions store="3031" contenteditable="true"><suggestion store="3032" contenteditable="true">Bio bank</suggestion><suggestion store="3033" contenteditable="true">Burbank</suggestion></suggestions></word><word store="3034" contenteditable="true"><text store="3035" contenteditable="true">Tg</text><suggestions store="3036" contenteditable="true"></suggestions></word><word store="3037" contenteditable="true"><text store="3038" contenteditable="true">Kruskal</text><suggestions store="3039" contenteditable="true"><suggestion store="3040" contenteditable="true">Kreskas</suggestion><suggestion store="3041" contenteditable="true">Kristal</suggestion><suggestion store="3042" contenteditable="true">Crustal</suggestion><suggestion store="3043" contenteditable="true">Ruska</suggestion><suggestion store="3044" contenteditable="true">Krystal</suggestion><suggestion store="3045" contenteditable="true">Rascal</suggestion><suggestion store="3046" contenteditable="true">Kuala</suggestion></suggestions></word><word store="3047" contenteditable="true"><text store="3048" contenteditable="true">monotherapy</text><suggestions store="3049" contenteditable="true"><suggestion store="3050" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3051" contenteditable="true"><text store="3052" contenteditable="true">monotherapy</text><suggestions store="3053" contenteditable="true"><suggestion store="3054" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3055" contenteditable="true"><text store="3056" contenteditable="true">monotherapy</text><suggestions store="3057" contenteditable="true"><suggestion store="3058" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3059" contenteditable="true"><text store="3060" contenteditable="true">monotherapy</text><suggestions store="3061" contenteditable="true"><suggestion store="3062" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3063" contenteditable="true"><text store="3064" contenteditable="true">monotherapy</text><suggestions store="3065" contenteditable="true"><suggestion store="3066" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3067" contenteditable="true"><text store="3068" contenteditable="true">monotherapy</text><suggestions store="3069" contenteditable="true"><suggestion store="3070" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3071" contenteditable="true"><text store="3072" contenteditable="true">monotherapy</text><suggestions store="3073" contenteditable="true"><suggestion store="3074" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3075" contenteditable="true"><text store="3076" contenteditable="true">pmol</text><suggestions store="3077" contenteditable="true"><suggestion store="3078" contenteditable="true">pool</suggestion><suggestion store="3079" contenteditable="true">poll</suggestion><suggestion store="3080" contenteditable="true">pole</suggestion><suggestion store="3081" contenteditable="true">polo</suggestion><suggestion store="3082" contenteditable="true">pomp</suggestion><suggestion store="3083" contenteditable="true">moll</suggestion><suggestion store="3084" contenteditable="true">pools</suggestion><suggestion store="3085" contenteditable="true">mole</suggestion><suggestion store="3086" contenteditable="true">prowl</suggestion><suggestion store="3087" contenteditable="true">pop</suggestion></suggestions></word><word store="3088" contenteditable="true"><text store="3089" contenteditable="true">pmol</text><suggestions store="3090" contenteditable="true"><suggestion store="3091" contenteditable="true">pool</suggestion><suggestion store="3092" contenteditable="true">poll</suggestion><suggestion store="3093" contenteditable="true">pole</suggestion><suggestion store="3094" contenteditable="true">polo</suggestion><suggestion store="3095" contenteditable="true">pomp</suggestion><suggestion store="3096" contenteditable="true">moll</suggestion><suggestion store="3097" contenteditable="true">pools</suggestion><suggestion store="3098" contenteditable="true">mole</suggestion><suggestion store="3099" contenteditable="true">prowl</suggestion><suggestion store="3100" contenteditable="true">pop</suggestion></suggestions></word><word store="3101" contenteditable="true"><text store="3102" contenteditable="true">mU</text><suggestions store="3103" contenteditable="true"><suggestion store="3104" contenteditable="true">mud</suggestion><suggestion store="3105" contenteditable="true">mug</suggestion><suggestion store="3106" contenteditable="true">mum</suggestion><suggestion store="3107" contenteditable="true">mo.</suggestion><suggestion store="3108" contenteditable="true">mi.</suggestion><suggestion store="3109" contenteditable="true">mow</suggestion><suggestion store="3110" contenteditable="true">much</suggestion><suggestion store="3111" contenteditable="true">must</suggestion><suggestion store="3112" contenteditable="true">mob</suggestion><suggestion store="3113" contenteditable="true">mom</suggestion></suggestions></word><word store="3114" contenteditable="true"><text store="3115" contenteditable="true">pmol</text><suggestions store="3116" contenteditable="true"><suggestion store="3117" contenteditable="true">pool</suggestion><suggestion store="3118" contenteditable="true">poll</suggestion><suggestion store="3119" contenteditable="true">pole</suggestion><suggestion store="3120" contenteditable="true">polo</suggestion><suggestion store="3121" contenteditable="true">pomp</suggestion><suggestion store="3122" contenteditable="true">moll</suggestion><suggestion store="3123" contenteditable="true">pools</suggestion><suggestion store="3124" contenteditable="true">mole</suggestion><suggestion store="3125" contenteditable="true">prowl</suggestion><suggestion store="3126" contenteditable="true">pop</suggestion></suggestions></word><word store="3127" contenteditable="true"><text store="3128" contenteditable="true">pmol</text><suggestions store="3129" contenteditable="true"><suggestion store="3130" contenteditable="true">pool</suggestion><suggestion store="3131" contenteditable="true">poll</suggestion><suggestion store="3132" contenteditable="true">pole</suggestion><suggestion store="3133" contenteditable="true">polo</suggestion><suggestion store="3134" contenteditable="true">pomp</suggestion><suggestion store="3135" contenteditable="true">moll</suggestion><suggestion store="3136" contenteditable="true">pools</suggestion><suggestion store="3137" contenteditable="true">mole</suggestion><suggestion store="3138" contenteditable="true">prowl</suggestion><suggestion store="3139" contenteditable="true">pop</suggestion></suggestions></word><word store="3140" contenteditable="true"><text store="3141" contenteditable="true">mU</text><suggestions store="3142" contenteditable="true"><suggestion store="3143" contenteditable="true">mud</suggestion><suggestion store="3144" contenteditable="true">mug</suggestion><suggestion store="3145" contenteditable="true">mum</suggestion><suggestion store="3146" contenteditable="true">mo.</suggestion><suggestion store="3147" contenteditable="true">mi.</suggestion><suggestion store="3148" contenteditable="true">mow</suggestion><suggestion store="3149" contenteditable="true">much</suggestion><suggestion store="3150" contenteditable="true">must</suggestion><suggestion store="3151" contenteditable="true">mob</suggestion><suggestion store="3152" contenteditable="true">mom</suggestion></suggestions></word><word store="3153" contenteditable="true"><text store="3154" contenteditable="true">mU</text><suggestions store="3155" contenteditable="true"><suggestion store="3156" contenteditable="true">mud</suggestion><suggestion store="3157" contenteditable="true">mug</suggestion><suggestion store="3158" contenteditable="true">mum</suggestion><suggestion store="3159" contenteditable="true">mo.</suggestion><suggestion store="3160" contenteditable="true">mi.</suggestion><suggestion store="3161" contenteditable="true">mow</suggestion><suggestion store="3162" contenteditable="true">much</suggestion><suggestion store="3163" contenteditable="true">must</suggestion><suggestion store="3164" contenteditable="true">mob</suggestion><suggestion store="3165" contenteditable="true">mom</suggestion></suggestions></word><word store="3166" contenteditable="true"><text store="3167" contenteditable="true">mU</text><suggestions store="3168" contenteditable="true"><suggestion store="3169" contenteditable="true">mud</suggestion><suggestion store="3170" contenteditable="true">mug</suggestion><suggestion store="3171" contenteditable="true">mum</suggestion><suggestion store="3172" contenteditable="true">mo.</suggestion><suggestion store="3173" contenteditable="true">mi.</suggestion><suggestion store="3174" contenteditable="true">mow</suggestion><suggestion store="3175" contenteditable="true">much</suggestion><suggestion store="3176" contenteditable="true">must</suggestion><suggestion store="3177" contenteditable="true">mob</suggestion><suggestion store="3178" contenteditable="true">mom</suggestion></suggestions></word><word store="3179" contenteditable="true"><text store="3180" contenteditable="true">mU</text><suggestions store="3181" contenteditable="true"><suggestion store="3182" contenteditable="true">mud</suggestion><suggestion store="3183" contenteditable="true">mug</suggestion><suggestion store="3184" contenteditable="true">mum</suggestion><suggestion store="3185" contenteditable="true">mo.</suggestion><suggestion store="3186" contenteditable="true">mi.</suggestion><suggestion store="3187" contenteditable="true">mow</suggestion><suggestion store="3188" contenteditable="true">much</suggestion><suggestion store="3189" contenteditable="true">must</suggestion><suggestion store="3190" contenteditable="true">mob</suggestion><suggestion store="3191" contenteditable="true">mom</suggestion></suggestions></word><word store="3192" contenteditable="true"><text store="3193" contenteditable="true">mU</text><suggestions store="3194" contenteditable="true"><suggestion store="3195" contenteditable="true">mud</suggestion><suggestion store="3196" contenteditable="true">mug</suggestion><suggestion store="3197" contenteditable="true">mum</suggestion><suggestion store="3198" contenteditable="true">mo.</suggestion><suggestion store="3199" contenteditable="true">mi.</suggestion><suggestion store="3200" contenteditable="true">mow</suggestion><suggestion store="3201" contenteditable="true">much</suggestion><suggestion store="3202" contenteditable="true">must</suggestion><suggestion store="3203" contenteditable="true">mob</suggestion><suggestion store="3204" contenteditable="true">mom</suggestion></suggestions></word><word store="3205" contenteditable="true"><text store="3206" contenteditable="true">monotherapy</text><suggestions store="3207" contenteditable="true"><suggestion store="3208" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3209" contenteditable="true"><text store="3210" contenteditable="true">pmol</text><suggestions store="3211" contenteditable="true"><suggestion store="3212" contenteditable="true">pool</suggestion><suggestion store="3213" contenteditable="true">poll</suggestion><suggestion store="3214" contenteditable="true">pole</suggestion><suggestion store="3215" contenteditable="true">polo</suggestion><suggestion store="3216" contenteditable="true">pomp</suggestion><suggestion store="3217" contenteditable="true">moll</suggestion><suggestion store="3218" contenteditable="true">pools</suggestion><suggestion store="3219" contenteditable="true">mole</suggestion><suggestion store="3220" contenteditable="true">prowl</suggestion><suggestion store="3221" contenteditable="true">pop</suggestion></suggestions></word><word store="3222" contenteditable="true"><text store="3223" contenteditable="true">pmol</text><suggestions store="3224" contenteditable="true"><suggestion store="3225" contenteditable="true">pool</suggestion><suggestion store="3226" contenteditable="true">poll</suggestion><suggestion store="3227" contenteditable="true">pole</suggestion><suggestion store="3228" contenteditable="true">polo</suggestion><suggestion store="3229" contenteditable="true">pomp</suggestion><suggestion store="3230" contenteditable="true">moll</suggestion><suggestion store="3231" contenteditable="true">pools</suggestion><suggestion store="3232" contenteditable="true">mole</suggestion><suggestion store="3233" contenteditable="true">prowl</suggestion><suggestion store="3234" contenteditable="true">pop</suggestion></suggestions></word><word store="3235" contenteditable="true"><text store="3236" contenteditable="true">mU</text><suggestions store="3237" contenteditable="true"><suggestion store="3238" contenteditable="true">mud</suggestion><suggestion store="3239" contenteditable="true">mug</suggestion><suggestion store="3240" contenteditable="true">mum</suggestion><suggestion store="3241" contenteditable="true">mo.</suggestion><suggestion store="3242" contenteditable="true">mi.</suggestion><suggestion store="3243" contenteditable="true">mow</suggestion><suggestion store="3244" contenteditable="true">much</suggestion><suggestion store="3245" contenteditable="true">must</suggestion><suggestion store="3246" contenteditable="true">mob</suggestion><suggestion store="3247" contenteditable="true">mom</suggestion></suggestions></word><word store="3248" contenteditable="true"><text store="3249" contenteditable="true">mU</text><suggestions store="3250" contenteditable="true"><suggestion store="3251" contenteditable="true">mud</suggestion><suggestion store="3252" contenteditable="true">mug</suggestion><suggestion store="3253" contenteditable="true">mum</suggestion><suggestion store="3254" contenteditable="true">mo.</suggestion><suggestion store="3255" contenteditable="true">mi.</suggestion><suggestion store="3256" contenteditable="true">mow</suggestion><suggestion store="3257" contenteditable="true">much</suggestion><suggestion store="3258" contenteditable="true">must</suggestion><suggestion store="3259" contenteditable="true">mob</suggestion><suggestion store="3260" contenteditable="true">mom</suggestion></suggestions></word><word store="3261" contenteditable="true"><text store="3262" contenteditable="true">pmol</text><suggestions store="3263" contenteditable="true"><suggestion store="3264" contenteditable="true">pool</suggestion><suggestion store="3265" contenteditable="true">poll</suggestion><suggestion store="3266" contenteditable="true">pole</suggestion><suggestion store="3267" contenteditable="true">polo</suggestion><suggestion store="3268" contenteditable="true">pomp</suggestion><suggestion store="3269" contenteditable="true">moll</suggestion><suggestion store="3270" contenteditable="true">pools</suggestion><suggestion store="3271" contenteditable="true">mole</suggestion><suggestion store="3272" contenteditable="true">prowl</suggestion><suggestion store="3273" contenteditable="true">pop</suggestion></suggestions></word><word store="3274" contenteditable="true"><text store="3275" contenteditable="true">thioamides</text><suggestions store="3276" contenteditable="true"><suggestion store="3277" contenteditable="true">thiazides</suggestion></suggestions></word><word store="3278" contenteditable="true"><text store="3279" contenteditable="true">mU</text><suggestions store="3280" contenteditable="true"><suggestion store="3281" contenteditable="true">mud</suggestion><suggestion store="3282" contenteditable="true">mug</suggestion><suggestion store="3283" contenteditable="true">mum</suggestion><suggestion store="3284" contenteditable="true">mo.</suggestion><suggestion store="3285" contenteditable="true">mi.</suggestion><suggestion store="3286" contenteditable="true">mow</suggestion><suggestion store="3287" contenteditable="true">much</suggestion><suggestion store="3288" contenteditable="true">must</suggestion><suggestion store="3289" contenteditable="true">mob</suggestion><suggestion store="3290" contenteditable="true">mom</suggestion></suggestions></word><word store="3291" contenteditable="true"><text store="3292" contenteditable="true">mU</text><suggestions store="3293" contenteditable="true"><suggestion store="3294" contenteditable="true">mud</suggestion><suggestion store="3295" contenteditable="true">mug</suggestion><suggestion store="3296" contenteditable="true">mum</suggestion><suggestion store="3297" contenteditable="true">mo.</suggestion><suggestion store="3298" contenteditable="true">mi.</suggestion><suggestion store="3299" contenteditable="true">mow</suggestion><suggestion store="3300" contenteditable="true">much</suggestion><suggestion store="3301" contenteditable="true">must</suggestion><suggestion store="3302" contenteditable="true">mob</suggestion><suggestion store="3303" contenteditable="true">mom</suggestion></suggestions></word><word store="3304" contenteditable="true"><text store="3305" contenteditable="true">mU</text><suggestions store="3306" contenteditable="true"><suggestion store="3307" contenteditable="true">mud</suggestion><suggestion store="3308" contenteditable="true">mug</suggestion><suggestion store="3309" contenteditable="true">mum</suggestion><suggestion store="3310" contenteditable="true">mo.</suggestion><suggestion store="3311" contenteditable="true">mi.</suggestion><suggestion store="3312" contenteditable="true">mow</suggestion><suggestion store="3313" contenteditable="true">much</suggestion><suggestion store="3314" contenteditable="true">must</suggestion><suggestion store="3315" contenteditable="true">mob</suggestion><suggestion store="3316" contenteditable="true">mom</suggestion></suggestions></word><word store="3317" contenteditable="true"><text store="3318" contenteditable="true">mU</text><suggestions store="3319" contenteditable="true"><suggestion store="3320" contenteditable="true">mud</suggestion><suggestion store="3321" contenteditable="true">mug</suggestion><suggestion store="3322" contenteditable="true">mum</suggestion><suggestion store="3323" contenteditable="true">mo.</suggestion><suggestion store="3324" contenteditable="true">mi.</suggestion><suggestion store="3325" contenteditable="true">mow</suggestion><suggestion store="3326" contenteditable="true">much</suggestion><suggestion store="3327" contenteditable="true">must</suggestion><suggestion store="3328" contenteditable="true">mob</suggestion><suggestion store="3329" contenteditable="true">mom</suggestion></suggestions></word><word store="3330" contenteditable="true"><text store="3331" contenteditable="true">Tg</text><suggestions store="3332" contenteditable="true"></suggestions></word><word store="3333" contenteditable="true"><text store="3334" contenteditable="true">TRAb</text><suggestions store="3335" contenteditable="true"></suggestions></word><word store="3336" contenteditable="true"><text store="3337" contenteditable="true">pembrolizumab</text><suggestions store="3338" contenteditable="true"></suggestions></word><word store="3339" contenteditable="true"><text store="3340" contenteditable="true">monotherapy</text><suggestions store="3341" contenteditable="true"><suggestion store="3342" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3343" contenteditable="true"><text store="3344" contenteditable="true">mL.</text><suggestions store="3345" contenteditable="true"></suggestions></word><word store="3346" contenteditable="true"><text store="3347" contenteditable="true">Tg</text><suggestions store="3348" contenteditable="true"></suggestions></word><word store="3349" contenteditable="true"><text store="3350" contenteditable="true">mL.</text><suggestions store="3351" contenteditable="true"></suggestions></word><word store="3352" contenteditable="true"><text store="3353" contenteditable="true">pembrolizumab</text><suggestions store="3354" contenteditable="true"></suggestions></word><word store="3355" contenteditable="true"><text store="3356" contenteditable="true">monotherapy</text><suggestions store="3357" contenteditable="true"><suggestion store="3358" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3359" contenteditable="true"><text store="3360" contenteditable="true">TRAb</text><suggestions store="3361" contenteditable="true"><suggestion store="3362" contenteditable="true">Tab</suggestion><suggestion store="3363" contenteditable="true">Tribe</suggestion><suggestion store="3364" contenteditable="true">Tar</suggestion><suggestion store="3365" contenteditable="true">Throb</suggestion><suggestion store="3366" contenteditable="true">Traps</suggestion><suggestion store="3367" contenteditable="true">Trobe</suggestion><suggestion store="3368" contenteditable="true">Trap</suggestion></suggestions></word><word store="3369" contenteditable="true"><text store="3370" contenteditable="true">pembrolizumab</text><suggestions store="3371" contenteditable="true"></suggestions></word><word store="3372" contenteditable="true"><text store="3373" contenteditable="true">monotherapy</text><suggestions store="3374" contenteditable="true"><suggestion store="3375" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3376" contenteditable="true"><text store="3377" contenteditable="true">Tg</text><suggestions store="3378" contenteditable="true"></suggestions></word><word store="3379" contenteditable="true"><text store="3380" contenteditable="true">TRAb</text><suggestions store="3381" contenteditable="true"><suggestion store="3382" contenteditable="true">Tab</suggestion><suggestion store="3383" contenteditable="true">Tribe</suggestion><suggestion store="3384" contenteditable="true">Tar</suggestion><suggestion store="3385" contenteditable="true">Throb</suggestion><suggestion store="3386" contenteditable="true">Traps</suggestion><suggestion store="3387" contenteditable="true">Trobe</suggestion><suggestion store="3388" contenteditable="true">Trap</suggestion></suggestions></word><word store="3389" contenteditable="true"><text store="3390" contenteditable="true">TRAb</text><suggestions store="3391" contenteditable="true"><suggestion store="3392" contenteditable="true">Tab</suggestion><suggestion store="3393" contenteditable="true">Tribe</suggestion><suggestion store="3394" contenteditable="true">Tar</suggestion><suggestion store="3395" contenteditable="true">Throb</suggestion><suggestion store="3396" contenteditable="true">Traps</suggestion><suggestion store="3397" contenteditable="true">Trobe</suggestion><suggestion store="3398" contenteditable="true">Trap</suggestion></suggestions></word><word store="3399" contenteditable="true"><text store="3400" contenteditable="true">Tg</text><suggestions store="3401" contenteditable="true"></suggestions></word><word store="3402" contenteditable="true"><text store="3403" contenteditable="true">monotherapy</text><suggestions store="3404" contenteditable="true"><suggestion store="3405" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3406" contenteditable="true"><text store="3407" contenteditable="true">monotherapy</text><suggestions store="3408" contenteditable="true"><suggestion store="3409" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3410" contenteditable="true"><text store="3411" contenteditable="true">irAEs</text><suggestions store="3412" contenteditable="true"><suggestion store="3413" contenteditable="true">iris</suggestion><suggestion store="3414" contenteditable="true">eras</suggestion><suggestion store="3415" contenteditable="true">irises</suggestion><suggestion store="3416" contenteditable="true">iratest</suggestion><suggestion store="3417" contenteditable="true">erases</suggestion><suggestion store="3418" contenteditable="true">ire</suggestion></suggestions></word><word store="3419" contenteditable="true"><text store="3420" contenteditable="true">thyrotoxic</text><suggestions store="3421" contenteditable="true"><suggestion store="3422" contenteditable="true">phytotoxic</suggestion><suggestion store="3423" contenteditable="true">thyrotoxicosis</suggestion></suggestions></word><word store="3424" contenteditable="true"><text store="3425" contenteditable="true">triphasic</text><suggestions store="3426" contenteditable="true"><suggestion store="3427" contenteditable="true">diphasic</suggestion></suggestions></word><word store="3428" contenteditable="true"><text store="3429" contenteditable="true">euthyroidism</text><suggestions store="3430" contenteditable="true"></suggestions></word><word store="3431" contenteditable="true"><text store="3432" contenteditable="true">euthyroidism</text><suggestions store="3433" contenteditable="true"></suggestions></word><word store="3434" contenteditable="true"><text store="3435" contenteditable="true">euthyroidism</text><suggestions store="3436" contenteditable="true"></suggestions></word><word store="3437" contenteditable="true"><text store="3438" contenteditable="true">thyroxine</text><suggestions store="3439" contenteditable="true"><suggestion store="3440" contenteditable="true">thyroxin</suggestion></suggestions></word><word store="3441" contenteditable="true"><text store="3442" contenteditable="true">monotherapy</text><suggestions store="3443" contenteditable="true"><suggestion store="3444" contenteditable="true">immunotherapy</suggestion></suggestions></word><word store="3445" contenteditable="true"><text store="3446" contenteditable="true">irAEs</text><suggestions store="3447" contenteditable="true"><suggestion store="3448" contenteditable="true">iris</suggestion><suggestion store="3449" contenteditable="true">eras</suggestion><suggestion store="3450" contenteditable="true">irises</suggestion><suggestion store="3451" contenteditable="true">iratest</suggestion><suggestion store="3452" contenteditable="true">erases</suggestion><suggestion store="3453" contenteditable="true">ire</suggestion></suggestions></word><word store="3454" contenteditable="true"><text store="3455" contenteditable="true">Tezzaro</text><suggestions store="3456" contenteditable="true"><suggestion store="3457" contenteditable="true">Tesoro</suggestion></suggestions></word><word store="3458" contenteditable="true"><text store="3459" contenteditable="true">Immunocore</text><suggestions store="3460" contenteditable="true"></suggestions></word><word store="3461" contenteditable="true"><text store="3462" contenteditable="true">Pharma</text><suggestions store="3463" contenteditable="true"><suggestion store="3464" contenteditable="true">Parma</suggestion><suggestion store="3465" contenteditable="true">Pharm</suggestion><suggestion store="3466" contenteditable="true">Pharms</suggestion><suggestion store="3467" contenteditable="true">Pharmacy</suggestion><suggestion store="3468" contenteditable="true">Pharmed</suggestion><suggestion store="3469" contenteditable="true">Pharm a</suggestion><suggestion store="3470" contenteditable="true">Dharma</suggestion><suggestion store="3471" contenteditable="true">Sharma</suggestion></suggestions></word><word store="3472" contenteditable="true"><text store="3473" contenteditable="true">Pharma</text><suggestions store="3474" contenteditable="true"><suggestion store="3475" contenteditable="true">Parma</suggestion><suggestion store="3476" contenteditable="true">Pharm</suggestion><suggestion store="3477" contenteditable="true">Pharms</suggestion><suggestion store="3478" contenteditable="true">Pharmacy</suggestion><suggestion store="3479" contenteditable="true">Pharmed</suggestion><suggestion store="3480" contenteditable="true">Pharm a</suggestion><suggestion store="3481" contenteditable="true">Dharma</suggestion><suggestion store="3482" contenteditable="true">Sharma</suggestion></suggestions></word><word store="3483" contenteditable="true"><text store="3484" contenteditable="true">Pirmohamed</text><suggestions store="3485" contenteditable="true"></suggestions></word><word store="3486" contenteditable="true"><text store="3487" contenteditable="true">Pharma</text><suggestions store="3488" contenteditable="true"><suggestion store="3489" contenteditable="true">Parma</suggestion><suggestion store="3490" contenteditable="true">Pharm</suggestion><suggestion store="3491" contenteditable="true">Pharms</suggestion><suggestion store="3492" contenteditable="true">Pharmacy</suggestion><suggestion store="3493" contenteditable="true">Pharmed</suggestion><suggestion store="3494" contenteditable="true">Pharm a</suggestion><suggestion store="3495" contenteditable="true">Dharma</suggestion><suggestion store="3496" contenteditable="true">Sharma</suggestion></suggestions></word><word store="3497" contenteditable="true"><text store="3498" contenteditable="true">Pharma</text><suggestions store="3499" contenteditable="true"><suggestion store="3500" contenteditable="true">Parma</suggestion><suggestion store="3501" contenteditable="true">Pharm</suggestion><suggestion store="3502" contenteditable="true">Pharms</suggestion><suggestion store="3503" contenteditable="true">Pharmacy</suggestion><suggestion store="3504" contenteditable="true">Pharmed</suggestion><suggestion store="3505" contenteditable="true">Pharm a</suggestion><suggestion store="3506" contenteditable="true">Dharma</suggestion><suggestion store="3507" contenteditable="true">Sharma</suggestion></suggestions></word><word store="3508" contenteditable="true"><text store="3509" contenteditable="true">Pharma</text><suggestions store="3510" contenteditable="true"><suggestion store="3511" contenteditable="true">Parma</suggestion><suggestion store="3512" contenteditable="true">Pharm</suggestion><suggestion store="3513" contenteditable="true">Pharms</suggestion><suggestion store="3514" contenteditable="true">Pharmacy</suggestion><suggestion store="3515" contenteditable="true">Pharmed</suggestion><suggestion store="3516" contenteditable="true">Pharm a</suggestion><suggestion store="3517" contenteditable="true">Dharma</suggestion><suggestion store="3518" contenteditable="true">Sharma</suggestion></suggestions></word><word store="3519" contenteditable="true"><text store="3520" contenteditable="true">Pharma</text><suggestions store="3521" contenteditable="true"><suggestion store="3522" contenteditable="true">Parma</suggestion><suggestion store="3523" contenteditable="true">Pharm</suggestion><suggestion store="3524" contenteditable="true">Pharms</suggestion><suggestion store="3525" contenteditable="true">Pharmacy</suggestion><suggestion store="3526" contenteditable="true">Pharmed</suggestion><suggestion store="3527" contenteditable="true">Pharm a</suggestion><suggestion store="3528" contenteditable="true">Dharma</suggestion><suggestion store="3529" contenteditable="true">Sharma</suggestion></suggestions></word></spellingerror></spellingerrors><history store="3530" contenteditable="true"><date-cont store="3531" contenteditable="true"><!--punc-->Received in final form <!--punc--><date date-type="received" store="3532" contenteditable="true"><day store="3533" contenteditable="true">31</day> <month store="3534" contenteditable="true">January</month> <year store="3535" contenteditable="true">2020</year></date></date-cont><date-cont store="3536" contenteditable="true"><!--punc-->Accepted <!--punc--><date date-type="accepted" store="3537" contenteditable="true"><day store="3538" contenteditable="true">11</day> <month store="3539" contenteditable="true">March</month> <year store="3540" contenteditable="true">2020</year></date></date-cont><date-cont store="3541" contenteditable="true"><!--punc-->Accepted Manuscript published online <!--punc--><date date-type="accepted" store="3542" contenteditable="true"><day store="3543" contenteditable="true">11</day> <month store="3544" contenteditable="true">March</month> <year store="3545" contenteditable="true">2020</year></date></date-cont></history></article></journal>